id	sid	tid	token	lemma	pos
cord-346842-ip4i3bdk	1	1	key	key	JJ
cord-346842-ip4i3bdk	1	2	:	:	:
cord-346842-ip4i3bdk	1	3	cord-346842-ip4i3bdk	cord-346842-ip4i3bdk	NNS
cord-346842-ip4i3bdk	1	4	authors	author	NNS
cord-346842-ip4i3bdk	1	5	:	:	:
cord-346842-ip4i3bdk	1	6	Jeon	Jeon	NNP
cord-346842-ip4i3bdk	1	7	,	,	,
cord-346842-ip4i3bdk	1	8	JuYeun	JuYeun	NNP
cord-346842-ip4i3bdk	1	9	;	;	:
cord-346842-ip4i3bdk	1	10	Kim	Kim	NNP
cord-346842-ip4i3bdk	1	11	,	,	,
cord-346842-ip4i3bdk	1	12	Hyeikyoung	Hyeikyoung	NNP
cord-346842-ip4i3bdk	1	13	;	;	:
cord-346842-ip4i3bdk	1	14	Yu	Yu	NNP
cord-346842-ip4i3bdk	1	15	,	,	,
cord-346842-ip4i3bdk	1	16	Kyung	Kyung	NNP
cord-346842-ip4i3bdk	1	17	-	-	HYPH
cord-346842-ip4i3bdk	1	18	Sang	Sang	NNP
cord-346842-ip4i3bdk	1	19	title	title	NN
cord-346842-ip4i3bdk	1	20	:	:	:
cord-346842-ip4i3bdk	1	21	The	the	DT
cord-346842-ip4i3bdk	1	22	Impact	Impact	NNP
cord-346842-ip4i3bdk	1	23	of	of	IN
cord-346842-ip4i3bdk	1	24	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	1	25	on	on	IN
cord-346842-ip4i3bdk	1	26	the	the	DT
cord-346842-ip4i3bdk	1	27	Conduct	conduct	NN
cord-346842-ip4i3bdk	1	28	of	of	IN
cord-346842-ip4i3bdk	1	29	Clinical	Clinical	NNP
cord-346842-ip4i3bdk	1	30	Trials	Trials	NNPS
cord-346842-ip4i3bdk	1	31	for	for	IN
cord-346842-ip4i3bdk	1	32	Medical	Medical	NNP
cord-346842-ip4i3bdk	1	33	Products	Products	NNPS
cord-346842-ip4i3bdk	1	34	in	in	IN
cord-346842-ip4i3bdk	1	35	Korea	Korea	NNP
cord-346842-ip4i3bdk	1	36	date	date	NN
cord-346842-ip4i3bdk	1	37	:	:	:
cord-346842-ip4i3bdk	1	38	2020	2020	CD
cord-346842-ip4i3bdk	1	39	-	-	HYPH
cord-346842-ip4i3bdk	1	40	09	09	CD
cord-346842-ip4i3bdk	1	41	-	-	HYPH
cord-346842-ip4i3bdk	1	42	07	07	CD
cord-346842-ip4i3bdk	1	43	journal	journal	NN
cord-346842-ip4i3bdk	1	44	:	:	:
cord-346842-ip4i3bdk	1	45	J	J	NNP
cord-346842-ip4i3bdk	1	46	Korean	Korean	NNP
cord-346842-ip4i3bdk	1	47	Med	Med	NNP
cord-346842-ip4i3bdk	1	48	Sci	Sci	NNP
cord-346842-ip4i3bdk	1	49	DOI	DOI	NNP
cord-346842-ip4i3bdk	1	50	:	:	:
cord-346842-ip4i3bdk	1	51	10.3346	10.3346	CD
cord-346842-ip4i3bdk	1	52	/	/	SYM
cord-346842-ip4i3bdk	1	53	jkms.2020.35.e329	jkms.2020.35.e329	NNS
cord-346842-ip4i3bdk	1	54	sha	sha	NNP
cord-346842-ip4i3bdk	1	55	:	:	:
cord-346842-ip4i3bdk	1	56	1f7dc71b3477a86cfa87085533810e3579fb1898	1f7dc71b3477a86cfa87085533810e3579fb1898	CD
cord-346842-ip4i3bdk	1	57	doc_id	doc_id	CD
cord-346842-ip4i3bdk	1	58	:	:	:
cord-346842-ip4i3bdk	1	59	346842	346842	CD
cord-346842-ip4i3bdk	1	60	cord_uid	cord_uid	NNS
cord-346842-ip4i3bdk	1	61	:	:	:
cord-346842-ip4i3bdk	2	1	ip4i3bdk	ip4i3bdk	NNP
cord-346842-ip4i3bdk	2	2	BACKGROUND	background	NN
cord-346842-ip4i3bdk	2	3	:	:	:
cord-346842-ip4i3bdk	3	1	The	the	DT
cord-346842-ip4i3bdk	3	2	number	number	NN
cord-346842-ip4i3bdk	3	3	of	of	IN
cord-346842-ip4i3bdk	3	4	clinical	clinical	JJ
cord-346842-ip4i3bdk	3	5	trials	trial	NNS
cord-346842-ip4i3bdk	3	6	conducted	conduct	VBN
cord-346842-ip4i3bdk	3	7	in	in	IN
cord-346842-ip4i3bdk	3	8	Korea	Korea	NNP
cord-346842-ip4i3bdk	3	9	continues	continue	VBZ
cord-346842-ip4i3bdk	3	10	to	to	TO
cord-346842-ip4i3bdk	3	11	increase	increase	VB
cord-346842-ip4i3bdk	3	12	and	and	CC
cord-346842-ip4i3bdk	3	13	an	an	DT
cord-346842-ip4i3bdk	3	14	increasing	increase	VBG
cord-346842-ip4i3bdk	3	15	proportion	proportion	NN
cord-346842-ip4i3bdk	3	16	focus	focus	NN
cord-346842-ip4i3bdk	3	17	on	on	IN
cord-346842-ip4i3bdk	3	18	severe	severe	JJ
cord-346842-ip4i3bdk	3	19	and	and	CC
cord-346842-ip4i3bdk	3	20	rare	rare	JJ
cord-346842-ip4i3bdk	3	21	incurable	incurable	JJ
cord-346842-ip4i3bdk	3	22	diseases	disease	NNS
cord-346842-ip4i3bdk	3	23	.	.	.
cord-346842-ip4i3bdk	4	1	After	after	IN
cord-346842-ip4i3bdk	4	2	the	the	DT
cord-346842-ip4i3bdk	4	3	start	start	NN
cord-346842-ip4i3bdk	4	4	of	of	IN
cord-346842-ip4i3bdk	4	5	the	the	DT
cord-346842-ip4i3bdk	4	6	severe	severe	JJ
cord-346842-ip4i3bdk	4	7	acute	acute	JJ
cord-346842-ip4i3bdk	4	8	respiratory	respiratory	JJ
cord-346842-ip4i3bdk	4	9	syndrome	syndrome	NN
cord-346842-ip4i3bdk	4	10	,	,	,
cord-346842-ip4i3bdk	4	11	coronavirus	coronavirus	NN
cord-346842-ip4i3bdk	4	12	disease	disease	NN
cord-346842-ip4i3bdk	4	13	2019	2019	CD
cord-346842-ip4i3bdk	4	14	(	(	-LRB-
cord-346842-ip4i3bdk	4	15	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	4	16	)	)	-RRB-
cord-346842-ip4i3bdk	4	17	,	,	,
cord-346842-ip4i3bdk	4	18	Korea	Korea	NNP
cord-346842-ip4i3bdk	4	19	Centers	Centers	NNPS
cord-346842-ip4i3bdk	4	20	for	for	IN
cord-346842-ip4i3bdk	4	21	Disease	Disease	NNP
cord-346842-ip4i3bdk	4	22	Control	Control	NNP
cord-346842-ip4i3bdk	4	23	and	and	CC
cord-346842-ip4i3bdk	4	24	Prevention	Prevention	NNP
cord-346842-ip4i3bdk	4	25	(	(	-LRB-
cord-346842-ip4i3bdk	4	26	KCDC	KCDC	NNP
cord-346842-ip4i3bdk	4	27	)	)	-RRB-
cord-346842-ip4i3bdk	4	28	developed	develop	VBD
cord-346842-ip4i3bdk	4	29	guidelines	guideline	NNS
cord-346842-ip4i3bdk	4	30	to	to	TO
cord-346842-ip4i3bdk	4	31	prevent	prevent	VB
cord-346842-ip4i3bdk	4	32	the	the	DT
cord-346842-ip4i3bdk	4	33	spread	spread	NN
cord-346842-ip4i3bdk	4	34	of	of	IN
cord-346842-ip4i3bdk	4	35	infection	infection	NN
cord-346842-ip4i3bdk	4	36	.	.	.
cord-346842-ip4i3bdk	5	1	This	this	DT
cord-346842-ip4i3bdk	5	2	study	study	NN
cord-346842-ip4i3bdk	5	3	evaluated	evaluate	VBD
cord-346842-ip4i3bdk	5	4	the	the	DT
cord-346842-ip4i3bdk	5	5	impact	impact	NN
cord-346842-ip4i3bdk	5	6	of	of	IN
cord-346842-ip4i3bdk	5	7	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	5	8	and	and	CC
cord-346842-ip4i3bdk	5	9	the	the	DT
cord-346842-ip4i3bdk	5	10	KCDC	KCDC	NNP
cord-346842-ip4i3bdk	5	11	guideline	guideline	NN
cord-346842-ip4i3bdk	5	12	on	on	IN
cord-346842-ip4i3bdk	5	13	the	the	DT
cord-346842-ip4i3bdk	5	14	conduct	conduct	NN
cord-346842-ip4i3bdk	5	15	of	of	IN
cord-346842-ip4i3bdk	5	16	clinical	clinical	JJ
cord-346842-ip4i3bdk	5	17	research	research	NN
cord-346842-ip4i3bdk	5	18	in	in	IN
cord-346842-ip4i3bdk	5	19	Korea	Korea	NNP
cord-346842-ip4i3bdk	5	20	.	.	.
cord-346842-ip4i3bdk	6	1	The	the	DT
cord-346842-ip4i3bdk	6	2	purpose	purpose	NN
cord-346842-ip4i3bdk	6	3	was	be	VBD
cord-346842-ip4i3bdk	6	4	to	to	TO
cord-346842-ip4i3bdk	6	5	develop	develop	VB
cord-346842-ip4i3bdk	6	6	recommendations	recommendation	NNS
cord-346842-ip4i3bdk	6	7	on	on	IN
cord-346842-ip4i3bdk	6	8	how	how	WRB
cord-346842-ip4i3bdk	6	9	to	to	TO
cord-346842-ip4i3bdk	6	10	minimize	minimize	VB
cord-346842-ip4i3bdk	6	11	the	the	DT
cord-346842-ip4i3bdk	6	12	risk	risk	NN
cord-346842-ip4i3bdk	6	13	of	of	IN
cord-346842-ip4i3bdk	6	14	infection	infection	NN
cord-346842-ip4i3bdk	6	15	while	while	IN
cord-346842-ip4i3bdk	6	16	enabling	enable	VBG
cord-346842-ip4i3bdk	6	17	subjects	subject	NNS
cord-346842-ip4i3bdk	6	18	to	to	TO
cord-346842-ip4i3bdk	6	19	take	take	VB
cord-346842-ip4i3bdk	6	20	part	part	NN
cord-346842-ip4i3bdk	6	21	in	in	IN
cord-346842-ip4i3bdk	6	22	the	the	DT
cord-346842-ip4i3bdk	6	23	trials	trial	NNS
cord-346842-ip4i3bdk	6	24	if	if	IN
cord-346842-ip4i3bdk	6	25	no	no	DT
cord-346842-ip4i3bdk	6	26	better	well	JJR
cord-346842-ip4i3bdk	6	27	alternative	alternative	JJ
cord-346842-ip4i3bdk	6	28	treatment	treatment	NN
cord-346842-ip4i3bdk	6	29	options	option	NNS
cord-346842-ip4i3bdk	6	30	were	be	VBD
cord-346842-ip4i3bdk	6	31	available	available	JJ
cord-346842-ip4i3bdk	6	32	.	.	.
cord-346842-ip4i3bdk	7	1	METHODS	methods	NN
cord-346842-ip4i3bdk	7	2	:	:	:
cord-346842-ip4i3bdk	8	1	The	the	DT
cord-346842-ip4i3bdk	8	2	impact	impact	NN
cord-346842-ip4i3bdk	8	3	on	on	IN
cord-346842-ip4i3bdk	8	4	subject	subject	NN
cord-346842-ip4i3bdk	8	5	's	's	POS
cord-346842-ip4i3bdk	8	6	scheduled	schedule	VBN
cord-346842-ip4i3bdk	8	7	visits	visit	NNS
cord-346842-ip4i3bdk	8	8	and	and	CC
cord-346842-ip4i3bdk	8	9	major	major	JJ
cord-346842-ip4i3bdk	8	10	milestones	milestone	NNS
cord-346842-ip4i3bdk	8	11	of	of	IN
cord-346842-ip4i3bdk	8	12	clinical	clinical	JJ
cord-346842-ip4i3bdk	8	13	trials	trial	NNS
cord-346842-ip4i3bdk	8	14	in	in	IN
cord-346842-ip4i3bdk	8	15	Korea	Korea	NNP
cord-346842-ip4i3bdk	8	16	were	be	VBD
cord-346842-ip4i3bdk	8	17	measured	measure	VBN
cord-346842-ip4i3bdk	8	18	by	by	IN
cord-346842-ip4i3bdk	8	19	conducting	conduct	VBG
cord-346842-ip4i3bdk	8	20	a	a	DT
cord-346842-ip4i3bdk	8	21	survey	survey	NN
cord-346842-ip4i3bdk	8	22	among	among	IN
cord-346842-ip4i3bdk	8	23	clinical	clinical	JJ
cord-346842-ip4i3bdk	8	24	project	project	NN
cord-346842-ip4i3bdk	8	25	manager	manager	NN
cord-346842-ip4i3bdk	8	26	(	(	-LRB-
cord-346842-ip4i3bdk	8	27	CPMs	CPMs	NNP
cord-346842-ip4i3bdk	8	28	)	)	-RRB-
cord-346842-ip4i3bdk	8	29	working	work	VBG
cord-346842-ip4i3bdk	8	30	at	at	IN
cord-346842-ip4i3bdk	8	31	global	global	JJ
cord-346842-ip4i3bdk	8	32	clinical	clinical	JJ
cord-346842-ip4i3bdk	8	33	research	research	NN
cord-346842-ip4i3bdk	8	34	organization	organization	NN
cord-346842-ip4i3bdk	8	35	.	.	.
cord-346842-ip4i3bdk	9	1	The	the	DT
cord-346842-ip4i3bdk	9	2	policy	policy	NN
cord-346842-ip4i3bdk	9	3	on	on	IN
cord-346842-ip4i3bdk	9	4	monitor	monitor	NN
cord-346842-ip4i3bdk	9	5	's	's	POS
cord-346842-ip4i3bdk	9	6	access	access	NN
cord-346842-ip4i3bdk	9	7	to	to	IN
cord-346842-ip4i3bdk	9	8	hospital	hospital	NN
cord-346842-ip4i3bdk	9	9	and	and	CC
cord-346842-ip4i3bdk	9	10	site	site	NN
cord-346842-ip4i3bdk	9	11	initiation	initiation	NN
cord-346842-ip4i3bdk	9	12	meetings	meeting	NNS
cord-346842-ip4i3bdk	9	13	was	be	VBD
cord-346842-ip4i3bdk	9	14	investigated	investigate	VBN
cord-346842-ip4i3bdk	9	15	through	through	IN
cord-346842-ip4i3bdk	9	16	correspondence	correspondence	NN
cord-346842-ip4i3bdk	9	17	with	with	IN
cord-346842-ip4i3bdk	9	18	clinical	clinical	JJ
cord-346842-ip4i3bdk	9	19	trial	trial	NN
cord-346842-ip4i3bdk	9	20	center	center	NN
cord-346842-ip4i3bdk	9	21	of	of	IN
cord-346842-ip4i3bdk	9	22	39	39	CD
cord-346842-ip4i3bdk	9	23	hospitals	hospital	NNS
cord-346842-ip4i3bdk	9	24	.	.	.
cord-346842-ip4i3bdk	10	1	The	the	DT
cord-346842-ip4i3bdk	10	2	Top	top	JJ
cord-346842-ip4i3bdk	10	3	25	25	CD
cord-346842-ip4i3bdk	10	4	pharmaceutical	pharmaceutical	NN
cord-346842-ip4i3bdk	10	5	companies	company	NNS
cord-346842-ip4i3bdk	10	6	'	'	POS
cord-346842-ip4i3bdk	10	7	official	official	JJ
cord-346842-ip4i3bdk	10	8	press	press	NN
cord-346842-ip4i3bdk	10	9	and	and	CC
cord-346842-ip4i3bdk	10	10	public	public	JJ
cord-346842-ip4i3bdk	10	11	clinical	clinical	JJ
cord-346842-ip4i3bdk	10	12	trial	trial	NN
cord-346842-ip4i3bdk	10	13	registry	registry	NN
cord-346842-ip4i3bdk	10	14	database	database	NN
cord-346842-ip4i3bdk	10	15	were	be	VBD
cord-346842-ip4i3bdk	10	16	used	use	VBN
cord-346842-ip4i3bdk	10	17	to	to	TO
cord-346842-ip4i3bdk	10	18	analyze	analyze	VB
cord-346842-ip4i3bdk	10	19	companies	company	NNS
cord-346842-ip4i3bdk	10	20	'	'	POS
cord-346842-ip4i3bdk	10	21	trial	trial	NN
cord-346842-ip4i3bdk	10	22	strategy	strategy	NN
cord-346842-ip4i3bdk	10	23	during	during	IN
cord-346842-ip4i3bdk	10	24	the	the	DT
cord-346842-ip4i3bdk	10	25	pandemic	pandemic	NN
cord-346842-ip4i3bdk	10	26	and	and	CC
cord-346842-ip4i3bdk	10	27	COVID-19	covid-19	VB
cord-346842-ip4i3bdk	10	28	clinical	clinical	JJ
cord-346842-ip4i3bdk	10	29	research	research	NN
cord-346842-ip4i3bdk	10	30	status	status	NN
cord-346842-ip4i3bdk	10	31	,	,	,
cord-346842-ip4i3bdk	10	32	respectively	respectively	RB
cord-346842-ip4i3bdk	10	33	.	.	.
cord-346842-ip4i3bdk	11	1	RESULTS	result	NNS
cord-346842-ip4i3bdk	11	2	:	:	:
cord-346842-ip4i3bdk	12	1	Of	of	IN
cord-346842-ip4i3bdk	12	2	85	85	CD
cord-346842-ip4i3bdk	12	3	CPMs	cpm	NNS
cord-346842-ip4i3bdk	12	4	,	,	,
cord-346842-ip4i3bdk	12	5	12	12	CD
cord-346842-ip4i3bdk	12	6	%	%	NN
cord-346842-ip4i3bdk	12	7	reported	report	VBD
cord-346842-ip4i3bdk	12	8	that	that	IN
cord-346842-ip4i3bdk	12	9	trial	trial	NN
cord-346842-ip4i3bdk	12	10	subjects	subject	NNS
cord-346842-ip4i3bdk	12	11	'	'	POS
cord-346842-ip4i3bdk	12	12	scheduled	schedule	VBN
cord-346842-ip4i3bdk	12	13	visits	visit	NNS
cord-346842-ip4i3bdk	12	14	had	have	VBD
cord-346842-ip4i3bdk	12	15	been	be	VBN
cord-346842-ip4i3bdk	12	16	affected	affect	VBN
cord-346842-ip4i3bdk	12	17	in	in	IN
cord-346842-ip4i3bdk	12	18	their	-PRON-	PRP$
cord-346842-ip4i3bdk	12	19	project	project	NN
cord-346842-ip4i3bdk	12	20	.	.	.
cord-346842-ip4i3bdk	13	1	Monitors	monitor	NNS
cord-346842-ip4i3bdk	13	2	'	'	POS
cord-346842-ip4i3bdk	13	3	access	access	NN
cord-346842-ip4i3bdk	13	4	to	to	IN
cord-346842-ip4i3bdk	13	5	hospital	hospital	NN
cord-346842-ip4i3bdk	13	6	for	for	IN
cord-346842-ip4i3bdk	13	7	source	source	NN
cord-346842-ip4i3bdk	13	8	data	datum	NNS
cord-346842-ip4i3bdk	13	9	verification	verification	NN
cord-346842-ip4i3bdk	13	10	was	be	VBD
cord-346842-ip4i3bdk	13	11	restricted	restrict	VBN
cord-346842-ip4i3bdk	13	12	at	at	IN
cord-346842-ip4i3bdk	13	13	all	all	DT
cord-346842-ip4i3bdk	13	14	sites	site	NNS
cord-346842-ip4i3bdk	13	15	in	in	IN
cord-346842-ip4i3bdk	13	16	February	February	NNP
cord-346842-ip4i3bdk	13	17	2020	2020	CD
cord-346842-ip4i3bdk	13	18	.	.	.
cord-346842-ip4i3bdk	14	1	Accordingly	accordingly	RB
cord-346842-ip4i3bdk	14	2	,	,	,
cord-346842-ip4i3bdk	14	3	43	43	CD
cord-346842-ip4i3bdk	14	4	%	%	NN
cord-346842-ip4i3bdk	14	5	of	of	IN
cord-346842-ip4i3bdk	14	6	105	105	CD
cord-346842-ip4i3bdk	14	7	CPMs	cpm	NNS
cord-346842-ip4i3bdk	14	8	reported	report	VBD
cord-346842-ip4i3bdk	14	9	that	that	IN
cord-346842-ip4i3bdk	14	10	the	the	DT
cord-346842-ip4i3bdk	14	11	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	14	12	epidemic	epidemic	NN
cord-346842-ip4i3bdk	14	13	had	have	VBD
cord-346842-ip4i3bdk	14	14	an	an	DT
cord-346842-ip4i3bdk	14	15	effect	effect	NN
cord-346842-ip4i3bdk	14	16	on	on	IN
cord-346842-ip4i3bdk	14	17	study	study	NN
cord-346842-ip4i3bdk	14	18	major	major	JJ
cord-346842-ip4i3bdk	14	19	milestones	milestone	NNS
cord-346842-ip4i3bdk	14	20	and	and	CC
cord-346842-ip4i3bdk	14	21	data	datum	NNS
cord-346842-ip4i3bdk	14	22	cleaning	cleaning	NN
cord-346842-ip4i3bdk	14	23	and	and	CC
cord-346842-ip4i3bdk	14	24	database	database	NN
cord-346842-ip4i3bdk	14	25	lock	lock	NN
cord-346842-ip4i3bdk	14	26	accounted	account	VBD
cord-346842-ip4i3bdk	14	27	for	for	IN
cord-346842-ip4i3bdk	14	28	>	>	XX
cord-346842-ip4i3bdk	14	29	60	60	CD
cord-346842-ip4i3bdk	14	30	%	%	NN
cord-346842-ip4i3bdk	14	31	of	of	IN
cord-346842-ip4i3bdk	14	32	milestones	milestone	NNS
cord-346842-ip4i3bdk	14	33	affected	affect	VBN
cord-346842-ip4i3bdk	14	34	.	.	.
cord-346842-ip4i3bdk	15	1	In	in	IN
cord-346842-ip4i3bdk	15	2	addition	addition	NN
cord-346842-ip4i3bdk	15	3	,	,	,
cord-346842-ip4i3bdk	15	4	87	87	CD
cord-346842-ip4i3bdk	15	5	%	%	NN
cord-346842-ip4i3bdk	15	6	sites	site	NNS
cord-346842-ip4i3bdk	15	7	advised	advise	VBD
cord-346842-ip4i3bdk	15	8	not	not	RB
cord-346842-ip4i3bdk	15	9	to	to	TO
cord-346842-ip4i3bdk	15	10	have	have	VB
cord-346842-ip4i3bdk	15	11	site	site	NN
cord-346842-ip4i3bdk	15	12	initiation	initiation	NN
cord-346842-ip4i3bdk	15	13	meetings	meeting	NNS
cord-346842-ip4i3bdk	15	14	and	and	CC
cord-346842-ip4i3bdk	15	15	52	52	CD
cord-346842-ip4i3bdk	15	16	%	%	NN
cord-346842-ip4i3bdk	15	17	pharmaceutical	pharmaceutical	JJ
cord-346842-ip4i3bdk	15	18	companies	company	NNS
cord-346842-ip4i3bdk	15	19	suspended	suspend	VBD
cord-346842-ip4i3bdk	15	20	recruitment	recruitment	NN
cord-346842-ip4i3bdk	15	21	or	or	CC
cord-346842-ip4i3bdk	15	22	new	new	JJ
cord-346842-ip4i3bdk	15	23	study	study	NN
cord-346842-ip4i3bdk	15	24	start	start	NN
cord-346842-ip4i3bdk	15	25	-	-	HYPH
cord-346842-ip4i3bdk	15	26	up	up	NN
cord-346842-ip4i3bdk	15	27	due	due	IN
cord-346842-ip4i3bdk	15	28	to	to	IN
cord-346842-ip4i3bdk	15	29	the	the	DT
cord-346842-ip4i3bdk	15	30	pandemic	pandemic	NN
cord-346842-ip4i3bdk	15	31	.	.	.
cord-346842-ip4i3bdk	16	1	On	on	IN
cord-346842-ip4i3bdk	16	2	the	the	DT
cord-346842-ip4i3bdk	16	3	other	other	JJ
cord-346842-ip4i3bdk	16	4	hands	hand	NNS
cord-346842-ip4i3bdk	16	5	,	,	,
cord-346842-ip4i3bdk	16	6	the	the	DT
cord-346842-ip4i3bdk	16	7	number	number	NN
cord-346842-ip4i3bdk	16	8	of	of	IN
cord-346842-ip4i3bdk	16	9	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	16	10	related	related	JJ
cord-346842-ip4i3bdk	16	11	clinical	clinical	JJ
cord-346842-ip4i3bdk	16	12	trials	trial	NNS
cord-346842-ip4i3bdk	16	13	increased	increase	VBD
cord-346842-ip4i3bdk	16	14	rapidly	rapidly	RB
cord-346842-ip4i3bdk	16	15	in	in	IN
cord-346842-ip4i3bdk	16	16	Korea	Korea	NNP
cord-346842-ip4i3bdk	16	17	and	and	CC
cord-346842-ip4i3bdk	16	18	worldwide	worldwide	RB
cord-346842-ip4i3bdk	16	19	,	,	,
cord-346842-ip4i3bdk	16	20	with	with	IN
cord-346842-ip4i3bdk	16	21	investigator	investigator	NN
cord-346842-ip4i3bdk	16	22	-	-	HYPH
cord-346842-ip4i3bdk	16	23	initiated	initiate	VBN
cord-346842-ip4i3bdk	16	24	trials	trial	NNS
cord-346842-ip4i3bdk	16	25	accounting	account	VBG
cord-346842-ip4i3bdk	16	26	for	for	IN
cord-346842-ip4i3bdk	16	27	47	47	CD
cord-346842-ip4i3bdk	16	28	%	%	NN
cord-346842-ip4i3bdk	16	29	and	and	CC
cord-346842-ip4i3bdk	16	30	63	63	CD
cord-346842-ip4i3bdk	16	31	%	%	NN
cord-346842-ip4i3bdk	16	32	of	of	IN
cord-346842-ip4i3bdk	16	33	all	all	DT
cord-346842-ip4i3bdk	16	34	trials	trial	NNS
cord-346842-ip4i3bdk	16	35	locally	locally	RB
cord-346842-ip4i3bdk	16	36	and	and	CC
cord-346842-ip4i3bdk	16	37	globally	globally	RB
cord-346842-ip4i3bdk	16	38	,	,	,
cord-346842-ip4i3bdk	16	39	respectively	respectively	RB
cord-346842-ip4i3bdk	16	40	.	.	.
cord-346842-ip4i3bdk	17	1	Most	Most	JJS
cord-346842-ip4i3bdk	17	2	trials	trial	NNS
cord-346842-ip4i3bdk	17	3	were	be	VBD
cord-346842-ip4i3bdk	17	4	phase	phase	NN
cord-346842-ip4i3bdk	17	5	2	2	CD
cord-346842-ip4i3bdk	17	6	and	and	CC
cord-346842-ip4i3bdk	17	7	were	be	VBD
cord-346842-ip4i3bdk	17	8	in	in	IN
cord-346842-ip4i3bdk	17	9	the	the	DT
cord-346842-ip4i3bdk	17	10	recruitment	recruitment	NN
cord-346842-ip4i3bdk	17	11	stage	stage	NN
cord-346842-ip4i3bdk	17	12	.	.	.
cord-346842-ip4i3bdk	18	1	CONCLUSION	conclusion	NN
cord-346842-ip4i3bdk	18	2	:	:	:
cord-346842-ip4i3bdk	19	1	The	the	DT
cord-346842-ip4i3bdk	19	2	COVID-19	covid-19	NN
cord-346842-ip4i3bdk	19	3	and	and	CC
cord-346842-ip4i3bdk	19	4	the	the	DT
cord-346842-ip4i3bdk	19	5	KCDC	KCDC	NNP
cord-346842-ip4i3bdk	19	6	guideline	guideline	NN
cord-346842-ip4i3bdk	19	7	influenced	influence	VBD
cord-346842-ip4i3bdk	19	8	all	all	DT
cord-346842-ip4i3bdk	19	9	parties	party	NNS
cord-346842-ip4i3bdk	19	10	involved	involve	VBN
cord-346842-ip4i3bdk	19	11	in	in	IN
cord-346842-ip4i3bdk	19	12	clinical	clinical	JJ
cord-346842-ip4i3bdk	19	13	trials	trial	NNS
cord-346842-ip4i3bdk	19	14	in	in	IN
cord-346842-ip4i3bdk	19	15	Korea	Korea	NNP
cord-346842-ip4i3bdk	19	16	.	.	.
cord-346842-ip4i3bdk	20	1	In	in	IN
cord-346842-ip4i3bdk	20	2	order	order	NN
cord-346842-ip4i3bdk	20	3	to	to	TO
cord-346842-ip4i3bdk	20	4	ensure	ensure	VB
cord-346842-ip4i3bdk	20	5	the	the	DT
cord-346842-ip4i3bdk	20	6	safety	safety	NN
cord-346842-ip4i3bdk	20	7	and	and	CC
cord-346842-ip4i3bdk	20	8	well	well	RB
cord-346842-ip4i3bdk	20	9	-	-	HYPH
cord-346842-ip4i3bdk	20	10	being	being	NN
cord-346842-ip4i3bdk	20	11	of	of	IN
cord-346842-ip4i3bdk	20	12	trial	trial	NN
cord-346842-ip4i3bdk	20	13	subjects	subject	NNS
cord-346842-ip4i3bdk	20	14	during	during	IN
cord-346842-ip4i3bdk	20	15	the	the	DT
cord-346842-ip4i3bdk	20	16	pandemic	pandemic	NN
cord-346842-ip4i3bdk	20	17	,	,	,
cord-346842-ip4i3bdk	20	18	new	new	JJ
cord-346842-ip4i3bdk	20	19	approaches	approach	NNS
cord-346842-ip4i3bdk	20	20	are	be	VBP
cord-346842-ip4i3bdk	20	21	required	require	VBN
cord-346842-ip4i3bdk	20	22	for	for	IN
cord-346842-ip4i3bdk	20	23	clinical	clinical	JJ
cord-346842-ip4i3bdk	20	24	trials	trial	NNS
cord-346842-ip4i3bdk	20	25	to	to	TO
cord-346842-ip4i3bdk	20	26	respond	respond	VB
cord-346842-ip4i3bdk	20	27	to	to	IN
cord-346842-ip4i3bdk	20	28	the	the	DT
cord-346842-ip4i3bdk	20	29	impact	impact	NN
cord-346842-ip4i3bdk	20	30	actively	actively	RB
cord-346842-ip4i3bdk	20	31	.	.	.
cord-346842-ip4i3bdk	21	1	Method	method	NN
cord-346842-ip4i3bdk	21	2	of	of	IN
cord-346842-ip4i3bdk	21	3	non	non	JJ
cord-346842-ip4i3bdk	21	4	-	-	JJ
cord-346842-ip4i3bdk	21	5	contact	contact	NN
cord-346842-ip4i3bdk	21	6	is	be	VBZ
cord-346842-ip4i3bdk	21	7	developed	develop	VBN
cord-346842-ip4i3bdk	21	8	to	to	TO
cord-346842-ip4i3bdk	21	9	replace	replace	VB
cord-346842-ip4i3bdk	21	10	and	and	CC
cord-346842-ip4i3bdk	21	11	supplement	supplement	VB
cord-346842-ip4i3bdk	21	12	the	the	DT
cord-346842-ip4i3bdk	21	13	face	face	NN
cord-346842-ip4i3bdk	21	14	-	-	HYPH
cord-346842-ip4i3bdk	21	15	to	to	IN
cord-346842-ip4i3bdk	21	16	-	-	HYPH
cord-346842-ip4i3bdk	21	17	face	face	NN
cord-346842-ip4i3bdk	21	18	contact	contact	NN
cord-346842-ip4i3bdk	21	19	and	and	CC
cord-346842-ip4i3bdk	21	20	alternatives	alternative	NNS
cord-346842-ip4i3bdk	21	21	to	to	TO
cord-346842-ip4i3bdk	21	22	reduce	reduce	VB
cord-346842-ip4i3bdk	21	23	the	the	DT
cord-346842-ip4i3bdk	21	24	travel	travel	NN
cord-346842-ip4i3bdk	21	25	is	be	VBZ
cord-346842-ip4i3bdk	21	26	introduced	introduce	VBN
cord-346842-ip4i3bdk	21	27	to	to	TO
cord-346842-ip4i3bdk	21	28	decrease	decrease	VB
cord-346842-ip4i3bdk	21	29	the	the	DT
cord-346842-ip4i3bdk	21	30	risk	risk	NN
cord-346842-ip4i3bdk	21	31	of	of	IN
cord-346842-ip4i3bdk	21	32	infection	infection	NN
cord-346842-ip4i3bdk	21	33	for	for	IN
cord-346842-ip4i3bdk	21	34	all	all	DT
cord-346842-ip4i3bdk	21	35	trial	trial	NN
cord-346842-ip4i3bdk	21	36	participants	participant	NNS
cord-346842-ip4i3bdk	21	37	in	in	IN
cord-346842-ip4i3bdk	21	38	whole	whole	JJ
cord-346842-ip4i3bdk	21	39	trial	trial	NN
cord-346842-ip4i3bdk	21	40	process	process	NN
cord-346842-ip4i3bdk	21	41	.	.	.
cord-346842-ip4i3bdk	22	1	The	the	DT
cord-346842-ip4i3bdk	22	2	relevant	relevant	JJ
cord-346842-ip4i3bdk	22	3	regulations	regulation	NNS
cord-346842-ip4i3bdk	22	4	should	should	MD
cord-346842-ip4i3bdk	22	5	be	be	VB
cord-346842-ip4i3bdk	22	6	developed	develop	VBN
cord-346842-ip4i3bdk	22	7	and	and	CC
cord-346842-ip4i3bdk	22	8	the	the	DT
cord-346842-ip4i3bdk	22	9	guidelines	guideline	NNS
cord-346842-ip4i3bdk	22	10	for	for	IN
cord-346842-ip4i3bdk	22	11	foreign	foreign	JJ
cord-346842-ip4i3bdk	22	12	countries	country	NNS
cord-346842-ip4i3bdk	22	13	need	need	VBP
cord-346842-ip4i3bdk	22	14	to	to	TO
cord-346842-ip4i3bdk	22	15	be	be	VB
cord-346842-ip4i3bdk	22	16	adopted	adopt	VBN
cord-346842-ip4i3bdk	22	17	in	in	IN
cord-346842-ip4i3bdk	22	18	accordance	accordance	NN
cord-346842-ip4i3bdk	22	19	with	with	IN
cord-346842-ip4i3bdk	22	20	the	the	DT
cord-346842-ip4i3bdk	22	21	situation	situation	NN
cord-346842-ip4i3bdk	22	22	in	in	IN
cord-346842-ip4i3bdk	22	23	Korea	Korea	NNP
cord-346842-ip4i3bdk	22	24	.	.	.
cord-346842-ip4i3bdk	23	1	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	23	2	trial	trial	NN
cord-346842-ip4i3bdk	23	3	is	be	VBZ
cord-346842-ip4i3bdk	23	4	rapidly	rapidly	RB
cord-346842-ip4i3bdk	23	5	increasing	increase	VBG
cord-346842-ip4i3bdk	23	6	worldwide	worldwide	RB
cord-346842-ip4i3bdk	23	7	and	and	CC
cord-346842-ip4i3bdk	23	8	continuous	continuous	JJ
cord-346842-ip4i3bdk	23	9	support	support	NN
cord-346842-ip4i3bdk	23	10	of	of	IN
cord-346842-ip4i3bdk	23	11	health	health	NN
cord-346842-ip4i3bdk	23	12	authorities	authority	NNS
cord-346842-ip4i3bdk	23	13	,	,	,
cord-346842-ip4i3bdk	23	14	regulation	regulation	NN
cord-346842-ip4i3bdk	23	15	,	,	,
cord-346842-ip4i3bdk	23	16	and	and	CC
cord-346842-ip4i3bdk	23	17	facilities	facility	NNS
cord-346842-ip4i3bdk	23	18	is	be	VBZ
cord-346842-ip4i3bdk	23	19	required	require	VBN
cord-346842-ip4i3bdk	23	20	for	for	IN
cord-346842-ip4i3bdk	23	21	developing	develop	VBG
cord-346842-ip4i3bdk	23	22	the	the	DT
cord-346842-ip4i3bdk	23	23	treatments	treatment	NNS
cord-346842-ip4i3bdk	23	24	with	with	IN
cord-346842-ip4i3bdk	23	25	protecting	protect	VBG
cord-346842-ip4i3bdk	23	26	all	all	DT
cord-346842-ip4i3bdk	23	27	trial	trial	NN
cord-346842-ip4i3bdk	23	28	participants	participant	NNS
cord-346842-ip4i3bdk	23	29	.	.	.
cord-346842-ip4i3bdk	24	1	In	in	IN
cord-346842-ip4i3bdk	24	2	terms	term	NNS
cord-346842-ip4i3bdk	24	3	of	of	IN
cord-346842-ip4i3bdk	24	4	the	the	DT
cord-346842-ip4i3bdk	24	5	clinical	clinical	JJ
cord-346842-ip4i3bdk	24	6	trial	trial	NN
cord-346842-ip4i3bdk	24	7	share	share	NN
cord-346842-ip4i3bdk	24	8	,	,	,
cord-346842-ip4i3bdk	24	9	Korea	Korea	NNP
cord-346842-ip4i3bdk	24	10	ranks	rank	VBZ
cord-346842-ip4i3bdk	24	11	eighth	eighth	JJ
cord-346842-ip4i3bdk	24	12	globally	globally	RB
cord-346842-ip4i3bdk	24	13	and	and	CC
cord-346842-ip4i3bdk	24	14	is	be	VBZ
cord-346842-ip4i3bdk	24	15	in	in	IN
cord-346842-ip4i3bdk	24	16	third	third	JJ
cord-346842-ip4i3bdk	24	17	place	place	NN
cord-346842-ip4i3bdk	24	18	in	in	IN
cord-346842-ip4i3bdk	24	19	a	a	DT
cord-346842-ip4i3bdk	24	20	single	single	JJ
cord-346842-ip4i3bdk	24	21	country	country	NN
cord-346842-ip4i3bdk	24	22	clinical	clinical	JJ
cord-346842-ip4i3bdk	24	23	trial	trial	NN
cord-346842-ip4i3bdk	24	24	basis	basis	NN
cord-346842-ip4i3bdk	24	25	.	.	.
cord-346842-ip4i3bdk	25	1	1	1	LS
cord-346842-ip4i3bdk	26	1	The	the	DT
cord-346842-ip4i3bdk	26	2	number	number	NN
cord-346842-ip4i3bdk	26	3	of	of	IN
cord-346842-ip4i3bdk	26	4	approved	approve	VBN
cord-346842-ip4i3bdk	26	5	clinical	clinical	JJ
cord-346842-ip4i3bdk	26	6	trials	trial	NNS
cord-346842-ip4i3bdk	26	7	for	for	IN
cord-346842-ip4i3bdk	26	8	medical	medical	JJ
cord-346842-ip4i3bdk	26	9	product	product	NN
cord-346842-ip4i3bdk	26	10	conducted	conduct	VBN
cord-346842-ip4i3bdk	26	11	in	in	IN
cord-346842-ip4i3bdk	26	12	Korea	Korea	NNP
cord-346842-ip4i3bdk	26	13	increased	increase	VBD
cord-346842-ip4i3bdk	26	14	from	from	IN
cord-346842-ip4i3bdk	26	15	143	143	CD
cord-346842-ip4i3bdk	26	16	cases	case	NNS
cord-346842-ip4i3bdk	26	17	in	in	IN
cord-346842-ip4i3bdk	26	18	2003	2003	CD
cord-346842-ip4i3bdk	26	19	to	to	IN
cord-346842-ip4i3bdk	26	20	679	679	CD
cord-346842-ip4i3bdk	26	21	in	in	IN
cord-346842-ip4i3bdk	26	22	2018	2018	CD
cord-346842-ip4i3bdk	26	23	.	.	.
cord-346842-ip4i3bdk	27	1	2	2	LS
cord-346842-ip4i3bdk	28	1	The	the	DT
cord-346842-ip4i3bdk	28	2	Ministry	Ministry	NNP
cord-346842-ip4i3bdk	28	3	of	of	IN
cord-346842-ip4i3bdk	28	4	Food	Food	NNP
cord-346842-ip4i3bdk	28	5	and	and	CC
cord-346842-ip4i3bdk	28	6	Drug	Drug	NNP
cord-346842-ip4i3bdk	28	7	Safety	Safety	NNP
cord-346842-ip4i3bdk	28	8	(	(	-LRB-
cord-346842-ip4i3bdk	28	9	MFDS	MFDS	NNP
cord-346842-ip4i3bdk	28	10	)	)	-RRB-
cord-346842-ip4i3bdk	28	11	has	have	VBZ
cord-346842-ip4i3bdk	28	12	reported	report	VBN
cord-346842-ip4i3bdk	28	13	an	an	DT
cord-346842-ip4i3bdk	28	14	increasing	increase	VBG
cord-346842-ip4i3bdk	28	15	trend	trend	NN
cord-346842-ip4i3bdk	28	16	of	of	IN
cord-346842-ip4i3bdk	28	17	trials	trial	NNS
cord-346842-ip4i3bdk	28	18	for	for	IN
cord-346842-ip4i3bdk	28	19	severe	severe	JJ
cord-346842-ip4i3bdk	28	20	and	and	CC
cord-346842-ip4i3bdk	28	21	rare	rare	JJ
cord-346842-ip4i3bdk	28	22	incurable	incurable	JJ
cord-346842-ip4i3bdk	28	23	diseases	disease	NNS
cord-346842-ip4i3bdk	28	24	.	.	.
cord-346842-ip4i3bdk	29	1	2	2	LS
cord-346842-ip4i3bdk	29	2	Anti	anti	JJ
cord-346842-ip4i3bdk	29	3	-	-	JJ
cord-346842-ip4i3bdk	29	4	cancer	cancer	JJ
cord-346842-ip4i3bdk	29	5	clinical	clinical	JJ
cord-346842-ip4i3bdk	29	6	trials	trial	NNS
cord-346842-ip4i3bdk	29	7	account	account	VBP
cord-346842-ip4i3bdk	29	8	for	for	IN
cord-346842-ip4i3bdk	29	9	36.4	36.4	CD
cord-346842-ip4i3bdk	29	10	%	%	NN
cord-346842-ip4i3bdk	29	11	of	of	IN
cord-346842-ip4i3bdk	29	12	all	all	DT
cord-346842-ip4i3bdk	29	13	clinical	clinical	JJ
cord-346842-ip4i3bdk	29	14	trials	trial	NNS
cord-346842-ip4i3bdk	29	15	,	,	,
cord-346842-ip4i3bdk	29	16	and	and	CC
cord-346842-ip4i3bdk	29	17	have	have	VBP
cord-346842-ip4i3bdk	29	18	been	be	VBN
cord-346842-ip4i3bdk	29	19	the	the	DT
cord-346842-ip4i3bdk	29	20	most	most	RBS
cord-346842-ip4i3bdk	29	21	common	common	JJ
cord-346842-ip4i3bdk	29	22	indication	indication	NN
cord-346842-ip4i3bdk	29	23	of	of	IN
cord-346842-ip4i3bdk	29	24	clinical	clinical	JJ
cord-346842-ip4i3bdk	29	25	trial	trial	NN
cord-346842-ip4i3bdk	29	26	for	for	IN
cord-346842-ip4i3bdk	29	27	3	3	CD
cord-346842-ip4i3bdk	29	28	consecutive	consecutive	JJ
cord-346842-ip4i3bdk	29	29	years	year	NNS
cord-346842-ip4i3bdk	29	30	.	.	.
cord-346842-ip4i3bdk	30	1	2	2	LS
cord-346842-ip4i3bdk	31	1	The	the	DT
cord-346842-ip4i3bdk	31	2	conduct	conduct	NN
cord-346842-ip4i3bdk	31	3	of	of	IN
cord-346842-ip4i3bdk	31	4	clinical	clinical	JJ
cord-346842-ip4i3bdk	31	5	trials	trial	NNS
cord-346842-ip4i3bdk	31	6	consists	consist	VBZ
cord-346842-ip4i3bdk	31	7	of	of	IN
cord-346842-ip4i3bdk	31	8	a	a	DT
cord-346842-ip4i3bdk	31	9	series	series	NN
cord-346842-ip4i3bdk	31	10	of	of	IN
cord-346842-ip4i3bdk	31	11	processes	process	NNS
cord-346842-ip4i3bdk	31	12	and	and	CC
cord-346842-ip4i3bdk	31	13	multiple	multiple	JJ
cord-346842-ip4i3bdk	31	14	parties	party	NNS
cord-346842-ip4i3bdk	31	15	are	be	VBP
cord-346842-ip4i3bdk	31	16	involved	involve	VBN
cord-346842-ip4i3bdk	31	17	in	in	IN
cord-346842-ip4i3bdk	31	18	the	the	DT
cord-346842-ip4i3bdk	31	19	overall	overall	JJ
cord-346842-ip4i3bdk	31	20	trial	trial	NN
cord-346842-ip4i3bdk	31	21	process	process	NN
cord-346842-ip4i3bdk	31	22	.	.	.
cord-346842-ip4i3bdk	32	1	3	3	LS
cord-346842-ip4i3bdk	33	1	Accordingly	accordingly	RB
cord-346842-ip4i3bdk	33	2	,	,	,
cord-346842-ip4i3bdk	33	3	face	face	VBP
cord-346842-ip4i3bdk	33	4	to	to	IN
cord-346842-ip4i3bdk	33	5	face	face	NN
cord-346842-ip4i3bdk	33	6	contact	contact	NN
cord-346842-ip4i3bdk	33	7	,	,	,
cord-346842-ip4i3bdk	33	8	meetings	meeting	NNS
cord-346842-ip4i3bdk	33	9	and	and	CC
cord-346842-ip4i3bdk	33	10	travel	travel	NN
cord-346842-ip4i3bdk	33	11	to	to	IN
cord-346842-ip4i3bdk	33	12	designated	designate	VBN
cord-346842-ip4i3bdk	33	13	places	place	NNS
cord-346842-ip4i3bdk	33	14	are	be	VBP
cord-346842-ip4i3bdk	33	15	required	require	VBN
cord-346842-ip4i3bdk	33	16	(	(	-LRB-
cord-346842-ip4i3bdk	33	17	Fig	Fig	NNP
cord-346842-ip4i3bdk	33	18	.	.	.
cord-346842-ip4i3bdk	33	19	1	1	CD
cord-346842-ip4i3bdk	33	20	)	)	-RRB-
cord-346842-ip4i3bdk	33	21	.	.	.
cord-346842-ip4i3bdk	34	1	Coronavirus	Coronavirus	NNP
cord-346842-ip4i3bdk	34	2	disease	disease	NN
cord-346842-ip4i3bdk	34	3	2019	2019	CD
cord-346842-ip4i3bdk	34	4	(	(	-LRB-
cord-346842-ip4i3bdk	34	5	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	34	6	)	)	-RRB-
cord-346842-ip4i3bdk	34	7	has	have	VBZ
cord-346842-ip4i3bdk	34	8	spread	spread	VBN
cord-346842-ip4i3bdk	34	9	globally	globally	RB
cord-346842-ip4i3bdk	34	10	since	since	IN
cord-346842-ip4i3bdk	34	11	the	the	DT
cord-346842-ip4i3bdk	34	12	first	first	JJ
cord-346842-ip4i3bdk	34	13	outbreak	outbreak	NN
cord-346842-ip4i3bdk	34	14	in	in	IN
cord-346842-ip4i3bdk	34	15	December	December	NNP
cord-346842-ip4i3bdk	34	16	2019	2019	CD
cord-346842-ip4i3bdk	34	17	from	from	IN
cord-346842-ip4i3bdk	34	18	Wuhan	Wuhan	NNP
cord-346842-ip4i3bdk	34	19	in	in	IN
cord-346842-ip4i3bdk	34	20	Hubei	Hubei	NNP
cord-346842-ip4i3bdk	34	21	Province	Province	NNP
cord-346842-ip4i3bdk	34	22	,	,	,
cord-346842-ip4i3bdk	34	23	China	China	NNP
cord-346842-ip4i3bdk	34	24	.	.	.
cord-346842-ip4i3bdk	35	1	4	4	LS
cord-346842-ip4i3bdk	36	1	The	the	DT
cord-346842-ip4i3bdk	36	2	first	first	JJ
cord-346842-ip4i3bdk	36	3	case	case	NN
cord-346842-ip4i3bdk	36	4	in	in	IN
cord-346842-ip4i3bdk	36	5	Korea	Korea	NNP
cord-346842-ip4i3bdk	36	6	was	be	VBD
cord-346842-ip4i3bdk	36	7	confirmed	confirm	VBN
cord-346842-ip4i3bdk	36	8	on	on	IN
cord-346842-ip4i3bdk	36	9	January	January	NNP
cord-346842-ip4i3bdk	36	10	20	20	CD
cord-346842-ip4i3bdk	36	11	,	,	,
cord-346842-ip4i3bdk	36	12	2020	2020	CD
cord-346842-ip4i3bdk	36	13	,	,	,
cord-346842-ip4i3bdk	36	14	in	in	IN
cord-346842-ip4i3bdk	36	15	an	an	DT
cord-346842-ip4i3bdk	36	16	individual	individual	NN
cord-346842-ip4i3bdk	36	17	who	who	WP
cord-346842-ip4i3bdk	36	18	entered	enter	VBD
cord-346842-ip4i3bdk	36	19	Korea	Korea	NNP
cord-346842-ip4i3bdk	36	20	from	from	IN
cord-346842-ip4i3bdk	36	21	Wuhan	Wuhan	NNP
cord-346842-ip4i3bdk	36	22	.	.	.
cord-346842-ip4i3bdk	36	23	4	4	CD
cord-346842-ip4i3bdk	37	1	Compared	compare	VBN
cord-346842-ip4i3bdk	37	2	to	to	IN
cord-346842-ip4i3bdk	37	3	previous	previous	JJ
cord-346842-ip4i3bdk	37	4	respiratory	respiratory	JJ
cord-346842-ip4i3bdk	37	5	syndrome	syndrome	NN
cord-346842-ip4i3bdk	37	6	,	,	,
cord-346842-ip4i3bdk	37	7	Middle	Middle	NNP
cord-346842-ip4i3bdk	37	8	East	East	NNP
cord-346842-ip4i3bdk	37	9	respiratory	respiratory	JJ
cord-346842-ip4i3bdk	37	10	syndrome	syndrome	NN
cord-346842-ip4i3bdk	37	11	(	(	-LRB-
cord-346842-ip4i3bdk	37	12	MERS	MERS	NNP
cord-346842-ip4i3bdk	37	13	)	)	-RRB-
cord-346842-ip4i3bdk	37	14	epidemic	epidemic	NN
cord-346842-ip4i3bdk	37	15	that	that	WDT
cord-346842-ip4i3bdk	37	16	occurred	occur	VBD
cord-346842-ip4i3bdk	37	17	in	in	IN
cord-346842-ip4i3bdk	37	18	2012	2012	CD
cord-346842-ip4i3bdk	37	19	-	-	SYM
cord-346842-ip4i3bdk	37	20	2015	2015	CD
cord-346842-ip4i3bdk	37	21	,	,	,
cord-346842-ip4i3bdk	37	22	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	37	23	had	have	VBD
cord-346842-ip4i3bdk	37	24	greater	great	JJR
cord-346842-ip4i3bdk	37	25	community	community	NN
cord-346842-ip4i3bdk	37	26	spread	spread	VB
cord-346842-ip4i3bdk	37	27	.	.	.
cord-346842-ip4i3bdk	38	1	5	5	LS
cord-346842-ip4i3bdk	39	1	The	the	DT
cord-346842-ip4i3bdk	39	2	first	first	JJ
cord-346842-ip4i3bdk	39	3	case	case	NN
cord-346842-ip4i3bdk	39	4	not	not	RB
cord-346842-ip4i3bdk	39	5	linked	link	VBN
cord-346842-ip4i3bdk	39	6	with	with	IN
cord-346842-ip4i3bdk	39	7	epidemiologic	epidemiologic	JJ
cord-346842-ip4i3bdk	39	8	evidence	evidence	NN
cord-346842-ip4i3bdk	39	9	,	,	,
cord-346842-ip4i3bdk	39	10	identified	identify	VBN
cord-346842-ip4i3bdk	39	11	on	on	IN
cord-346842-ip4i3bdk	39	12	February	February	NNP
cord-346842-ip4i3bdk	39	13	16	16	CD
cord-346842-ip4i3bdk	39	14	,	,	,
cord-346842-ip4i3bdk	39	15	2020	2020	CD
cord-346842-ip4i3bdk	39	16	,	,	,
cord-346842-ip4i3bdk	39	17	accelerated	accelerate	VBN
cord-346842-ip4i3bdk	39	18	increase	increase	NN
cord-346842-ip4i3bdk	39	19	in	in	IN
cord-346842-ip4i3bdk	39	20	the	the	DT
cord-346842-ip4i3bdk	39	21	number	number	NN
cord-346842-ip4i3bdk	39	22	of	of	IN
cord-346842-ip4i3bdk	39	23	confirmed	confirm	VBN
cord-346842-ip4i3bdk	39	24	cases	case	NNS
cord-346842-ip4i3bdk	39	25	due	due	JJ
cord-346842-ip4i3bdk	39	26	to	to	IN
cord-346842-ip4i3bdk	39	27	community	community	NN
cord-346842-ip4i3bdk	39	28	transmission	transmission	NN
cord-346842-ip4i3bdk	39	29	.	.	.
cord-346842-ip4i3bdk	40	1	4	4	LS
cord-346842-ip4i3bdk	41	1	The	the	DT
cord-346842-ip4i3bdk	41	2	Korea	Korea	NNP
cord-346842-ip4i3bdk	41	3	Centers	Centers	NNPS
cord-346842-ip4i3bdk	41	4	for	for	IN
cord-346842-ip4i3bdk	41	5	Disease	Disease	NNP
cord-346842-ip4i3bdk	41	6	Control	Control	NNP
cord-346842-ip4i3bdk	41	7	and	and	CC
cord-346842-ip4i3bdk	41	8	Prevention	Prevention	NNP
cord-346842-ip4i3bdk	41	9	(	(	-LRB-
cord-346842-ip4i3bdk	41	10	KCDC	KCDC	NNP
cord-346842-ip4i3bdk	41	11	)	)	-RRB-
cord-346842-ip4i3bdk	41	12	raised	raise	VBD
cord-346842-ip4i3bdk	41	13	the	the	DT
cord-346842-ip4i3bdk	41	14	disease	disease	NN
cord-346842-ip4i3bdk	41	15	alert	alert	JJ
cord-346842-ip4i3bdk	41	16	to	to	IN
cord-346842-ip4i3bdk	41	17	the	the	DT
cord-346842-ip4i3bdk	41	18	highest	high	JJS
cord-346842-ip4i3bdk	41	19	level	level	NN
cord-346842-ip4i3bdk	41	20	on	on	IN
cord-346842-ip4i3bdk	41	21	February	February	NNP
cord-346842-ip4i3bdk	41	22	23	23	CD
cord-346842-ip4i3bdk	41	23	,	,	,
cord-346842-ip4i3bdk	41	24	2020	2020	CD
cord-346842-ip4i3bdk	41	25	to	to	TO
cord-346842-ip4i3bdk	41	26	heighten	heighten	VB
cord-346842-ip4i3bdk	41	27	the	the	DT
cord-346842-ip4i3bdk	41	28	response	response	NN
cord-346842-ip4i3bdk	41	29	(	(	-LRB-
cord-346842-ip4i3bdk	41	30	Fig	Fig	NNP
cord-346842-ip4i3bdk	41	31	.	.	NNP
cord-346842-ip4i3bdk	41	32	2	2	CD
cord-346842-ip4i3bdk	41	33	)	)	-RRB-
cord-346842-ip4i3bdk	41	34	.	.	.
cord-346842-ip4i3bdk	42	1	4	4	LS
cord-346842-ip4i3bdk	43	1	As	as	IN
cord-346842-ip4i3bdk	43	2	there	there	EX
cord-346842-ip4i3bdk	43	3	was	be	VBD
cord-346842-ip4i3bdk	43	4	no	no	DT
cord-346842-ip4i3bdk	43	5	available	available	JJ
cord-346842-ip4i3bdk	43	6	treatment	treatment	NN
cord-346842-ip4i3bdk	43	7	approved	approve	VBN
cord-346842-ip4i3bdk	43	8	for	for	IN
cord-346842-ip4i3bdk	43	9	COVID	COVID	NNP
cord-346842-ip4i3bdk	43	10	-19	-19	NN
cord-346842-ip4i3bdk	43	11	in	in	IN
cord-346842-ip4i3bdk	43	12	Korea	Korea	NNP
cord-346842-ip4i3bdk	44	1	yet	yet	RB
cord-346842-ip4i3bdk	44	2	,	,	,
cord-346842-ip4i3bdk	44	3	the	the	DT
cord-346842-ip4i3bdk	44	4	government	government	NN
cord-346842-ip4i3bdk	44	5	emphasized	emphasize	VBD
cord-346842-ip4i3bdk	44	6	prevention	prevention	NN
cord-346842-ip4i3bdk	44	7	,	,	,
cord-346842-ip4i3bdk	44	8	to	to	TO
cord-346842-ip4i3bdk	44	9	avoid	avoid	VB
cord-346842-ip4i3bdk	44	10	the	the	DT
cord-346842-ip4i3bdk	44	11	spread	spread	NN
cord-346842-ip4i3bdk	44	12	of	of	IN
cord-346842-ip4i3bdk	44	13	infection	infection	NN
cord-346842-ip4i3bdk	44	14	.	.	.
cord-346842-ip4i3bdk	45	1	This	this	DT
cord-346842-ip4i3bdk	45	2	strategy	strategy	NN
cord-346842-ip4i3bdk	45	3	influenced	influence	VBN
cord-346842-ip4i3bdk	45	4	not	not	RB
cord-346842-ip4i3bdk	45	5	only	only	RB
cord-346842-ip4i3bdk	45	6	personal	personal	JJ
cord-346842-ip4i3bdk	45	7	lifestyles	lifestyle	NNS
cord-346842-ip4i3bdk	45	8	but	but	CC
cord-346842-ip4i3bdk	45	9	also	also	RB
cord-346842-ip4i3bdk	45	10	the	the	DT
cord-346842-ip4i3bdk	45	11	conduct	conduct	NN
cord-346842-ip4i3bdk	45	12	of	of	IN
cord-346842-ip4i3bdk	45	13	clinical	clinical	JJ
cord-346842-ip4i3bdk	45	14	trials	trial	NNS
cord-346842-ip4i3bdk	45	15	of	of	IN
cord-346842-ip4i3bdk	45	16	medical	medical	JJ
cord-346842-ip4i3bdk	45	17	products	product	NNS
cord-346842-ip4i3bdk	45	18	.	.	.
cord-346842-ip4i3bdk	46	1	There	there	EX
cord-346842-ip4i3bdk	46	2	were	be	VBD
cord-346842-ip4i3bdk	46	3	no	no	DT
cord-346842-ip4i3bdk	46	4	exceptions	exception	NNS
cord-346842-ip4i3bdk	46	5	made	make	VBN
cord-346842-ip4i3bdk	46	6	to	to	IN
cord-346842-ip4i3bdk	46	7	compliance	compliance	NN
cord-346842-ip4i3bdk	46	8	with	with	IN
cord-346842-ip4i3bdk	46	9	KCDC	KCDC	NNP
cord-346842-ip4i3bdk	46	10	guideline	guideline	NN
cord-346842-ip4i3bdk	46	11	when	when	WRB
cord-346842-ip4i3bdk	46	12	conducting	conduct	VBG
cord-346842-ip4i3bdk	46	13	clinical	clinical	JJ
cord-346842-ip4i3bdk	46	14	trials	trial	NNS
cord-346842-ip4i3bdk	46	15	,	,	,
cord-346842-ip4i3bdk	46	16	because	because	IN
cord-346842-ip4i3bdk	46	17	of	of	IN
cord-346842-ip4i3bdk	46	18	the	the	DT
cord-346842-ip4i3bdk	46	19	concern	concern	NN
cord-346842-ip4i3bdk	46	20	about	about	IN
cord-346842-ip4i3bdk	46	21	infection	infection	NN
cord-346842-ip4i3bdk	46	22	during	during	IN
cord-346842-ip4i3bdk	46	23	the	the	DT
cord-346842-ip4i3bdk	46	24	operation	operation	NN
cord-346842-ip4i3bdk	46	25	of	of	IN
cord-346842-ip4i3bdk	46	26	trial	trial	NN
cord-346842-ip4i3bdk	46	27	.	.	.
cord-346842-ip4i3bdk	47	1	The	the	DT
cord-346842-ip4i3bdk	47	2	guideline	guideline	NN
cord-346842-ip4i3bdk	47	3	called	call	VBD
cord-346842-ip4i3bdk	47	4	on	on	IN
cord-346842-ip4i3bdk	47	5	all	all	DT
cord-346842-ip4i3bdk	47	6	citizens	citizen	NNS
cord-346842-ip4i3bdk	47	7	to	to	TO
cord-346842-ip4i3bdk	47	8	maintain	maintain	VB
cord-346842-ip4i3bdk	47	9	social	social	JJ
cord-346842-ip4i3bdk	47	10	distancing	distancing	NN
cord-346842-ip4i3bdk	47	11	,	,	,
cord-346842-ip4i3bdk	47	12	refrain	refrain	VB
cord-346842-ip4i3bdk	47	13	from	from	IN
cord-346842-ip4i3bdk	47	14	visiting	visit	VBG
cord-346842-ip4i3bdk	47	15	crowded	crowded	JJ
cord-346842-ip4i3bdk	47	16	places	place	NNS
cord-346842-ip4i3bdk	47	17	and	and	CC
cord-346842-ip4i3bdk	47	18	reduce	reduce	VB
cord-346842-ip4i3bdk	47	19	gatherings	gathering	NNS
cord-346842-ip4i3bdk	47	20	as	as	RB
cord-346842-ip4i3bdk	47	21	well	well	RB
cord-346842-ip4i3bdk	47	22	as	as	IN
cord-346842-ip4i3bdk	47	23	outdoor	outdoor	JJ
cord-346842-ip4i3bdk	47	24	activities	activity	NNS
cord-346842-ip4i3bdk	47	25	.	.	.
cord-346842-ip4i3bdk	48	1	6	6	CD
cord-346842-ip4i3bdk	49	1	Conducting	conduct	VBG
cord-346842-ip4i3bdk	49	2	clinical	clinical	JJ
cord-346842-ip4i3bdk	49	3	trials	trial	NNS
cord-346842-ip4i3bdk	49	4	results	result	NNS
cord-346842-ip4i3bdk	49	5	in	in	IN
cord-346842-ip4i3bdk	49	6	an	an	DT
cord-346842-ip4i3bdk	49	7	increased	increase	VBN
cord-346842-ip4i3bdk	49	8	number	number	NN
cord-346842-ip4i3bdk	49	9	of	of	IN
cord-346842-ip4i3bdk	49	10	subject	subject	JJ
cord-346842-ip4i3bdk	49	11	visits	visit	NNS
cord-346842-ip4i3bdk	49	12	to	to	IN
cord-346842-ip4i3bdk	49	13	hospitals	hospital	NNS
cord-346842-ip4i3bdk	49	14	,	,	,
cord-346842-ip4i3bdk	49	15	face	face	VBP
cord-346842-ip4i3bdk	49	16	to	to	IN
cord-346842-ip4i3bdk	49	17	face	face	NN
cord-346842-ip4i3bdk	49	18	contact	contact	NN
cord-346842-ip4i3bdk	49	19	and	and	CC
cord-346842-ip4i3bdk	49	20	meetings	meeting	NNS
cord-346842-ip4i3bdk	49	21	.	.	.
cord-346842-ip4i3bdk	50	1	There	there	EX
cord-346842-ip4i3bdk	50	2	was	be	VBD
cord-346842-ip4i3bdk	50	3	thus	thus	RB
cord-346842-ip4i3bdk	50	4	a	a	DT
cord-346842-ip4i3bdk	50	5	conflict	conflict	NN
cord-346842-ip4i3bdk	50	6	between	between	IN
cord-346842-ip4i3bdk	50	7	being	be	VBG
cord-346842-ip4i3bdk	50	8	compliant	compliant	JJ
cord-346842-ip4i3bdk	50	9	with	with	IN
cord-346842-ip4i3bdk	50	10	the	the	DT
cord-346842-ip4i3bdk	50	11	KCDC	KCDC	NNP
cord-346842-ip4i3bdk	50	12	guideline	guideline	NN
cord-346842-ip4i3bdk	50	13	firmly	firmly	RB
cord-346842-ip4i3bdk	50	14	and	and	CC
cord-346842-ip4i3bdk	50	15	clinical	clinical	JJ
cord-346842-ip4i3bdk	50	16	trials	trial	NNS
cord-346842-ip4i3bdk	50	17	activities	activity	NNS
cord-346842-ip4i3bdk	50	18	,	,	,
cord-346842-ip4i3bdk	50	19	including	include	VBG
cord-346842-ip4i3bdk	50	20	encouraging	encourage	VBG
cord-346842-ip4i3bdk	50	21	subjects	subject	NNS
cord-346842-ip4i3bdk	50	22	'	'	POS
cord-346842-ip4i3bdk	50	23	continuous	continuous	JJ
cord-346842-ip4i3bdk	50	24	participation	participation	NN
cord-346842-ip4i3bdk	50	25	.	.	.
cord-346842-ip4i3bdk	51	1	New	new	JJ
cord-346842-ip4i3bdk	51	2	approaches	approach	NNS
cord-346842-ip4i3bdk	51	3	were	be	VBD
cord-346842-ip4i3bdk	51	4	necessary	necessary	JJ
cord-346842-ip4i3bdk	51	5	in	in	IN
cord-346842-ip4i3bdk	51	6	clinical	clinical	JJ
cord-346842-ip4i3bdk	51	7	trials	trial	NNS
cord-346842-ip4i3bdk	51	8	to	to	TO
cord-346842-ip4i3bdk	51	9	eliminate	eliminate	VB
cord-346842-ip4i3bdk	51	10	the	the	DT
cord-346842-ip4i3bdk	51	11	risk	risk	NN
cord-346842-ip4i3bdk	51	12	of	of	IN
cord-346842-ip4i3bdk	51	13	infection	infection	NN
cord-346842-ip4i3bdk	51	14	by	by	IN
cord-346842-ip4i3bdk	51	15	complying	comply	VBG
cord-346842-ip4i3bdk	51	16	with	with	IN
cord-346842-ip4i3bdk	51	17	the	the	DT
cord-346842-ip4i3bdk	51	18	guideline	guideline	NN
cord-346842-ip4i3bdk	51	19	and	and	CC
cord-346842-ip4i3bdk	51	20	enable	enable	VB
cord-346842-ip4i3bdk	51	21	subjects	subject	NNS
cord-346842-ip4i3bdk	51	22	to	to	TO
cord-346842-ip4i3bdk	51	23	continue	continue	VB
cord-346842-ip4i3bdk	51	24	to	to	TO
cord-346842-ip4i3bdk	51	25	participate	participate	VB
cord-346842-ip4i3bdk	51	26	in	in	IN
cord-346842-ip4i3bdk	51	27	trials	trial	NNS
cord-346842-ip4i3bdk	51	28	if	if	IN
cord-346842-ip4i3bdk	51	29	no	no	DT
cord-346842-ip4i3bdk	51	30	better	well	JJR
cord-346842-ip4i3bdk	51	31	alternative	alternative	JJ
cord-346842-ip4i3bdk	51	32	treatment	treatment	NN
cord-346842-ip4i3bdk	51	33	options	option	NNS
cord-346842-ip4i3bdk	51	34	were	be	VBD
cord-346842-ip4i3bdk	51	35	available	available	JJ
cord-346842-ip4i3bdk	51	36	,	,	,
cord-346842-ip4i3bdk	51	37	for	for	IN
cord-346842-ip4i3bdk	51	38	protecting	protect	VBG
cord-346842-ip4i3bdk	51	39	the	the	DT
cord-346842-ip4i3bdk	51	40	subjects	subject	NNS
cord-346842-ip4i3bdk	51	41	'	'	POS
cord-346842-ip4i3bdk	51	42	safety	safety	NN
cord-346842-ip4i3bdk	51	43	and	and	CC
cord-346842-ip4i3bdk	51	44	well	well	RB
cord-346842-ip4i3bdk	51	45	-	-	HYPH
cord-346842-ip4i3bdk	51	46	being	being	NN
cord-346842-ip4i3bdk	51	47	.	.	.
cord-346842-ip4i3bdk	52	1	The	the	DT
cord-346842-ip4i3bdk	52	2	impact	impact	NN
cord-346842-ip4i3bdk	52	3	of	of	IN
cord-346842-ip4i3bdk	52	4	the	the	DT
cord-346842-ip4i3bdk	52	5	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	52	6	pandemic	pandemic	NN
cord-346842-ip4i3bdk	52	7	has	have	VBZ
cord-346842-ip4i3bdk	52	8	not	not	RB
cord-346842-ip4i3bdk	52	9	been	be	VBN
cord-346842-ip4i3bdk	52	10	addressed	address	VBN
cord-346842-ip4i3bdk	52	11	on	on	IN
cord-346842-ip4i3bdk	52	12	clinical	clinical	JJ
cord-346842-ip4i3bdk	52	13	trials	trial	NNS
cord-346842-ip4i3bdk	52	14	in	in	IN
cord-346842-ip4i3bdk	52	15	Korea	Korea	NNP
cord-346842-ip4i3bdk	52	16	.	.	.
cord-346842-ip4i3bdk	53	1	The	the	DT
cord-346842-ip4i3bdk	53	2	study	study	NN
cord-346842-ip4i3bdk	53	3	evaluated	evaluate	VBD
cord-346842-ip4i3bdk	53	4	the	the	DT
cord-346842-ip4i3bdk	53	5	impact	impact	NN
cord-346842-ip4i3bdk	53	6	of	of	IN
cord-346842-ip4i3bdk	53	7	the	the	DT
cord-346842-ip4i3bdk	53	8	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	53	9	epidemic	epidemic	NN
cord-346842-ip4i3bdk	53	10	and	and	CC
cord-346842-ip4i3bdk	53	11	the	the	DT
cord-346842-ip4i3bdk	53	12	KCDC	KCDC	NNP
cord-346842-ip4i3bdk	53	13	disease	disease	NNP
cord-346842-ip4i3bdk	53	14	control	control	NNP
cord-346842-ip4i3bdk	53	15	guideline	guideline	NN
cord-346842-ip4i3bdk	53	16	on	on	IN
cord-346842-ip4i3bdk	53	17	the	the	DT
cord-346842-ip4i3bdk	53	18	conduct	conduct	NN
cord-346842-ip4i3bdk	53	19	of	of	IN
cord-346842-ip4i3bdk	53	20	clinical	clinical	JJ
cord-346842-ip4i3bdk	53	21	research	research	NN
cord-346842-ip4i3bdk	53	22	in	in	IN
cord-346842-ip4i3bdk	53	23	Korea	Korea	NNP
cord-346842-ip4i3bdk	53	24	,	,	,
cord-346842-ip4i3bdk	53	25	on	on	IN
cord-346842-ip4i3bdk	53	26	subjects	subject	NNS
cord-346842-ip4i3bdk	53	27	,	,	,
cord-346842-ip4i3bdk	53	28	investigators	investigator	NNS
cord-346842-ip4i3bdk	53	29	,	,	,
cord-346842-ip4i3bdk	53	30	monitor	monitor	NN
cord-346842-ip4i3bdk	53	31	,	,	,
cord-346842-ip4i3bdk	53	32	pharmaceutical	pharmaceutical	JJ
cord-346842-ip4i3bdk	53	33	companies	company	NNS
cord-346842-ip4i3bdk	53	34	,	,	,
cord-346842-ip4i3bdk	53	35	Institutional	Institutional	NNP
cord-346842-ip4i3bdk	53	36	Review	Review	NNP
cord-346842-ip4i3bdk	53	37	Boards	Boards	NNP
cord-346842-ip4i3bdk	53	38	(	(	-LRB-
cord-346842-ip4i3bdk	53	39	IRBs	irb	NNS
cord-346842-ip4i3bdk	53	40	)	)	-RRB-
cord-346842-ip4i3bdk	53	41	and	and	CC
cord-346842-ip4i3bdk	53	42	regulatory	regulatory	JJ
cord-346842-ip4i3bdk	53	43	authorities	authority	NNS
cord-346842-ip4i3bdk	53	44	(	(	-LRB-
cord-346842-ip4i3bdk	53	45	RAs	RAs	NNP
cord-346842-ip4i3bdk	53	46	)	)	-RRB-
cord-346842-ip4i3bdk	53	47	,	,	,
cord-346842-ip4i3bdk	53	48	in	in	IN
cord-346842-ip4i3bdk	53	49	order	order	NN
cord-346842-ip4i3bdk	53	50	to	to	TO
cord-346842-ip4i3bdk	53	51	suggest	suggest	VB
cord-346842-ip4i3bdk	53	52	recommendations	recommendation	NNS
cord-346842-ip4i3bdk	53	53	for	for	IN
cord-346842-ip4i3bdk	53	54	conducting	conduct	VBG
cord-346842-ip4i3bdk	53	55	clinical	clinical	JJ
cord-346842-ip4i3bdk	53	56	trials	trial	NNS
cord-346842-ip4i3bdk	53	57	during	during	IN
cord-346842-ip4i3bdk	53	58	the	the	DT
cord-346842-ip4i3bdk	53	59	pandemic	pandemic	NN
cord-346842-ip4i3bdk	53	60	.	.	.
cord-346842-ip4i3bdk	54	1	To	to	TO
cord-346842-ip4i3bdk	54	2	measure	measure	VB
cord-346842-ip4i3bdk	54	3	the	the	DT
cord-346842-ip4i3bdk	54	4	impact	impact	NN
cord-346842-ip4i3bdk	54	5	of	of	IN
cord-346842-ip4i3bdk	54	6	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	54	7	,	,	,
cord-346842-ip4i3bdk	54	8	the	the	DT
cord-346842-ip4i3bdk	54	9	study	study	NN
cord-346842-ip4i3bdk	54	10	selected	select	VBD
cord-346842-ip4i3bdk	54	11	individual	individual	JJ
cord-346842-ip4i3bdk	54	12	indicators	indicator	NNS
cord-346842-ip4i3bdk	54	13	for	for	IN
cord-346842-ip4i3bdk	54	14	each	each	DT
cord-346842-ip4i3bdk	54	15	involved	involve	VBN
cord-346842-ip4i3bdk	54	16	party	party	NN
cord-346842-ip4i3bdk	54	17	in	in	IN
cord-346842-ip4i3bdk	54	18	clinical	clinical	JJ
cord-346842-ip4i3bdk	54	19	trials	trial	NNS
cord-346842-ip4i3bdk	54	20	.	.	.
cord-346842-ip4i3bdk	55	1	To	to	TO
cord-346842-ip4i3bdk	55	2	evaluate	evaluate	VB
cord-346842-ip4i3bdk	55	3	the	the	DT
cord-346842-ip4i3bdk	55	4	impact	impact	NN
cord-346842-ip4i3bdk	55	5	on	on	IN
cord-346842-ip4i3bdk	55	6	subjects	subject	NNS
cord-346842-ip4i3bdk	55	7	'	'	POS
cord-346842-ip4i3bdk	55	8	study	study	NN
cord-346842-ip4i3bdk	55	9	visits	visit	NNS
cord-346842-ip4i3bdk	55	10	and	and	CC
cord-346842-ip4i3bdk	55	11	study	study	VB
cord-346842-ip4i3bdk	55	12	major	major	JJ
cord-346842-ip4i3bdk	55	13	milestones	milestone	NNS
cord-346842-ip4i3bdk	55	14	,	,	,
cord-346842-ip4i3bdk	55	15	a	a	DT
cord-346842-ip4i3bdk	55	16	questionnaire	questionnaire	NN
cord-346842-ip4i3bdk	55	17	was	be	VBD
cord-346842-ip4i3bdk	55	18	administered	administer	VBN
cord-346842-ip4i3bdk	55	19	.	.	.
cord-346842-ip4i3bdk	56	1	The	the	DT
cord-346842-ip4i3bdk	56	2	survey	survey	NN
cord-346842-ip4i3bdk	56	3	was	be	VBD
cord-346842-ip4i3bdk	56	4	distributed	distribute	VBN
cord-346842-ip4i3bdk	56	5	to	to	TO
cord-346842-ip4i3bdk	56	6	total	total	VB
cord-346842-ip4i3bdk	56	7	140	140	CD
cord-346842-ip4i3bdk	56	8	clinical	clinical	JJ
cord-346842-ip4i3bdk	56	9	project	project	NN
cord-346842-ip4i3bdk	56	10	manager	manager	NN
cord-346842-ip4i3bdk	56	11	(	(	-LRB-
cord-346842-ip4i3bdk	56	12	CPMs	CPMs	NNP
cord-346842-ip4i3bdk	56	13	)	)	-RRB-
cord-346842-ip4i3bdk	56	14	who	who	WP
cord-346842-ip4i3bdk	56	15	were	be	VBD
cord-346842-ip4i3bdk	56	16	working	work	VBG
cord-346842-ip4i3bdk	56	17	at	at	IN
cord-346842-ip4i3bdk	56	18	global	global	JJ
cord-346842-ip4i3bdk	56	19	clinical	clinical	JJ
cord-346842-ip4i3bdk	56	20	research	research	NN
cord-346842-ip4i3bdk	56	21	organization	organization	NN
cord-346842-ip4i3bdk	56	22	and	and	CC
cord-346842-ip4i3bdk	56	23	responsible	responsible	JJ
cord-346842-ip4i3bdk	56	24	for	for	IN
cord-346842-ip4i3bdk	56	25	trials	trial	NNS
cord-346842-ip4i3bdk	56	26	performed	perform	VBN
cord-346842-ip4i3bdk	56	27	in	in	IN
cord-346842-ip4i3bdk	56	28	Korea	Korea	NNP
cord-346842-ip4i3bdk	56	29	,	,	,
cord-346842-ip4i3bdk	56	30	according	accord	VBG
cord-346842-ip4i3bdk	56	31	to	to	IN
cord-346842-ip4i3bdk	56	32	method	method	NN
cord-346842-ip4i3bdk	56	33	of	of	IN
cord-346842-ip4i3bdk	56	34	simple	simple	JJ
cord-346842-ip4i3bdk	56	35	random	random	JJ
cord-346842-ip4i3bdk	56	36	sampling	sampling	NN
cord-346842-ip4i3bdk	56	37	from	from	IN
cord-346842-ip4i3bdk	56	38	February	February	NNP
cord-346842-ip4i3bdk	56	39	24	24	CD
cord-346842-ip4i3bdk	56	40	,	,	,
cord-346842-ip4i3bdk	56	41	2020	2020	CD
cord-346842-ip4i3bdk	56	42	to	to	IN
cord-346842-ip4i3bdk	56	43	March	March	NNP
cord-346842-ip4i3bdk	56	44	7	7	CD
cord-346842-ip4i3bdk	56	45	,	,	,
cord-346842-ip4i3bdk	56	46	2020	2020	CD
cord-346842-ip4i3bdk	56	47	.	.	.
cord-346842-ip4i3bdk	57	1	The	the	DT
cord-346842-ip4i3bdk	57	2	questionnaire	questionnaire	NN
cord-346842-ip4i3bdk	57	3	included	include	VBD
cord-346842-ip4i3bdk	57	4	questions	question	NNS
cord-346842-ip4i3bdk	57	5	on	on	IN
cord-346842-ip4i3bdk	57	6	whether	whether	IN
cord-346842-ip4i3bdk	57	7	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	57	8	had	have	VBD
cord-346842-ip4i3bdk	57	9	an	an	DT
cord-346842-ip4i3bdk	57	10	effect	effect	NN
cord-346842-ip4i3bdk	57	11	on	on	IN
cord-346842-ip4i3bdk	57	12	trial	trial	NN
cord-346842-ip4i3bdk	57	13	subjects	subject	NNS
cord-346842-ip4i3bdk	57	14	'	'	POS
cord-346842-ip4i3bdk	57	15	scheduled	scheduled	JJ
cord-346842-ip4i3bdk	57	16	study	study	NN
cord-346842-ip4i3bdk	57	17	visits	visit	NNS
cord-346842-ip4i3bdk	57	18	and	and	CC
cord-346842-ip4i3bdk	57	19	whether	whether	IN
cord-346842-ip4i3bdk	57	20	there	there	EX
cord-346842-ip4i3bdk	57	21	was	be	VBD
cord-346842-ip4i3bdk	57	22	any	any	DT
cord-346842-ip4i3bdk	57	23	major	major	JJ
cord-346842-ip4i3bdk	57	24	milestone	milestone	NN
cord-346842-ip4i3bdk	57	25	influenced	influence	VBN
cord-346842-ip4i3bdk	57	26	or	or	CC
cord-346842-ip4i3bdk	57	27	expected	expect	VBN
cord-346842-ip4i3bdk	57	28	to	to	TO
cord-346842-ip4i3bdk	57	29	be	be	VB
cord-346842-ip4i3bdk	57	30	delayed	delay	VBN
cord-346842-ip4i3bdk	57	31	by	by	IN
cord-346842-ip4i3bdk	57	32	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	57	33	.	.	.
cord-346842-ip4i3bdk	58	1	The	the	DT
cord-346842-ip4i3bdk	58	2	milestones	milestone	NNS
cord-346842-ip4i3bdk	58	3	could	could	MD
cord-346842-ip4i3bdk	58	4	be	be	VB
cord-346842-ip4i3bdk	58	5	described	describe	VBN
cord-346842-ip4i3bdk	58	6	by	by	IN
cord-346842-ip4i3bdk	58	7	the	the	DT
cord-346842-ip4i3bdk	58	8	CPMs	cpm	NNS
cord-346842-ip4i3bdk	58	9	and	and	CC
cord-346842-ip4i3bdk	58	10	in	in	IN
cord-346842-ip4i3bdk	58	11	the	the	DT
cord-346842-ip4i3bdk	58	12	process	process	NN
cord-346842-ip4i3bdk	58	13	of	of	IN
cord-346842-ip4i3bdk	58	14	data	datum	NNS
cord-346842-ip4i3bdk	58	15	analysis	analysis	NN
cord-346842-ip4i3bdk	58	16	,	,	,
cord-346842-ip4i3bdk	58	17	they	-PRON-	PRP
cord-346842-ip4i3bdk	58	18	were	be	VBD
cord-346842-ip4i3bdk	58	19	classified	classify	VBN
cord-346842-ip4i3bdk	58	20	as	as	IN
cord-346842-ip4i3bdk	58	21	site	site	NN
cord-346842-ip4i3bdk	58	22	initiation	initiation	NN
cord-346842-ip4i3bdk	58	23	,	,	,
cord-346842-ip4i3bdk	58	24	close	close	VB
cord-346842-ip4i3bdk	58	25	out	out	RB
cord-346842-ip4i3bdk	58	26	,	,	,
cord-346842-ip4i3bdk	58	27	first	first	JJ
cord-346842-ip4i3bdk	58	28	patients	patient	NNS
cord-346842-ip4i3bdk	58	29	in	in	IN
cord-346842-ip4i3bdk	58	30	/	/	SYM
cord-346842-ip4i3bdk	58	31	last	last	JJ
cord-346842-ip4i3bdk	58	32	patient	patient	NN
cord-346842-ip4i3bdk	58	33	in	in	IN
cord-346842-ip4i3bdk	58	34	/	/	SYM
cord-346842-ip4i3bdk	58	35	last	last	JJ
cord-346842-ip4i3bdk	58	36	patient	patient	NN
cord-346842-ip4i3bdk	58	37	out	out	RP
cord-346842-ip4i3bdk	58	38	,	,	,
cord-346842-ip4i3bdk	58	39	data	datum	NNS
cord-346842-ip4i3bdk	58	40	cleaning	cleaning	NN
cord-346842-ip4i3bdk	58	41	and	and	CC
cord-346842-ip4i3bdk	58	42	database	database	NN
cord-346842-ip4i3bdk	58	43	lock	lock	NN
cord-346842-ip4i3bdk	58	44	.	.	.
cord-346842-ip4i3bdk	59	1	If	if	IN
cord-346842-ip4i3bdk	59	2	a	a	DT
cord-346842-ip4i3bdk	59	3	CPM	CPM	NNP
cord-346842-ip4i3bdk	59	4	reported	report	VBD
cord-346842-ip4i3bdk	59	5	that	that	IN
cord-346842-ip4i3bdk	59	6	there	there	EX
cord-346842-ip4i3bdk	59	7	was	be	VBD
cord-346842-ip4i3bdk	59	8	an	an	DT
cord-346842-ip4i3bdk	59	9	impact	impact	NN
cord-346842-ip4i3bdk	59	10	on	on	IN
cord-346842-ip4i3bdk	59	11	the	the	DT
cord-346842-ip4i3bdk	59	12	milestone	milestone	NN
cord-346842-ip4i3bdk	59	13	however	however	RB
cord-346842-ip4i3bdk	59	14	did	do	VBD
cord-346842-ip4i3bdk	59	15	not	not	RB
cord-346842-ip4i3bdk	59	16	provide	provide	VB
cord-346842-ip4i3bdk	59	17	details	detail	NNS
cord-346842-ip4i3bdk	59	18	,	,	,
cord-346842-ip4i3bdk	59	19	they	-PRON-	PRP
cord-346842-ip4i3bdk	59	20	were	be	VBD
cord-346842-ip4i3bdk	59	21	contacted	contact	VBN
cord-346842-ip4i3bdk	59	22	to	to	TO
cord-346842-ip4i3bdk	59	23	try	try	VB
cord-346842-ip4i3bdk	59	24	to	to	TO
cord-346842-ip4i3bdk	59	25	obtain	obtain	VB
cord-346842-ip4i3bdk	59	26	further	further	JJ
cord-346842-ip4i3bdk	59	27	information	information	NN
cord-346842-ip4i3bdk	59	28	.	.	.
cord-346842-ip4i3bdk	60	1	If	if	IN
cord-346842-ip4i3bdk	60	2	response	response	NN
cord-346842-ip4i3bdk	60	3	was	be	VBD
cord-346842-ip4i3bdk	60	4	not	not	RB
cord-346842-ip4i3bdk	60	5	received	receive	VBN
cord-346842-ip4i3bdk	60	6	,	,	,
cord-346842-ip4i3bdk	60	7	the	the	DT
cord-346842-ip4i3bdk	60	8	impact	impact	NN
cord-346842-ip4i3bdk	60	9	was	be	VBD
cord-346842-ip4i3bdk	60	10	classified	classify	VBN
cord-346842-ip4i3bdk	60	11	as	as	IN
cord-346842-ip4i3bdk	60	12	not	not	RB
cord-346842-ip4i3bdk	60	13	specified	specify	VBN
cord-346842-ip4i3bdk	60	14	.	.	.
cord-346842-ip4i3bdk	61	1	The	the	DT
cord-346842-ip4i3bdk	61	2	impact	impact	NN
cord-346842-ip4i3bdk	61	3	of	of	IN
cord-346842-ip4i3bdk	61	4	the	the	DT
cord-346842-ip4i3bdk	61	5	policy	policy	NN
cord-346842-ip4i3bdk	61	6	by	by	IN
cord-346842-ip4i3bdk	61	7	trial	trial	NN
cord-346842-ip4i3bdk	61	8	sites	site	NNS
cord-346842-ip4i3bdk	61	9	on	on	IN
cord-346842-ip4i3bdk	61	10	monitor	monitor	NN
cord-346842-ip4i3bdk	61	11	's	's	POS
cord-346842-ip4i3bdk	61	12	access	access	NN
cord-346842-ip4i3bdk	61	13	to	to	IN
cord-346842-ip4i3bdk	61	14	monitoring	monitor	VBG
cord-346842-ip4i3bdk	61	15	room	room	NN
cord-346842-ip4i3bdk	61	16	and	and	CC
cord-346842-ip4i3bdk	61	17	site	site	NN
cord-346842-ip4i3bdk	61	18	initiation	initiation	NN
cord-346842-ip4i3bdk	61	19	was	be	VBD
cord-346842-ip4i3bdk	61	20	investigated	investigate	VBN
cord-346842-ip4i3bdk	61	21	by	by	IN
cord-346842-ip4i3bdk	61	22	contacting	contact	VBG
cord-346842-ip4i3bdk	61	23	clinical	clinical	JJ
cord-346842-ip4i3bdk	61	24	trial	trial	NN
cord-346842-ip4i3bdk	61	25	center	center	NN
cord-346842-ip4i3bdk	61	26	in	in	IN
cord-346842-ip4i3bdk	61	27	39	39	CD
cord-346842-ip4i3bdk	61	28	hospitals	hospital	NNS
cord-346842-ip4i3bdk	61	29	.	.	.
cord-346842-ip4i3bdk	62	1	Majority	majority	NN
cord-346842-ip4i3bdk	62	2	of	of	IN
cord-346842-ip4i3bdk	62	3	hospitals	hospital	NNS
cord-346842-ip4i3bdk	62	4	(	(	-LRB-
cord-346842-ip4i3bdk	62	5	95	95	CD
cord-346842-ip4i3bdk	62	6	%	%	NN
cord-346842-ip4i3bdk	62	7	)	)	-RRB-
cord-346842-ip4i3bdk	62	8	were	be	VBD
cord-346842-ip4i3bdk	62	9	selected	select	VBN
cord-346842-ip4i3bdk	62	10	in	in	IN
cord-346842-ip4i3bdk	62	11	Seoul	Seoul	NNP
cord-346842-ip4i3bdk	62	12	and	and	CC
cord-346842-ip4i3bdk	62	13	Gyeonggi	Gyeonggi	NNP
cord-346842-ip4i3bdk	62	14	-	-	HYPH
cord-346842-ip4i3bdk	62	15	do	do	VBP
cord-346842-ip4i3bdk	62	16	where	where	WRB
cord-346842-ip4i3bdk	62	17	clinical	clinical	JJ
cord-346842-ip4i3bdk	62	18	trials	trial	NNS
cord-346842-ip4i3bdk	62	19	were	be	VBD
cord-346842-ip4i3bdk	62	20	actively	actively	RB
cord-346842-ip4i3bdk	62	21	performed	perform	VBN
cord-346842-ip4i3bdk	62	22	in	in	IN
cord-346842-ip4i3bdk	62	23	Korea	Korea	NNP
cord-346842-ip4i3bdk	62	24	and	and	CC
cord-346842-ip4i3bdk	62	25	Gyeongsangbuk	Gyeongsangbuk	NNP
cord-346842-ip4i3bdk	62	26	-	-	:
cord-346842-ip4i3bdk	62	27	do	do	NNP
cord-346842-ip4i3bdk	62	28	and	and	CC
cord-346842-ip4i3bdk	62	29	Daegu	Daegu	NNP
cord-346842-ip4i3bdk	62	30	where	where	WRB
cord-346842-ip4i3bdk	62	31	high	high	JJ
cord-346842-ip4i3bdk	62	32	infection	infection	NN
cord-346842-ip4i3bdk	62	33	rate	rate	NN
cord-346842-ip4i3bdk	62	34	was	be	VBD
cord-346842-ip4i3bdk	62	35	shown	show	VBN
cord-346842-ip4i3bdk	62	36	.	.	.
cord-346842-ip4i3bdk	63	1	They	-PRON-	PRP
cord-346842-ip4i3bdk	63	2	were	be	VBD
cord-346842-ip4i3bdk	63	3	contacted	contact	VBN
cord-346842-ip4i3bdk	63	4	for	for	IN
cord-346842-ip4i3bdk	63	5	the	the	DT
cord-346842-ip4i3bdk	63	6	week	week	NN
cord-346842-ip4i3bdk	63	7	of	of	IN
cord-346842-ip4i3bdk	63	8	February	February	NNP
cord-346842-ip4i3bdk	63	9	24	24	CD
cord-346842-ip4i3bdk	63	10	,	,	,
cord-346842-ip4i3bdk	63	11	2020	2020	CD
cord-346842-ip4i3bdk	63	12	to	to	IN
cord-346842-ip4i3bdk	63	13	March	March	NNP
cord-346842-ip4i3bdk	63	14	1	1	CD
cord-346842-ip4i3bdk	63	15	,	,	,
cord-346842-ip4i3bdk	63	16	2020	2020	CD
cord-346842-ip4i3bdk	63	17	,	,	,
cord-346842-ip4i3bdk	63	18	when	when	WRB
cord-346842-ip4i3bdk	63	19	the	the	DT
cord-346842-ip4i3bdk	63	20	confirmed	confirm	VBN
cord-346842-ip4i3bdk	63	21	cases	case	NNS
cord-346842-ip4i3bdk	63	22	increased	increase	VBD
cord-346842-ip4i3bdk	63	23	dramatically	dramatically	RB
cord-346842-ip4i3bdk	63	24	and	and	CC
cord-346842-ip4i3bdk	63	25	the	the	DT
cord-346842-ip4i3bdk	63	26	week	week	NN
cord-346842-ip4i3bdk	63	27	of	of	IN
cord-346842-ip4i3bdk	63	28	April	April	NNP
cord-346842-ip4i3bdk	63	29	23	23	CD
cord-346842-ip4i3bdk	63	30	to	to	IN
cord-346842-ip4i3bdk	63	31	29	29	CD
cord-346842-ip4i3bdk	63	32	,	,	,
cord-346842-ip4i3bdk	63	33	2020	2020	CD
cord-346842-ip4i3bdk	63	34	,	,	,
cord-346842-ip4i3bdk	63	35	when	when	WRB
cord-346842-ip4i3bdk	63	36	the	the	DT
cord-346842-ip4i3bdk	63	37	daily	daily	NN
cord-346842-ip4i3bdk	63	38	confirmed	confirm	VBN
cord-346842-ip4i3bdk	63	39	cases	case	NNS
cord-346842-ip4i3bdk	63	40	decreased	decrease	VBD
cord-346842-ip4i3bdk	63	41	less	less	JJR
cord-346842-ip4i3bdk	63	42	than	than	IN
cord-346842-ip4i3bdk	63	43	10	10	CD
cord-346842-ip4i3bdk	63	44	in	in	IN
cord-346842-ip4i3bdk	63	45	Korea	Korea	NNP
cord-346842-ip4i3bdk	63	46	.	.	.
cord-346842-ip4i3bdk	64	1	The	the	DT
cord-346842-ip4i3bdk	64	2	response	response	NN
cord-346842-ip4i3bdk	64	3	on	on	IN
cord-346842-ip4i3bdk	64	4	the	the	DT
cord-346842-ip4i3bdk	64	5	access	access	NN
cord-346842-ip4i3bdk	64	6	of	of	IN
cord-346842-ip4i3bdk	64	7	monitor	monitor	NN
cord-346842-ip4i3bdk	64	8	was	be	VBD
cord-346842-ip4i3bdk	64	9	classified	classify	VBN
cord-346842-ip4i3bdk	64	10	as	as	IN
cord-346842-ip4i3bdk	64	11	total	total	JJ
cord-346842-ip4i3bdk	64	12	closure	closure	NN
cord-346842-ip4i3bdk	64	13	,	,	,
cord-346842-ip4i3bdk	64	14	partially	partially	RB
cord-346842-ip4i3bdk	64	15	available	available	JJ
cord-346842-ip4i3bdk	64	16	and	and	CC
cord-346842-ip4i3bdk	64	17	available	available	JJ
cord-346842-ip4i3bdk	64	18	,	,	,
cord-346842-ip4i3bdk	64	19	depending	depend	VBG
cord-346842-ip4i3bdk	64	20	on	on	IN
cord-346842-ip4i3bdk	64	21	the	the	DT
cord-346842-ip4i3bdk	64	22	degree	degree	NN
cord-346842-ip4i3bdk	64	23	of	of	IN
cord-346842-ip4i3bdk	64	24	access	access	NN
cord-346842-ip4i3bdk	64	25	that	that	WDT
cord-346842-ip4i3bdk	64	26	monitors	monitor	NNS
cord-346842-ip4i3bdk	64	27	were	be	VBD
cord-346842-ip4i3bdk	64	28	permitted	permit	VBN
cord-346842-ip4i3bdk	64	29	.	.	.
cord-346842-ip4i3bdk	65	1	The	the	DT
cord-346842-ip4i3bdk	65	2	official	official	JJ
cord-346842-ip4i3bdk	65	3	press	press	NN
cord-346842-ip4i3bdk	65	4	statement	statement	NN
cord-346842-ip4i3bdk	65	5	of	of	IN
cord-346842-ip4i3bdk	65	6	the	the	DT
cord-346842-ip4i3bdk	65	7	top	top	JJ
cord-346842-ip4i3bdk	65	8	25	25	CD
cord-346842-ip4i3bdk	65	9	pharmaceutical	pharmaceutical	JJ
cord-346842-ip4i3bdk	65	10	companies	company	NNS
cord-346842-ip4i3bdk	65	11	on	on	IN
cord-346842-ip4i3bdk	65	12	the	the	DT
cord-346842-ip4i3bdk	65	13	conduct	conduct	NN
cord-346842-ip4i3bdk	65	14	of	of	IN
cord-346842-ip4i3bdk	65	15	their	-PRON-	PRP$
cord-346842-ip4i3bdk	65	16	clinical	clinical	JJ
cord-346842-ip4i3bdk	65	17	trials	trial	NNS
cord-346842-ip4i3bdk	65	18	during	during	IN
cord-346842-ip4i3bdk	65	19	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	65	20	pandemic	pandemic	NN
cord-346842-ip4i3bdk	65	21	were	be	VBD
cord-346842-ip4i3bdk	65	22	reviewed	review	VBN
cord-346842-ip4i3bdk	65	23	in	in	IN
cord-346842-ip4i3bdk	65	24	April	April	NNP
cord-346842-ip4i3bdk	65	25	2020	2020	CD
cord-346842-ip4i3bdk	65	26	and	and	CC
cord-346842-ip4i3bdk	65	27	their	-PRON-	PRP$
cord-346842-ip4i3bdk	65	28	decision	decision	NN
cord-346842-ip4i3bdk	65	29	were	be	VBD
cord-346842-ip4i3bdk	65	30	classified	classify	VBN
cord-346842-ip4i3bdk	65	31	.	.	.
cord-346842-ip4i3bdk	66	1	7	7	CD
cord-346842-ip4i3bdk	66	2	 	 	_SP
cord-346842-ip4i3bdk	66	3	10,000	10,000	CD
cord-346842-ip4i3bdk	66	4	4,000	4,000	CD
cord-346842-ip4i3bdk	66	5	of	of	IN
cord-346842-ip4i3bdk	66	6	Health	Health	NNP
cord-346842-ip4i3bdk	66	7	were	be	VBD
cord-346842-ip4i3bdk	66	8	analyzed	analyze	VBN
cord-346842-ip4i3bdk	66	9	,	,	,
cord-346842-ip4i3bdk	66	10	during	during	IN
cord-346842-ip4i3bdk	66	11	the	the	DT
cord-346842-ip4i3bdk	66	12	week	week	NN
cord-346842-ip4i3bdk	66	13	of	of	IN
cord-346842-ip4i3bdk	66	14	June	June	NNP
cord-346842-ip4i3bdk	66	15	22	22	CD
cord-346842-ip4i3bdk	66	16	to	to	IN
cord-346842-ip4i3bdk	66	17	28	28	CD
cord-346842-ip4i3bdk	66	18	,	,	,
cord-346842-ip4i3bdk	66	19	2020	2020	CD
cord-346842-ip4i3bdk	66	20	,	,	,
cord-346842-ip4i3bdk	66	21	according	accord	VBG
cord-346842-ip4i3bdk	66	22	to	to	IN
cord-346842-ip4i3bdk	66	23	the	the	DT
cord-346842-ip4i3bdk	66	24	used	use	VBN
cord-346842-ip4i3bdk	66	25	investigational	investigational	JJ
cord-346842-ip4i3bdk	66	26	products	product	NNS
cord-346842-ip4i3bdk	66	27	,	,	,
cord-346842-ip4i3bdk	66	28	study	study	NN
cord-346842-ip4i3bdk	66	29	status	status	NN
cord-346842-ip4i3bdk	66	30	,	,	,
cord-346842-ip4i3bdk	66	31	phase	phase	NN
cord-346842-ip4i3bdk	66	32	and	and	CC
cord-346842-ip4i3bdk	66	33	initiating	initiate	VBG
cord-346842-ip4i3bdk	66	34	parties	party	NNS
cord-346842-ip4i3bdk	66	35	,	,	,
cord-346842-ip4i3bdk	66	36	using	use	VBG
cord-346842-ip4i3bdk	66	37	the	the	DT
cord-346842-ip4i3bdk	66	38	pivot	pivot	NN
cord-346842-ip4i3bdk	66	39	table	table	NN
cord-346842-ip4i3bdk	66	40	function	function	NN
cord-346842-ip4i3bdk	66	41	.	.	.
cord-346842-ip4i3bdk	67	1	8	8	CD
cord-346842-ip4i3bdk	67	2	,	,	,
cord-346842-ip4i3bdk	67	3	9	9	CD
cord-346842-ip4i3bdk	68	1	For	for	IN
cord-346842-ip4i3bdk	68	2	investigational	investigational	JJ
cord-346842-ip4i3bdk	68	3	products	product	NNS
cord-346842-ip4i3bdk	68	4	-	-	HYPH
cord-346842-ip4i3bdk	68	5	based	base	VBN
cord-346842-ip4i3bdk	68	6	analysis	analysis	NN
cord-346842-ip4i3bdk	68	7	,	,	,
cord-346842-ip4i3bdk	68	8	drug	drug	NN
cord-346842-ip4i3bdk	68	9	intervention	intervention	NN
cord-346842-ip4i3bdk	68	10	studies	study	NNS
cord-346842-ip4i3bdk	68	11	for	for	IN
cord-346842-ip4i3bdk	68	12	COVID-19	covid-19	CD
cord-346842-ip4i3bdk	68	13	from	from	IN
cord-346842-ip4i3bdk	68	14	both	both	DT
cord-346842-ip4i3bdk	68	15	database	database	NN
cord-346842-ip4i3bdk	68	16	were	be	VBD
cord-346842-ip4i3bdk	68	17	included	include	VBN
cord-346842-ip4i3bdk	68	18	.	.	.
cord-346842-ip4i3bdk	69	1	The	the	DT
cord-346842-ip4i3bdk	69	2	used	use	VBN
cord-346842-ip4i3bdk	69	3	drugs	drug	NNS
cord-346842-ip4i3bdk	69	4	in	in	IN
cord-346842-ip4i3bdk	69	5	each	each	DT
cord-346842-ip4i3bdk	69	6	arm	arm	NN
cord-346842-ip4i3bdk	69	7	of	of	IN
cord-346842-ip4i3bdk	69	8	individual	individual	JJ
cord-346842-ip4i3bdk	69	9	trial	trial	NN
cord-346842-ip4i3bdk	69	10	were	be	VBD
cord-346842-ip4i3bdk	69	11	classified	classify	VBN
cord-346842-ip4i3bdk	69	12	and	and	CC
cord-346842-ip4i3bdk	69	13	if	if	IN
cord-346842-ip4i3bdk	69	14	2	2	CD
cord-346842-ip4i3bdk	69	15	or	or	CC
cord-346842-ip4i3bdk	69	16	more	more	JJR
cord-346842-ip4i3bdk	69	17	products	product	NNS
cord-346842-ip4i3bdk	69	18	were	be	VBD
cord-346842-ip4i3bdk	69	19	being	be	VBG
cord-346842-ip4i3bdk	69	20	administered	administer	VBN
cord-346842-ip4i3bdk	69	21	in	in	IN
cord-346842-ip4i3bdk	69	22	the	the	DT
cord-346842-ip4i3bdk	69	23	same	same	JJ
cord-346842-ip4i3bdk	69	24	arm	arm	NN
cord-346842-ip4i3bdk	69	25	as	as	IN
cord-346842-ip4i3bdk	69	26	a	a	DT
cord-346842-ip4i3bdk	69	27	combination	combination	NN
cord-346842-ip4i3bdk	69	28	,	,	,
cord-346842-ip4i3bdk	69	29	each	each	DT
cord-346842-ip4i3bdk	69	30	product	product	NN
cord-346842-ip4i3bdk	69	31	was	be	VBD
cord-346842-ip4i3bdk	69	32	counted	count	VBN
cord-346842-ip4i3bdk	69	33	separately	separately	RB
cord-346842-ip4i3bdk	69	34	.	.	.
cord-346842-ip4i3bdk	70	1	Of	of	IN
cord-346842-ip4i3bdk	70	2	140	140	CD
cord-346842-ip4i3bdk	70	3	CPMs	cpm	NNS
cord-346842-ip4i3bdk	70	4	,	,	,
cord-346842-ip4i3bdk	70	5	survey	survey	NN
cord-346842-ip4i3bdk	70	6	was	be	VBD
cord-346842-ip4i3bdk	70	7	retrieved	retrieve	VBN
cord-346842-ip4i3bdk	70	8	from	from	IN
cord-346842-ip4i3bdk	70	9	total	total	JJ
cord-346842-ip4i3bdk	70	10	105	105	CD
cord-346842-ip4i3bdk	70	11	(	(	-LRB-
cord-346842-ip4i3bdk	70	12	75	75	CD
cord-346842-ip4i3bdk	70	13	%	%	NN
cord-346842-ip4i3bdk	70	14	)	)	-RRB-
cord-346842-ip4i3bdk	70	15	.	.	.
cord-346842-ip4i3bdk	71	1	Of	of	IN
cord-346842-ip4i3bdk	71	2	105	105	CD
cord-346842-ip4i3bdk	71	3	respondents	respondent	NNS
cord-346842-ip4i3bdk	71	4	,	,	,
cord-346842-ip4i3bdk	71	5	84	84	CD
cord-346842-ip4i3bdk	71	6	CPMs	cpm	NNS
cord-346842-ip4i3bdk	71	7	provided	provide	VBD
cord-346842-ip4i3bdk	71	8	valid	valid	JJ
cord-346842-ip4i3bdk	71	9	answer	answer	NN
cord-346842-ip4i3bdk	71	10	on	on	IN
cord-346842-ip4i3bdk	71	11	the	the	DT
cord-346842-ip4i3bdk	71	12	question	question	NN
cord-346842-ip4i3bdk	71	13	about	about	IN
cord-346842-ip4i3bdk	71	14	the	the	DT
cord-346842-ip4i3bdk	71	15	impact	impact	NN
cord-346842-ip4i3bdk	71	16	of	of	IN
cord-346842-ip4i3bdk	71	17	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	71	18	on	on	IN
cord-346842-ip4i3bdk	71	19	subject	subject	JJ
cord-346842-ip4i3bdk	71	20	study	study	NN
cord-346842-ip4i3bdk	71	21	visits	visit	NNS
cord-346842-ip4i3bdk	71	22	in	in	IN
cord-346842-ip4i3bdk	71	23	Korea	Korea	NNP
cord-346842-ip4i3bdk	71	24	and	and	CC
cord-346842-ip4i3bdk	71	25	others	other	NNS
cord-346842-ip4i3bdk	71	26	left	leave	VBD
cord-346842-ip4i3bdk	71	27	it	-PRON-	PRP
cord-346842-ip4i3bdk	71	28	blank	blank	JJ
cord-346842-ip4i3bdk	71	29	.	.	.
cord-346842-ip4i3bdk	72	1	Of	of	IN
cord-346842-ip4i3bdk	72	2	84	84	CD
cord-346842-ip4i3bdk	72	3	CPMs	cpm	NNS
cord-346842-ip4i3bdk	72	4	,	,	,
cord-346842-ip4i3bdk	72	5	12	12	CD
cord-346842-ip4i3bdk	72	6	%	%	NN
cord-346842-ip4i3bdk	72	7	reported	report	VBD
cord-346842-ip4i3bdk	72	8	that	that	IN
cord-346842-ip4i3bdk	72	9	they	-PRON-	PRP
cord-346842-ip4i3bdk	72	10	had	have	VBD
cord-346842-ip4i3bdk	72	11	an	an	DT
cord-346842-ip4i3bdk	72	12	impact	impact	NN
cord-346842-ip4i3bdk	72	13	of	of	IN
cord-346842-ip4i3bdk	72	14	COVID-19	covid-19	CD
cord-346842-ip4i3bdk	72	15	in	in	IN
cord-346842-ip4i3bdk	72	16	their	-PRON-	PRP$
cord-346842-ip4i3bdk	72	17	project	project	NN
cord-346842-ip4i3bdk	72	18	,	,	,
cord-346842-ip4i3bdk	72	19	55	55	CD
cord-346842-ip4i3bdk	72	20	%	%	NN
cord-346842-ip4i3bdk	72	21	reported	report	VBD
cord-346842-ip4i3bdk	72	22	there	there	EX
cord-346842-ip4i3bdk	72	23	was	be	VBD
cord-346842-ip4i3bdk	72	24	no	no	DT
cord-346842-ip4i3bdk	72	25	impact	impact	NN
cord-346842-ip4i3bdk	72	26	on	on	IN
cord-346842-ip4i3bdk	72	27	the	the	DT
cord-346842-ip4i3bdk	72	28	subject	subject	JJ
cord-346842-ip4i3bdk	72	29	visits	visit	NNS
cord-346842-ip4i3bdk	72	30	,	,	,
cord-346842-ip4i3bdk	72	31	29	29	CD
cord-346842-ip4i3bdk	72	32	%	%	NN
cord-346842-ip4i3bdk	72	33	reported	report	VBD
cord-346842-ip4i3bdk	72	34	that	that	IN
cord-346842-ip4i3bdk	72	35	they	-PRON-	PRP
cord-346842-ip4i3bdk	72	36	had	have	VBD
cord-346842-ip4i3bdk	72	37	no	no	DT
cord-346842-ip4i3bdk	72	38	planned	plan	VBN
cord-346842-ip4i3bdk	72	39	subject	subject	NN
cord-346842-ip4i3bdk	72	40	's	's	POS
cord-346842-ip4i3bdk	72	41	visit	visit	NN
cord-346842-ip4i3bdk	72	42	during	during	IN
cord-346842-ip4i3bdk	72	43	the	the	DT
cord-346842-ip4i3bdk	72	44	survey	survey	NN
cord-346842-ip4i3bdk	72	45	period	period	NN
cord-346842-ip4i3bdk	73	1	so	so	IN
cord-346842-ip4i3bdk	73	2	the	the	DT
cord-346842-ip4i3bdk	73	3	impact	impact	NN
cord-346842-ip4i3bdk	73	4	could	could	MD
cord-346842-ip4i3bdk	73	5	not	not	RB
cord-346842-ip4i3bdk	73	6	be	be	VB
cord-346842-ip4i3bdk	73	7	estimated	estimate	VBN
cord-346842-ip4i3bdk	73	8	,	,	,
cord-346842-ip4i3bdk	73	9	and	and	CC
cord-346842-ip4i3bdk	73	10	4	4	CD
cord-346842-ip4i3bdk	73	11	%	%	NN
cord-346842-ip4i3bdk	73	12	reported	report	VBD
cord-346842-ip4i3bdk	73	13	that	that	IN
cord-346842-ip4i3bdk	73	14	they	-PRON-	PRP
cord-346842-ip4i3bdk	73	15	did	do	VBD
cord-346842-ip4i3bdk	73	16	n't	not	RB
cord-346842-ip4i3bdk	73	17	have	have	VB
cord-346842-ip4i3bdk	73	18	active	active	JJ
cord-346842-ip4i3bdk	73	19	subjects	subject	NNS
cord-346842-ip4i3bdk	73	20	in	in	IN
cord-346842-ip4i3bdk	73	21	Korea	Korea	NNP
cord-346842-ip4i3bdk	73	22	at	at	IN
cord-346842-ip4i3bdk	73	23	the	the	DT
cord-346842-ip4i3bdk	73	24	time	time	NN
cord-346842-ip4i3bdk	73	25	of	of	IN
cord-346842-ip4i3bdk	73	26	survey	survey	NN
cord-346842-ip4i3bdk	73	27	,	,	,
cord-346842-ip4i3bdk	73	28	because	because	IN
cord-346842-ip4i3bdk	73	29	recruitment	recruitment	NN
cord-346842-ip4i3bdk	73	30	was	be	VBD
cord-346842-ip4i3bdk	73	31	not	not	RB
cord-346842-ip4i3bdk	73	32	initiated	initiate	VBN
cord-346842-ip4i3bdk	73	33	,	,	,
cord-346842-ip4i3bdk	73	34	or	or	CC
cord-346842-ip4i3bdk	73	35	all	all	DT
cord-346842-ip4i3bdk	73	36	subject	subject	JJ
cord-346842-ip4i3bdk	73	37	visits	visit	NNS
cord-346842-ip4i3bdk	73	38	were	be	VBD
cord-346842-ip4i3bdk	73	39	already	already	RB
cord-346842-ip4i3bdk	73	40	completed	complete	VBN
cord-346842-ip4i3bdk	73	41	(	(	-LRB-
cord-346842-ip4i3bdk	74	1	Fig	Fig	NNP
cord-346842-ip4i3bdk	74	2	.	.	NNP
cord-346842-ip4i3bdk	74	3	3	3	CD
cord-346842-ip4i3bdk	74	4	)	)	-RRB-
cord-346842-ip4i3bdk	74	5	.	.	.
cord-346842-ip4i3bdk	75	1	The	the	DT
cord-346842-ip4i3bdk	75	2	confirmed	confirmed	JJ
cord-346842-ip4i3bdk	75	3	reason	reason	NN
cord-346842-ip4i3bdk	75	4	was	be	VBD
cord-346842-ip4i3bdk	75	5	that	that	IN
cord-346842-ip4i3bdk	75	6	hospitals	hospital	NNS
cord-346842-ip4i3bdk	75	7	started	start	VBD
cord-346842-ip4i3bdk	75	8	restricting	restrict	VBG
cord-346842-ip4i3bdk	75	9	patient	patient	NN
cord-346842-ip4i3bdk	75	10	's	's	POS
cord-346842-ip4i3bdk	75	11	physical	physical	JJ
cord-346842-ip4i3bdk	75	12	visit	visit	NN
cord-346842-ip4i3bdk	75	13	from	from	IN
cord-346842-ip4i3bdk	75	14	2	2	CD
cord-346842-ip4i3bdk	75	15	local	local	JJ
cord-346842-ip4i3bdk	75	16	cluster	cluster	NN
cord-346842-ip4i3bdk	75	17	,	,	,
cord-346842-ip4i3bdk	75	18	Daegu	Daegu	NNP
cord-346842-ip4i3bdk	75	19	and	and	CC
cord-346842-ip4i3bdk	75	20	Gyeongsangbuk	Gyeongsangbuk	NNP
cord-346842-ip4i3bdk	75	21	-	-	HYPH
cord-346842-ip4i3bdk	75	22	do	do	NNP
cord-346842-ip4i3bdk	75	23	,	,	,
cord-346842-ip4i3bdk	75	24	with	with	IN
cord-346842-ip4i3bdk	75	25	the	the	DT
cord-346842-ip4i3bdk	75	26	highest	high	JJS
cord-346842-ip4i3bdk	75	27	infection	infection	NN
cord-346842-ip4i3bdk	75	28	rates	rate	NNS
cord-346842-ip4i3bdk	75	29	,	,	,
cord-346842-ip4i3bdk	75	30	89.7	89.7	CD
cord-346842-ip4i3bdk	75	31	%	%	NN
cord-346842-ip4i3bdk	75	32	in	in	IN
cord-346842-ip4i3bdk	75	33	Korea	Korea	NNP
cord-346842-ip4i3bdk	75	34	,	,	,
cord-346842-ip4i3bdk	75	35	while	while	IN
cord-346842-ip4i3bdk	75	36	Seoul	Seoul	NNP
cord-346842-ip4i3bdk	75	37	had	have	VBD
cord-346842-ip4i3bdk	75	38	a	a	DT
cord-346842-ip4i3bdk	75	39	1.8	1.8	CD
cord-346842-ip4i3bdk	75	40	%	%	NN
cord-346842-ip4i3bdk	75	41	infection	infection	NN
cord-346842-ip4i3bdk	75	42	rate	rate	NN
cord-346842-ip4i3bdk	75	43	at	at	IN
cord-346842-ip4i3bdk	75	44	the	the	DT
cord-346842-ip4i3bdk	75	45	time	time	NN
cord-346842-ip4i3bdk	75	46	of	of	IN
cord-346842-ip4i3bdk	75	47	the	the	DT
cord-346842-ip4i3bdk	75	48	survey	survey	NN
cord-346842-ip4i3bdk	75	49	.	.	.
cord-346842-ip4i3bdk	76	1	10	10	CD
cord-346842-ip4i3bdk	77	1	The	the	DT
cord-346842-ip4i3bdk	77	2	number	number	NN
cord-346842-ip4i3bdk	77	3	of	of	IN
cord-346842-ip4i3bdk	77	4	outpatients	outpatient	NNS
cord-346842-ip4i3bdk	77	5	visiting	visit	VBG
cord-346842-ip4i3bdk	77	6	hospitals	hospital	NNS
cord-346842-ip4i3bdk	77	7	was	be	VBD
cord-346842-ip4i3bdk	77	8	lower	low	JJR
cord-346842-ip4i3bdk	77	9	during	during	IN
cord-346842-ip4i3bdk	77	10	the	the	DT
cord-346842-ip4i3bdk	77	11	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	77	12	epidemic	epidemic	NN
cord-346842-ip4i3bdk	77	13	that	that	WDT
cord-346842-ip4i3bdk	77	14	in	in	IN
cord-346842-ip4i3bdk	77	15	the	the	DT
cord-346842-ip4i3bdk	77	16	corresponding	corresponding	JJ
cord-346842-ip4i3bdk	77	17	period	period	NN
cord-346842-ip4i3bdk	77	18	in	in	IN
cord-346842-ip4i3bdk	77	19	2019	2019	CD
cord-346842-ip4i3bdk	77	20	and	and	CC
cord-346842-ip4i3bdk	77	21	there	there	EX
cord-346842-ip4i3bdk	77	22	were	be	VBD
cord-346842-ip4i3bdk	77	23	some	some	DT
cord-346842-ip4i3bdk	77	24	trial	trial	NN
cord-346842-ip4i3bdk	77	25	subjects	subject	NNS
cord-346842-ip4i3bdk	77	26	who	who	WP
cord-346842-ip4i3bdk	77	27	requested	request	VBD
cord-346842-ip4i3bdk	77	28	to	to	TO
cord-346842-ip4i3bdk	77	29	postpone	postpone	VB
cord-346842-ip4i3bdk	77	30	hospitals	hospital	NNS
cord-346842-ip4i3bdk	77	31	visits	visit	NNS
cord-346842-ip4i3bdk	77	32	because	because	IN
cord-346842-ip4i3bdk	77	33	of	of	IN
cord-346842-ip4i3bdk	77	34	concern	concern	NN
cord-346842-ip4i3bdk	77	35	about	about	IN
cord-346842-ip4i3bdk	77	36	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	77	37	.	.	.
cord-346842-ip4i3bdk	77	38	11	11	CD
cord-346842-ip4i3bdk	78	1	Of	of	IN
cord-346842-ip4i3bdk	78	2	total	total	JJ
cord-346842-ip4i3bdk	78	3	39	39	CD
cord-346842-ip4i3bdk	78	4	sites	site	NNS
cord-346842-ip4i3bdk	78	5	contacted	contact	VBN
cord-346842-ip4i3bdk	78	6	,	,	,
cord-346842-ip4i3bdk	78	7	during	during	IN
cord-346842-ip4i3bdk	78	8	the	the	DT
cord-346842-ip4i3bdk	78	9	week	week	NN
cord-346842-ip4i3bdk	78	10	of	of	IN
cord-346842-ip4i3bdk	78	11	February	February	NNP
cord-346842-ip4i3bdk	78	12	24	24	CD
cord-346842-ip4i3bdk	78	13	,	,	,
cord-346842-ip4i3bdk	78	14	2020	2020	CD
cord-346842-ip4i3bdk	78	15	to	to	IN
cord-346842-ip4i3bdk	78	16	March	March	NNP
cord-346842-ip4i3bdk	78	17	1	1	CD
cord-346842-ip4i3bdk	78	18	,	,	,
cord-346842-ip4i3bdk	78	19	2020	2020	CD
cord-346842-ip4i3bdk	78	20	,	,	,
cord-346842-ip4i3bdk	78	21	all	all	DT
cord-346842-ip4i3bdk	78	22	sites	site	NNS
cord-346842-ip4i3bdk	78	23	(	(	-LRB-
cord-346842-ip4i3bdk	78	24	100	100	CD
cord-346842-ip4i3bdk	78	25	%	%	NN
cord-346842-ip4i3bdk	78	26	)	)	-RRB-
cord-346842-ip4i3bdk	78	27	restricted	restrict	VBN
cord-346842-ip4i3bdk	78	28	external	external	JJ
cord-346842-ip4i3bdk	78	29	visitor	visitor	NN
cord-346842-ip4i3bdk	78	30	's	's	POS
cord-346842-ip4i3bdk	78	31	access	access	NN
cord-346842-ip4i3bdk	78	32	to	to	IN
cord-346842-ip4i3bdk	78	33	the	the	DT
cord-346842-ip4i3bdk	78	34	hospital	hospital	NN
cord-346842-ip4i3bdk	78	35	,	,	,
cord-346842-ip4i3bdk	78	36	including	include	VBG
cord-346842-ip4i3bdk	78	37	that	that	DT
cord-346842-ip4i3bdk	78	38	of	of	IN
cord-346842-ip4i3bdk	78	39	monitors	monitor	NNS
cord-346842-ip4i3bdk	78	40	.	.	.
cord-346842-ip4i3bdk	79	1	Four	four	CD
cord-346842-ip4i3bdk	79	2	of	of	IN
cord-346842-ip4i3bdk	79	3	the	the	DT
cord-346842-ip4i3bdk	79	4	sites	site	NNS
cord-346842-ip4i3bdk	79	5	(	(	-LRB-
cord-346842-ip4i3bdk	79	6	10	10	CD
cord-346842-ip4i3bdk	79	7	%	%	NN
cord-346842-ip4i3bdk	79	8	)	)	-RRB-
cord-346842-ip4i3bdk	79	9	allowed	allow	VBN
cord-346842-ip4i3bdk	79	10	only	only	RB
cord-346842-ip4i3bdk	79	11	urgent	urgent	JJ
cord-346842-ip4i3bdk	79	12	monitoring	monitoring	NN
cord-346842-ip4i3bdk	79	13	to	to	TO
cord-346842-ip4i3bdk	79	14	comply	comply	VB
cord-346842-ip4i3bdk	79	15	with	with	IN
cord-346842-ip4i3bdk	79	16	the	the	DT
cord-346842-ip4i3bdk	79	17	KCDC	KCDC	NNP
cord-346842-ip4i3bdk	79	18	guideline	guideline	NN
cord-346842-ip4i3bdk	79	19	.	.	.
cord-346842-ip4i3bdk	80	1	For	for	IN
cord-346842-ip4i3bdk	80	2	the	the	DT
cord-346842-ip4i3bdk	80	3	week	week	NN
cord-346842-ip4i3bdk	80	4	of	of	IN
cord-346842-ip4i3bdk	80	5	April	April	NNP
cord-346842-ip4i3bdk	80	6	24	24	CD
cord-346842-ip4i3bdk	80	7	to	to	IN
cord-346842-ip4i3bdk	80	8	30	30	CD
cord-346842-ip4i3bdk	80	9	,	,	,
cord-346842-ip4i3bdk	80	10	2020	2020	CD
cord-346842-ip4i3bdk	80	11	,	,	,
cord-346842-ip4i3bdk	80	12	as	as	IN
cord-346842-ip4i3bdk	80	13	the	the	DT
cord-346842-ip4i3bdk	80	14	number	number	NN
cord-346842-ip4i3bdk	80	15	of	of	IN
cord-346842-ip4i3bdk	80	16	daily	daily	JJ
cord-346842-ip4i3bdk	80	17	confirmed	confirm	VBN
cord-346842-ip4i3bdk	80	18	cases	case	NNS
cord-346842-ip4i3bdk	80	19	decreased	decrease	VBD
cord-346842-ip4i3bdk	80	20	,	,	,
cord-346842-ip4i3bdk	80	21	sites	site	NNS
cord-346842-ip4i3bdk	80	22	started	start	VBD
cord-346842-ip4i3bdk	80	23	opening	open	VBG
cord-346842-ip4i3bdk	80	24	the	the	DT
cord-346842-ip4i3bdk	80	25	monitoring	monitor	VBG
cord-346842-ip4i3bdk	80	26	rooms	room	NNS
cord-346842-ip4i3bdk	80	27	again	again	RB
cord-346842-ip4i3bdk	80	28	.	.	.
cord-346842-ip4i3bdk	81	1	Of	of	IN
cord-346842-ip4i3bdk	81	2	39	39	CD
cord-346842-ip4i3bdk	81	3	sites	site	NNS
cord-346842-ip4i3bdk	81	4	,	,	,
cord-346842-ip4i3bdk	81	5	20	20	CD
cord-346842-ip4i3bdk	81	6	(	(	-LRB-
cord-346842-ip4i3bdk	81	7	51	51	CD
cord-346842-ip4i3bdk	81	8	%	%	NN
cord-346842-ip4i3bdk	81	9	)	)	-RRB-
cord-346842-ip4i3bdk	81	10	partially	partially	RB
cord-346842-ip4i3bdk	81	11	opened	open	VBD
cord-346842-ip4i3bdk	81	12	the	the	DT
cord-346842-ip4i3bdk	81	13	room	room	NN
cord-346842-ip4i3bdk	81	14	with	with	IN
cord-346842-ip4i3bdk	81	15	only	only	RB
cord-346842-ip4i3bdk	81	16	limited	limited	JJ
cord-346842-ip4i3bdk	81	17	seats	seat	NNS
cord-346842-ip4i3bdk	81	18	available	available	JJ
cord-346842-ip4i3bdk	81	19	to	to	TO
cord-346842-ip4i3bdk	81	20	maintain	maintain	VB
cord-346842-ip4i3bdk	81	21	social	social	JJ
cord-346842-ip4i3bdk	81	22	distancing	distancing	NN
cord-346842-ip4i3bdk	81	23	,	,	,
cord-346842-ip4i3bdk	81	24	9	9	CD
cord-346842-ip4i3bdk	81	25	(	(	-LRB-
cord-346842-ip4i3bdk	81	26	23	23	CD
cord-346842-ip4i3bdk	81	27	%	%	NN
cord-346842-ip4i3bdk	81	28	)	)	-RRB-
cord-346842-ip4i3bdk	81	29	made	make	VBD
cord-346842-ip4i3bdk	81	30	the	the	DT
cord-346842-ip4i3bdk	81	31	room	room	NN
cord-346842-ip4i3bdk	81	32	available	available	JJ
cord-346842-ip4i3bdk	81	33	,	,	,
cord-346842-ip4i3bdk	81	34	and	and	CC
cord-346842-ip4i3bdk	81	35	10	10	CD
cord-346842-ip4i3bdk	81	36	(	(	-LRB-
cord-346842-ip4i3bdk	81	37	26	26	CD
cord-346842-ip4i3bdk	81	38	%	%	NN
cord-346842-ip4i3bdk	81	39	)	)	-RRB-
cord-346842-ip4i3bdk	81	40	remained	remain	VBD
cord-346842-ip4i3bdk	81	41	closed	close	VBD
cord-346842-ip4i3bdk	81	42	the	the	DT
cord-346842-ip4i3bdk	81	43	room	room	NN
cord-346842-ip4i3bdk	81	44	but	but	CC
cord-346842-ip4i3bdk	81	45	planned	plan	VBD
cord-346842-ip4i3bdk	81	46	to	to	TO
cord-346842-ip4i3bdk	81	47	reopen	reopen	VB
cord-346842-ip4i3bdk	81	48	on	on	IN
cord-346842-ip4i3bdk	81	49	May	May	NNP
cord-346842-ip4i3bdk	81	50	1	1	CD
cord-346842-ip4i3bdk	81	51	,	,	,
cord-346842-ip4i3bdk	81	52	2020	2020	CD
cord-346842-ip4i3bdk	82	1	(	(	-LRB-
cord-346842-ip4i3bdk	82	2	Fig	Fig	NNP
cord-346842-ip4i3bdk	82	3	.	.	NNP
cord-346842-ip4i3bdk	82	4	4	4	CD
cord-346842-ip4i3bdk	82	5	)	)	-RRB-
cord-346842-ip4i3bdk	82	6	.	.	.
cord-346842-ip4i3bdk	83	1	Even	even	RB
cord-346842-ip4i3bdk	83	2	the	the	DT
cord-346842-ip4i3bdk	83	3	sites	site	NNS
cord-346842-ip4i3bdk	83	4	that	that	WDT
cord-346842-ip4i3bdk	83	5	had	have	VBD
cord-346842-ip4i3bdk	83	6	reopened	reopen	VBN
cord-346842-ip4i3bdk	83	7	the	the	DT
cord-346842-ip4i3bdk	83	8	room	room	NN
cord-346842-ip4i3bdk	83	9	,	,	,
cord-346842-ip4i3bdk	83	10	applied	apply	VBD
cord-346842-ip4i3bdk	83	11	the	the	DT
cord-346842-ip4i3bdk	83	12	guidance	guidance	NN
cord-346842-ip4i3bdk	83	13	for	for	IN
cord-346842-ip4i3bdk	83	14	preventing	prevent	VBG
cord-346842-ip4i3bdk	83	15	spread	spread	NN
cord-346842-ip4i3bdk	83	16	of	of	IN
cord-346842-ip4i3bdk	83	17	infection	infection	NN
cord-346842-ip4i3bdk	83	18	.	.	.
cord-346842-ip4i3bdk	84	1	Monitors	monitor	NNS
cord-346842-ip4i3bdk	84	2	who	who	WP
cord-346842-ip4i3bdk	84	3	had	have	VBD
cord-346842-ip4i3bdk	84	4	visited	visit	VBN
cord-346842-ip4i3bdk	84	5	countries	country	NNS
cord-346842-ip4i3bdk	84	6	with	with	IN
cord-346842-ip4i3bdk	84	7	a	a	DT
cord-346842-ip4i3bdk	84	8	high	high	JJ
cord-346842-ip4i3bdk	84	9	incidence	incidence	NN
cord-346842-ip4i3bdk	84	10	of	of	IN
cord-346842-ip4i3bdk	84	11	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	84	12	or	or	CC
cord-346842-ip4i3bdk	84	13	lived	live	VBD
cord-346842-ip4i3bdk	84	14	with	with	IN
cord-346842-ip4i3bdk	84	15	someone	someone	NN
cord-346842-ip4i3bdk	84	16	who	who	WP
cord-346842-ip4i3bdk	84	17	had	have	VBD
cord-346842-ip4i3bdk	84	18	visited	visit	VBN
cord-346842-ip4i3bdk	84	19	a	a	DT
cord-346842-ip4i3bdk	84	20	high	high	JJ
cord-346842-ip4i3bdk	84	21	incidence	incidence	NN
cord-346842-ip4i3bdk	84	22	country	country	NN
cord-346842-ip4i3bdk	84	23	within	within	IN
cord-346842-ip4i3bdk	84	24	14	14	CD
cord-346842-ip4i3bdk	84	25	days	day	NNS
cord-346842-ip4i3bdk	84	26	were	be	VBD
cord-346842-ip4i3bdk	84	27	still	still	RB
cord-346842-ip4i3bdk	84	28	restricted	restrict	VBN
cord-346842-ip4i3bdk	84	29	from	from	IN
cord-346842-ip4i3bdk	84	30	visiting	visit	VBG
cord-346842-ip4i3bdk	84	31	the	the	DT
cord-346842-ip4i3bdk	84	32	monitoring	monitoring	NN
cord-346842-ip4i3bdk	84	33	room	room	NN
cord-346842-ip4i3bdk	84	34	.	.	.
cord-346842-ip4i3bdk	85	1	Some	some	DT
cord-346842-ip4i3bdk	85	2	sites	site	NNS
cord-346842-ip4i3bdk	85	3	requested	request	VBD
cord-346842-ip4i3bdk	85	4	non	non	JJ
cord-346842-ip4i3bdk	85	5	-	-	JJ
cord-346842-ip4i3bdk	85	6	contact	contact	JJ
cord-346842-ip4i3bdk	85	7	communication	communication	NN
cord-346842-ip4i3bdk	85	8	with	with	IN
cord-346842-ip4i3bdk	85	9	site	site	NN
cord-346842-ip4i3bdk	85	10	staff	staff	NN
cord-346842-ip4i3bdk	85	11	.	.	.
cord-346842-ip4i3bdk	86	1	Of	of	IN
cord-346842-ip4i3bdk	86	2	140	140	CD
cord-346842-ip4i3bdk	86	3	CPMs	cpm	NNS
cord-346842-ip4i3bdk	86	4	,	,	,
cord-346842-ip4i3bdk	86	5	a	a	DT
cord-346842-ip4i3bdk	86	6	total	total	JJ
cord-346842-ip4i3bdk	86	7	105	105	CD
cord-346842-ip4i3bdk	86	8	CPMs	cpm	NNS
cord-346842-ip4i3bdk	86	9	(	(	-LRB-
cord-346842-ip4i3bdk	86	10	75	75	CD
cord-346842-ip4i3bdk	86	11	%	%	NN
cord-346842-ip4i3bdk	86	12	)	)	-RRB-
cord-346842-ip4i3bdk	86	13	answered	answer	VBD
cord-346842-ip4i3bdk	86	14	the	the	DT
cord-346842-ip4i3bdk	86	15	question	question	NN
cord-346842-ip4i3bdk	86	16	of	of	IN
cord-346842-ip4i3bdk	86	17	survey	survey	NN
cord-346842-ip4i3bdk	86	18	about	about	IN
cord-346842-ip4i3bdk	86	19	impact	impact	NN
cord-346842-ip4i3bdk	86	20	on	on	IN
cord-346842-ip4i3bdk	86	21	study	study	NN
cord-346842-ip4i3bdk	86	22	milestone	milestone	NN
cord-346842-ip4i3bdk	86	23	by	by	IN
cord-346842-ip4i3bdk	86	24	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	86	25	in	in	IN
cord-346842-ip4i3bdk	86	26	Korea	Korea	NNP
cord-346842-ip4i3bdk	86	27	.	.	.
cord-346842-ip4i3bdk	87	1	Of	of	IN
cord-346842-ip4i3bdk	87	2	105	105	CD
cord-346842-ip4i3bdk	87	3	CPMs	cpm	NNS
cord-346842-ip4i3bdk	87	4	,	,	,
cord-346842-ip4i3bdk	87	5	43	43	CD
cord-346842-ip4i3bdk	87	6	%	%	NN
cord-346842-ip4i3bdk	87	7	reported	report	VBD
cord-346842-ip4i3bdk	87	8	that	that	IN
cord-346842-ip4i3bdk	87	9	they	-PRON-	PRP
cord-346842-ip4i3bdk	87	10	expected	expect	VBD
cord-346842-ip4i3bdk	87	11	the	the	DT
cord-346842-ip4i3bdk	87	12	impact	impact	NN
cord-346842-ip4i3bdk	87	13	in	in	IN
cord-346842-ip4i3bdk	87	14	their	-PRON-	PRP$
cord-346842-ip4i3bdk	87	15	project	project	NN
cord-346842-ip4i3bdk	87	16	.	.	.
cord-346842-ip4i3bdk	88	1	53	53	CD
cord-346842-ip4i3bdk	88	2	%	%	NN
cord-346842-ip4i3bdk	88	3	reported	report	VBD
cord-346842-ip4i3bdk	88	4	that	that	DT
cord-346842-ip4i3bdk	88	5	study	study	NN
cord-346842-ip4i3bdk	88	6	milestone	milestone	NN
cord-346842-ip4i3bdk	88	7	was	be	VBD
cord-346842-ip4i3bdk	88	8	not	not	RB
cord-346842-ip4i3bdk	88	9	affected	affect	VBN
cord-346842-ip4i3bdk	88	10	,	,	,
cord-346842-ip4i3bdk	88	11	and	and	CC
cord-346842-ip4i3bdk	88	12	4	4	CD
cord-346842-ip4i3bdk	88	13	%	%	NN
cord-346842-ip4i3bdk	88	14	reported	report	VBD
cord-346842-ip4i3bdk	88	15	that	that	IN
cord-346842-ip4i3bdk	88	16	the	the	DT
cord-346842-ip4i3bdk	88	17	study	study	NN
cord-346842-ip4i3bdk	88	18	had	have	VBD
cord-346842-ip4i3bdk	88	19	been	be	VBN
cord-346842-ip4i3bdk	88	20	completed	complete	VBN
cord-346842-ip4i3bdk	88	21	so	so	IN
cord-346842-ip4i3bdk	88	22	the	the	DT
cord-346842-ip4i3bdk	88	23	question	question	NN
cord-346842-ip4i3bdk	88	24	was	be	VBD
cord-346842-ip4i3bdk	88	25	not	not	RB
cord-346842-ip4i3bdk	88	26	applicable	applicable	JJ
cord-346842-ip4i3bdk	88	27	.	.	.
cord-346842-ip4i3bdk	89	1	Data	datum	NNS
cord-346842-ip4i3bdk	89	2	cleaning	cleaning	NN
cord-346842-ip4i3bdk	89	3	and	and	CC
cord-346842-ip4i3bdk	89	4	database	database	NN
cord-346842-ip4i3bdk	89	5	lock	lock	NN
cord-346842-ip4i3bdk	89	6	were	be	VBD
cord-346842-ip4i3bdk	89	7	the	the	DT
cord-346842-ip4i3bdk	89	8	most	most	RBS
cord-346842-ip4i3bdk	89	9	common	common	JJ
cord-346842-ip4i3bdk	89	10	milestone	milestone	NN
cord-346842-ip4i3bdk	89	11	affected	affect	VBN
cord-346842-ip4i3bdk	89	12	(	(	-LRB-
cord-346842-ip4i3bdk	89	13	>	>	NFP
cord-346842-ip4i3bdk	89	14	60	60	CD
cord-346842-ip4i3bdk	89	15	%	%	NN
cord-346842-ip4i3bdk	89	16	)	)	-RRB-
cord-346842-ip4i3bdk	89	17	,	,	,
cord-346842-ip4i3bdk	89	18	as	as	IN
cord-346842-ip4i3bdk	89	19	a	a	DT
cord-346842-ip4i3bdk	89	20	result	result	NN
cord-346842-ip4i3bdk	89	21	of	of	IN
cord-346842-ip4i3bdk	89	22	restriction	restriction	NN
cord-346842-ip4i3bdk	89	23	of	of	IN
cord-346842-ip4i3bdk	89	24	monitor	monitor	NN
cord-346842-ip4i3bdk	89	25	's	's	POS
cord-346842-ip4i3bdk	89	26	access	access	NN
cord-346842-ip4i3bdk	89	27	to	to	IN
cord-346842-ip4i3bdk	89	28	the	the	DT
cord-346842-ip4i3bdk	89	29	sites	site	NNS
cord-346842-ip4i3bdk	89	30	which	which	WDT
cord-346842-ip4i3bdk	89	31	resulted	result	VBD
cord-346842-ip4i3bdk	89	32	in	in	IN
cord-346842-ip4i3bdk	89	33	delayed	delay	VBN
cord-346842-ip4i3bdk	89	34	source	source	NN
cord-346842-ip4i3bdk	89	35	data	datum	NNS
cord-346842-ip4i3bdk	89	36	verification	verification	NN
cord-346842-ip4i3bdk	89	37	(	(	-LRB-
cord-346842-ip4i3bdk	89	38	Fig	Fig	NNP
cord-346842-ip4i3bdk	89	39	.	.	.
cord-346842-ip4i3bdk	89	40	5	5	CD
cord-346842-ip4i3bdk	89	41	)	)	-RRB-
cord-346842-ip4i3bdk	89	42	.	.	.
cord-346842-ip4i3bdk	90	1	The	the	DT
cord-346842-ip4i3bdk	90	2	site	site	NN
cord-346842-ip4i3bdk	90	3	initiation	initiation	NN
cord-346842-ip4i3bdk	90	4	meeting	meeting	NN
cord-346842-ip4i3bdk	90	5	is	be	VBZ
cord-346842-ip4i3bdk	90	6	an	an	DT
cord-346842-ip4i3bdk	90	7	important	important	JJ
cord-346842-ip4i3bdk	90	8	milestone	milestone	NN
cord-346842-ip4i3bdk	90	9	that	that	WDT
cord-346842-ip4i3bdk	90	10	marks	mark	VBZ
cord-346842-ip4i3bdk	90	11	the	the	DT
cord-346842-ip4i3bdk	90	12	trial	trial	NN
cord-346842-ip4i3bdk	90	13	start	start	NN
cord-346842-ip4i3bdk	90	14	at	at	IN
cord-346842-ip4i3bdk	90	15	the	the	DT
cord-346842-ip4i3bdk	90	16	site	site	NN
cord-346842-ip4i3bdk	90	17	.	.	.
cord-346842-ip4i3bdk	91	1	Some	some	DT
cord-346842-ip4i3bdk	91	2	trial	trial	NN
cord-346842-ip4i3bdk	91	3	sites	site	NNS
cord-346842-ip4i3bdk	91	4	prohibited	prohibit	VBD
cord-346842-ip4i3bdk	91	5	visits	visit	NNS
cord-346842-ip4i3bdk	91	6	from	from	IN
cord-346842-ip4i3bdk	91	7	subjects	subject	NNS
cord-346842-ip4i3bdk	91	8	living	live	VBG
cord-346842-ip4i3bdk	91	9	in	in	IN
cord-346842-ip4i3bdk	91	10	area	area	NN
cord-346842-ip4i3bdk	91	11	with	with	IN
cord-346842-ip4i3bdk	91	12	high	high	JJ
cord-346842-ip4i3bdk	91	13	infection	infection	NN
cord-346842-ip4i3bdk	91	14	rates	rate	NNS
cord-346842-ip4i3bdk	91	15	,	,	,
cord-346842-ip4i3bdk	91	16	and	and	CC
cord-346842-ip4i3bdk	91	17	subjects	subject	NNS
cord-346842-ip4i3bdk	91	18	who	who	WP
cord-346842-ip4i3bdk	91	19	were	be	VBD
cord-346842-ip4i3bdk	91	20	exposed	expose	VBN
cord-346842-ip4i3bdk	91	21	to	to	IN
cord-346842-ip4i3bdk	91	22	infectious	infectious	JJ
cord-346842-ip4i3bdk	91	23	agents	agent	NNS
cord-346842-ip4i3bdk	91	24	were	be	VBD
cord-346842-ip4i3bdk	91	25	required	require	VBN
cord-346842-ip4i3bdk	91	26	to	to	TO
cord-346842-ip4i3bdk	91	27	be	be	VB
cord-346842-ip4i3bdk	91	28	quarantined	quarantine	VBN
cord-346842-ip4i3bdk	91	29	according	accord	VBG
cord-346842-ip4i3bdk	91	30	to	to	IN
cord-346842-ip4i3bdk	91	31	the	the	DT
cord-346842-ip4i3bdk	91	32	KCDC	KCDC	NNP
cord-346842-ip4i3bdk	91	33	guideline	guideline	NN
cord-346842-ip4i3bdk	91	34	,	,	,
cord-346842-ip4i3bdk	91	35	so	so	IN
cord-346842-ip4i3bdk	91	36	some	some	DT
cord-346842-ip4i3bdk	91	37	subjects	subject	NNS
cord-346842-ip4i3bdk	91	38	were	be	VBD
cord-346842-ip4i3bdk	91	39	unable	unable	JJ
cord-346842-ip4i3bdk	91	40	to	to	TO
cord-346842-ip4i3bdk	91	41	attend	attend	VB
cord-346842-ip4i3bdk	91	42	scheduled	scheduled	JJ
cord-346842-ip4i3bdk	91	43	study	study	NN
cord-346842-ip4i3bdk	91	44	visits	visit	NNS
cord-346842-ip4i3bdk	91	45	.	.	.
cord-346842-ip4i3bdk	92	1	6	6	CD
cord-346842-ip4i3bdk	93	1	Although	although	IN
cord-346842-ip4i3bdk	93	2	clinical	clinical	JJ
cord-346842-ip4i3bdk	93	3	trial	trial	NN
cord-346842-ip4i3bdk	93	4	drugs	drug	NNS
cord-346842-ip4i3bdk	93	5	could	could	MD
cord-346842-ip4i3bdk	93	6	be	be	VB
cord-346842-ip4i3bdk	93	7	delivered	deliver	VBN
cord-346842-ip4i3bdk	93	8	in	in	IN
cord-346842-ip4i3bdk	93	9	accordance	accordance	NN
cord-346842-ip4i3bdk	93	10	with	with	IN
cord-346842-ip4i3bdk	93	11	exceptional	exceptional	JJ
cord-346842-ip4i3bdk	93	12	regulation	regulation	NN
cord-346842-ip4i3bdk	93	13	permit	permit	NN
cord-346842-ip4i3bdk	93	14	,	,	,
cord-346842-ip4i3bdk	93	15	appropriate	appropriate	JJ
cord-346842-ip4i3bdk	93	16	examination	examination	NN
cord-346842-ip4i3bdk	93	17	should	should	MD
cord-346842-ip4i3bdk	93	18	be	be	VB
cord-346842-ip4i3bdk	93	19	conducted	conduct	VBN
cord-346842-ip4i3bdk	93	20	for	for	IN
cord-346842-ip4i3bdk	93	21	subject	subject	NN
cord-346842-ip4i3bdk	93	22	's	's	POS
cord-346842-ip4i3bdk	93	23	safety	safety	NN
cord-346842-ip4i3bdk	93	24	by	by	IN
cord-346842-ip4i3bdk	93	25	investigators	investigator	NNS
cord-346842-ip4i3bdk	93	26	.	.	.
cord-346842-ip4i3bdk	94	1	12	12	CD
cord-346842-ip4i3bdk	95	1	Through	through	IN
cord-346842-ip4i3bdk	95	2	temporally	temporally	RB
cord-346842-ip4i3bdk	95	3	allowed	allow	VBN
cord-346842-ip4i3bdk	95	4	remote	remote	JJ
cord-346842-ip4i3bdk	95	5	assessment	assessment	NN
cord-346842-ip4i3bdk	95	6	by	by	IN
cord-346842-ip4i3bdk	95	7	MFDS	MFDS	NNP
cord-346842-ip4i3bdk	95	8	for	for	IN
cord-346842-ip4i3bdk	95	9	trial	trial	NN
cord-346842-ip4i3bdk	95	10	subjects	subject	NNS
cord-346842-ip4i3bdk	95	11	,	,	,
cord-346842-ip4i3bdk	95	12	it	-PRON-	PRP
cord-346842-ip4i3bdk	95	13	is	be	VBZ
cord-346842-ip4i3bdk	95	14	required	require	VBN
cord-346842-ip4i3bdk	95	15	for	for	IN
cord-346842-ip4i3bdk	95	16	investigator	investigator	NN
cord-346842-ip4i3bdk	95	17	to	to	TO
cord-346842-ip4i3bdk	95	18	evaluate	evaluate	VB
cord-346842-ip4i3bdk	95	19	the	the	DT
cord-346842-ip4i3bdk	95	20	subjects	subject	NNS
cord-346842-ip4i3bdk	95	21	'	'	POS
cord-346842-ip4i3bdk	95	22	condition	condition	NN
cord-346842-ip4i3bdk	95	23	even	even	RB
cord-346842-ip4i3bdk	95	24	during	during	IN
cord-346842-ip4i3bdk	95	25	their	-PRON-	PRP$
cord-346842-ip4i3bdk	95	26	isolation	isolation	NN
cord-346842-ip4i3bdk	95	27	whether	whether	IN
cord-346842-ip4i3bdk	95	28	it	-PRON-	PRP
cord-346842-ip4i3bdk	95	29	is	be	VBZ
cord-346842-ip4i3bdk	95	30	suitable	suitable	JJ
cord-346842-ip4i3bdk	95	31	to	to	TO
cord-346842-ip4i3bdk	95	32	prescribe	prescribe	VB
cord-346842-ip4i3bdk	95	33	same	same	JJ
cord-346842-ip4i3bdk	95	34	investigational	investigational	JJ
cord-346842-ip4i3bdk	95	35	products	product	NNS
cord-346842-ip4i3bdk	95	36	repeatedly	repeatedly	RB
cord-346842-ip4i3bdk	95	37	and	and	CC
cord-346842-ip4i3bdk	95	38	whether	whether	IN
cord-346842-ip4i3bdk	95	39	laboratory	laboratory	NN
cord-346842-ip4i3bdk	95	40	tests	test	NNS
cord-346842-ip4i3bdk	95	41	could	could	MD
cord-346842-ip4i3bdk	95	42	be	be	VB
cord-346842-ip4i3bdk	95	43	omitted	omit	VBN
cord-346842-ip4i3bdk	95	44	.	.	.
cord-346842-ip4i3bdk	96	1	12	12	CD
cord-346842-ip4i3bdk	97	1	As	as	IN
cord-346842-ip4i3bdk	97	2	a	a	DT
cord-346842-ip4i3bdk	97	3	final	final	JJ
cord-346842-ip4i3bdk	97	4	decision	decision	NN
cord-346842-ip4i3bdk	97	5	-	-	HYPH
cord-346842-ip4i3bdk	97	6	making	make	VBG
cord-346842-ip4i3bdk	97	7	authority	authority	NN
cord-346842-ip4i3bdk	97	8	on	on	IN
cord-346842-ip4i3bdk	97	9	continuation	continuation	NN
cord-346842-ip4i3bdk	97	10	and	and	CC
cord-346842-ip4i3bdk	97	11	suspension	suspension	NN
cord-346842-ip4i3bdk	97	12	of	of	IN
cord-346842-ip4i3bdk	97	13	their	-PRON-	PRP$
cord-346842-ip4i3bdk	97	14	clinical	clinical	JJ
cord-346842-ip4i3bdk	97	15	trials	trial	NNS
cord-346842-ip4i3bdk	97	16	,	,	,
cord-346842-ip4i3bdk	97	17	the	the	DT
cord-346842-ip4i3bdk	97	18	limitation	limitation	NN
cord-346842-ip4i3bdk	97	19	and	and	CC
cord-346842-ip4i3bdk	97	20	reluctance	reluctance	NN
cord-346842-ip4i3bdk	97	21	of	of	IN
cord-346842-ip4i3bdk	97	22	subject	subject	NN
cord-346842-ip4i3bdk	97	23	to	to	TO
cord-346842-ip4i3bdk	97	24	visit	visit	VB
cord-346842-ip4i3bdk	97	25	hospitals	hospital	NNS
cord-346842-ip4i3bdk	97	26	and	and	CC
cord-346842-ip4i3bdk	97	27	medical	medical	JJ
cord-346842-ip4i3bdk	97	28	profession	profession	NN
cord-346842-ip4i3bdk	97	29	's	's	POS
cord-346842-ip4i3bdk	97	30	burden	burden	NN
cord-346842-ip4i3bdk	97	31	for	for	IN
cord-346842-ip4i3bdk	98	1	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	98	2	control	control	NN
cord-346842-ip4i3bdk	98	3	are	be	VBP
cord-346842-ip4i3bdk	98	4	the	the	DT
cord-346842-ip4i3bdk	98	5	factors	factor	NNS
cord-346842-ip4i3bdk	98	6	to	to	TO
cord-346842-ip4i3bdk	98	7	consider	consider	VB
cord-346842-ip4i3bdk	98	8	when	when	WRB
cord-346842-ip4i3bdk	98	9	deciding	decide	VBG
cord-346842-ip4i3bdk	98	10	whether	whether	IN
cord-346842-ip4i3bdk	98	11	to	to	TO
cord-346842-ip4i3bdk	98	12	proceed	proceed	VB
cord-346842-ip4i3bdk	98	13	with	with	IN
cord-346842-ip4i3bdk	98	14	trials	trial	NNS
cord-346842-ip4i3bdk	98	15	,	,	,
cord-346842-ip4i3bdk	98	16	based	base	VBN
cord-346842-ip4i3bdk	98	17	on	on	IN
cord-346842-ip4i3bdk	98	18	risk	risk	NN
cord-346842-ip4i3bdk	98	19	and	and	CC
cord-346842-ip4i3bdk	98	20	benefit	benefit	VB
cord-346842-ip4i3bdk	98	21	assessments	assessment	NNS
cord-346842-ip4i3bdk	98	22	.	.	.
cord-346842-ip4i3bdk	99	1	3,11	3,11	CD
cord-346842-ip4i3bdk	99	2	RA	RA	NNP
cord-346842-ip4i3bdk	99	3	of	of	IN
cord-346842-ip4i3bdk	99	4	United	United	NNP
cord-346842-ip4i3bdk	99	5	Kingdom	Kingdom	NNP
cord-346842-ip4i3bdk	99	6	,	,	,
cord-346842-ip4i3bdk	99	7	Medicines	Medicines	NNP
cord-346842-ip4i3bdk	99	8	and	and	CC
cord-346842-ip4i3bdk	99	9	Healthcare	Healthcare	NNP
cord-346842-ip4i3bdk	99	10	products	product	NNS
cord-346842-ip4i3bdk	99	11	Regulatory	Regulatory	NNP
cord-346842-ip4i3bdk	99	12	Agency	Agency	NNP
cord-346842-ip4i3bdk	99	13	,	,	,
cord-346842-ip4i3bdk	99	14	advised	advise	VBD
cord-346842-ip4i3bdk	99	15	for	for	IN
cord-346842-ip4i3bdk	99	16	the	the	DT
cord-346842-ip4i3bdk	99	17	early	early	JJ
cord-346842-ip4i3bdk	99	18	phase	phase	NN
cord-346842-ip4i3bdk	99	19	healthy	healthy	JJ
cord-346842-ip4i3bdk	99	20	volunteer	volunteer	NN
cord-346842-ip4i3bdk	99	21	trials	trial	NNS
cord-346842-ip4i3bdk	99	22	,	,	,
cord-346842-ip4i3bdk	99	23	where	where	WRB
cord-346842-ip4i3bdk	99	24	there	there	EX
cord-346842-ip4i3bdk	99	25	is	be	VBZ
cord-346842-ip4i3bdk	99	26	no	no	DT
cord-346842-ip4i3bdk	99	27	therapeutic	therapeutic	JJ
cord-346842-ip4i3bdk	99	28	benefit	benefit	NN
cord-346842-ip4i3bdk	99	29	to	to	IN
cord-346842-ip4i3bdk	99	30	the	the	DT
cord-346842-ip4i3bdk	99	31	volunteer	volunteer	NN
cord-346842-ip4i3bdk	99	32	but	but	CC
cord-346842-ip4i3bdk	99	33	taking	take	VBG
cord-346842-ip4i3bdk	99	34	part	part	NN
cord-346842-ip4i3bdk	99	35	in	in	IN
cord-346842-ip4i3bdk	99	36	the	the	DT
cord-346842-ip4i3bdk	99	37	trial	trial	NN
cord-346842-ip4i3bdk	99	38	dose	dose	NN
cord-346842-ip4i3bdk	99	39	pose	pose	VBP
cord-346842-ip4i3bdk	99	40	a	a	DT
cord-346842-ip4i3bdk	99	41	risk	risk	NN
cord-346842-ip4i3bdk	99	42	of	of	IN
cord-346842-ip4i3bdk	99	43	infection	infection	NN
cord-346842-ip4i3bdk	99	44	.	.	.
cord-346842-ip4i3bdk	100	1	14	14	CD
cord-346842-ip4i3bdk	101	1	To	to	TO
cord-346842-ip4i3bdk	101	2	avoid	avoid	VB
cord-346842-ip4i3bdk	101	3	adding	add	VBG
cord-346842-ip4i3bdk	101	4	to	to	IN
cord-346842-ip4i3bdk	101	5	demands	demand	NNS
cord-346842-ip4i3bdk	101	6	on	on	IN
cord-346842-ip4i3bdk	101	7	healthcare	healthcare	NN
cord-346842-ip4i3bdk	101	8	system	system	NN
cord-346842-ip4i3bdk	101	9	during	during	IN
cord-346842-ip4i3bdk	101	10	this	this	DT
cord-346842-ip4i3bdk	101	11	unprecedented	unprecedented	JJ
cord-346842-ip4i3bdk	101	12	crisis	crisis	NN
cord-346842-ip4i3bdk	101	13	with	with	IN
cord-346842-ip4i3bdk	101	14	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	101	15	epidemic	epidemic	NN
cord-346842-ip4i3bdk	101	16	and	and	CC
cord-346842-ip4i3bdk	101	17	to	to	TO
cord-346842-ip4i3bdk	101	18	reduce	reduce	VB
cord-346842-ip4i3bdk	101	19	the	the	DT
cord-346842-ip4i3bdk	101	20	possibility	possibility	NN
cord-346842-ip4i3bdk	101	21	of	of	IN
cord-346842-ip4i3bdk	101	22	infection	infection	NN
cord-346842-ip4i3bdk	101	23	of	of	IN
cord-346842-ip4i3bdk	101	24	trial	trial	NN
cord-346842-ip4i3bdk	101	25	participants	participant	NNS
cord-346842-ip4i3bdk	101	26	,	,	,
cord-346842-ip4i3bdk	101	27	13	13	CD
cord-346842-ip4i3bdk	101	28	(	(	-LRB-
cord-346842-ip4i3bdk	101	29	52	52	CD
cord-346842-ip4i3bdk	101	30	%	%	NN
cord-346842-ip4i3bdk	101	31	)	)	-RRB-
cord-346842-ip4i3bdk	101	32	of	of	IN
cord-346842-ip4i3bdk	101	33	the	the	DT
cord-346842-ip4i3bdk	101	34	25	25	CD
cord-346842-ip4i3bdk	101	35	top	top	JJ
cord-346842-ip4i3bdk	101	36	pharmaceutical	pharmaceutical	JJ
cord-346842-ip4i3bdk	101	37	companies	company	NNS
cord-346842-ip4i3bdk	101	38	declared	declare	VBD
cord-346842-ip4i3bdk	101	39	to	to	TO
cord-346842-ip4i3bdk	101	40	hold	hold	VB
cord-346842-ip4i3bdk	101	41	recruitment	recruitment	NN
cord-346842-ip4i3bdk	101	42	or	or	CC
cord-346842-ip4i3bdk	101	43	activation	activation	NN
cord-346842-ip4i3bdk	101	44	of	of	IN
cord-346842-ip4i3bdk	101	45	the	the	DT
cord-346842-ip4i3bdk	101	46	new	new	JJ
cord-346842-ip4i3bdk	101	47	trials	trial	NNS
cord-346842-ip4i3bdk	101	48	at	at	IN
cord-346842-ip4i3bdk	101	49	least	least	JJS
cord-346842-ip4i3bdk	101	50	partially	partially	RB
cord-346842-ip4i3bdk	101	51	.	.	.
cord-346842-ip4i3bdk	102	1	7	7	CD
cord-346842-ip4i3bdk	102	2	Five	five	CD
cord-346842-ip4i3bdk	102	3	(	(	-LRB-
cord-346842-ip4i3bdk	102	4	20	20	CD
cord-346842-ip4i3bdk	102	5	%	%	NN
cord-346842-ip4i3bdk	102	6	)	)	-RRB-
cord-346842-ip4i3bdk	102	7	companies	company	NNS
cord-346842-ip4i3bdk	102	8	continued	continue	VBD
cord-346842-ip4i3bdk	102	9	ongoing	ongoing	JJ
cord-346842-ip4i3bdk	102	10	trials	trial	NNS
cord-346842-ip4i3bdk	102	11	in	in	IN
cord-346842-ip4i3bdk	102	12	close	close	JJ
cord-346842-ip4i3bdk	102	13	discussion	discussion	NN
cord-346842-ip4i3bdk	102	14	with	with	IN
cord-346842-ip4i3bdk	102	15	the	the	DT
cord-346842-ip4i3bdk	102	16	trial	trial	NN
cord-346842-ip4i3bdk	102	17	investigators	investigator	NNS
cord-346842-ip4i3bdk	102	18	in	in	IN
cord-346842-ip4i3bdk	102	19	all	all	PDT
cord-346842-ip4i3bdk	102	20	the	the	DT
cord-346842-ip4i3bdk	102	21	participating	participate	VBG
cord-346842-ip4i3bdk	102	22	countries	country	NNS
cord-346842-ip4i3bdk	102	23	.	.	.
cord-346842-ip4i3bdk	103	1	Seven	seven	CD
cord-346842-ip4i3bdk	103	2	(	(	-LRB-
cord-346842-ip4i3bdk	103	3	28	28	CD
cord-346842-ip4i3bdk	103	4	%	%	NN
cord-346842-ip4i3bdk	103	5	)	)	-RRB-
cord-346842-ip4i3bdk	104	1	pharmaceutical	pharmaceutical	JJ
cord-346842-ip4i3bdk	104	2	companies	company	NNS
cord-346842-ip4i3bdk	104	3	did	do	VBD
cord-346842-ip4i3bdk	104	4	not	not	RB
cord-346842-ip4i3bdk	104	5	mention	mention	VB
cord-346842-ip4i3bdk	104	6	a	a	DT
cord-346842-ip4i3bdk	104	7	change	change	NN
cord-346842-ip4i3bdk	104	8	in	in	IN
cord-346842-ip4i3bdk	104	9	their	-PRON-	PRP$
cord-346842-ip4i3bdk	104	10	conduct	conduct	NN
cord-346842-ip4i3bdk	104	11	of	of	IN
cord-346842-ip4i3bdk	104	12	trials	trial	NNS
cord-346842-ip4i3bdk	104	13	on	on	IN
cord-346842-ip4i3bdk	104	14	their	-PRON-	PRP$
cord-346842-ip4i3bdk	104	15	official	official	JJ
cord-346842-ip4i3bdk	104	16	website	website	NN
cord-346842-ip4i3bdk	104	17	or	or	CC
cord-346842-ip4i3bdk	104	18	in	in	IN
cord-346842-ip4i3bdk	104	19	press	press	NN
cord-346842-ip4i3bdk	104	20	release	release	NN
cord-346842-ip4i3bdk	105	1	(	(	-LRB-
cord-346842-ip4i3bdk	105	2	Fig	Fig	NNP
cord-346842-ip4i3bdk	105	3	.	.	.
cord-346842-ip4i3bdk	105	4	6	6	CD
cord-346842-ip4i3bdk	105	5	)	)	-RRB-
cord-346842-ip4i3bdk	105	6	.	.	.
cord-346842-ip4i3bdk	106	1	Multiple	multiple	JJ
cord-346842-ip4i3bdk	106	2	countries	country	NNS
cord-346842-ip4i3bdk	106	3	are	be	VBP
cord-346842-ip4i3bdk	106	4	turning	turn	VBG
cord-346842-ip4i3bdk	106	5	to	to	IN
cord-346842-ip4i3bdk	106	6	pharmaceutical	pharmaceutical	JJ
cord-346842-ip4i3bdk	106	7	companies	company	NNS
cord-346842-ip4i3bdk	106	8	to	to	TO
cord-346842-ip4i3bdk	106	9	develop	develop	VB
cord-346842-ip4i3bdk	106	10	coronavirus	coronavirus	NN
cord-346842-ip4i3bdk	106	11	treatments	treatment	NNS
cord-346842-ip4i3bdk	106	12	,	,	,
cord-346842-ip4i3bdk	106	13	so	so	RB
cord-346842-ip4i3bdk	106	14	accordingly	accordingly	RB
cord-346842-ip4i3bdk	106	15	,	,	,
cord-346842-ip4i3bdk	106	16	the	the	DT
cord-346842-ip4i3bdk	106	17	number	number	NN
cord-346842-ip4i3bdk	106	18	of	of	IN
cord-346842-ip4i3bdk	106	19	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	106	20	related	related	JJ
cord-346842-ip4i3bdk	106	21	clinical	clinical	JJ
cord-346842-ip4i3bdk	106	22	trials	trial	NNS
cord-346842-ip4i3bdk	106	23	is	be	VBZ
cord-346842-ip4i3bdk	106	24	growing	grow	VBG
cord-346842-ip4i3bdk	106	25	very	very	RB
cord-346842-ip4i3bdk	106	26	rapidly	rapidly	RB
cord-346842-ip4i3bdk	106	27	worldwide	worldwide	RB
cord-346842-ip4i3bdk	106	28	.	.	.
cord-346842-ip4i3bdk	107	1	15	15	CD
cord-346842-ip4i3bdk	108	1	A	a	DT
cord-346842-ip4i3bdk	108	2	notable	notable	JJ
cord-346842-ip4i3bdk	108	3	feature	feature	NN
cord-346842-ip4i3bdk	108	4	of	of	IN
cord-346842-ip4i3bdk	108	5	the	the	DT
cord-346842-ip4i3bdk	108	6	global	global	JJ
cord-346842-ip4i3bdk	108	7	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	108	8	treatment	treatment	NN
cord-346842-ip4i3bdk	108	9	clinical	clinical	JJ
cord-346842-ip4i3bdk	108	10	study	study	NN
cord-346842-ip4i3bdk	108	11	is	be	VBZ
cord-346842-ip4i3bdk	108	12	that	that	IN
cord-346842-ip4i3bdk	108	13	the	the	DT
cord-346842-ip4i3bdk	108	14	existing	exist	VBG
cord-346842-ip4i3bdk	108	15	licensed	licensed	JJ
cord-346842-ip4i3bdk	108	16	treatment	treatment	NN
cord-346842-ip4i3bdk	108	17	or	or	CC
cord-346842-ip4i3bdk	108	18	new	new	JJ
cord-346842-ip4i3bdk	108	19	drug	drug	NN
cord-346842-ip4i3bdk	108	20	candidate	candidate	NN
cord-346842-ip4i3bdk	108	21	material	material	NN
cord-346842-ip4i3bdk	108	22	is	be	VBZ
cord-346842-ip4i3bdk	108	23	being	be	VBG
cord-346842-ip4i3bdk	108	24	evaluated	evaluate	VBN
cord-346842-ip4i3bdk	108	25	to	to	TO
cord-346842-ip4i3bdk	108	26	determine	determine	VB
cord-346842-ip4i3bdk	108	27	whether	whether	IN
cord-346842-ip4i3bdk	108	28	they	-PRON-	PRP
cord-346842-ip4i3bdk	108	29	can	can	MD
cord-346842-ip4i3bdk	108	30	be	be	VB
cord-346842-ip4i3bdk	108	31	repurposed	repurpose	VBN
cord-346842-ip4i3bdk	108	32	for	for	IN
cord-346842-ip4i3bdk	108	33	treating	treat	VBG
cord-346842-ip4i3bdk	108	34	In	in	IN
cord-346842-ip4i3bdk	108	35	Korea	Korea	NNP
cord-346842-ip4i3bdk	108	36	,	,	,
cord-346842-ip4i3bdk	108	37	the	the	DT
cord-346842-ip4i3bdk	108	38	MFDS	MFDS	NNP
cord-346842-ip4i3bdk	108	39	approved	approve	VBD
cord-346842-ip4i3bdk	108	40	a	a	DT
cord-346842-ip4i3bdk	108	41	total	total	NN
cord-346842-ip4i3bdk	108	42	of	of	IN
cord-346842-ip4i3bdk	108	43	15	15	CD
cord-346842-ip4i3bdk	108	44	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	108	45	clinical	clinical	JJ
cord-346842-ip4i3bdk	108	46	trials	trial	NNS
cord-346842-ip4i3bdk	108	47	,	,	,
cord-346842-ip4i3bdk	108	48	6	6	CD
cord-346842-ip4i3bdk	108	49	in	in	IN
cord-346842-ip4i3bdk	108	50	March	March	NNP
cord-346842-ip4i3bdk	108	51	2020	2020	CD
cord-346842-ip4i3bdk	108	52	and	and	CC
cord-346842-ip4i3bdk	108	53	3	3	CD
cord-346842-ip4i3bdk	108	54	in	in	IN
cord-346842-ip4i3bdk	108	55	each	each	DT
cord-346842-ip4i3bdk	108	56	of	of	IN
cord-346842-ip4i3bdk	108	57	the	the	DT
cord-346842-ip4i3bdk	108	58	following	following	JJ
cord-346842-ip4i3bdk	108	59	3	3	CD
cord-346842-ip4i3bdk	108	60	months	month	NNS
cord-346842-ip4i3bdk	108	61	.	.	.
cord-346842-ip4i3bdk	109	1	8	8	CD
cord-346842-ip4i3bdk	109	2	Two	two	CD
cord-346842-ip4i3bdk	109	3	trials	trial	NNS
cord-346842-ip4i3bdk	109	4	(	(	-LRB-
cord-346842-ip4i3bdk	109	5	13	13	CD
cord-346842-ip4i3bdk	109	6	%	%	NN
cord-346842-ip4i3bdk	109	7	)	)	-RRB-
cord-346842-ip4i3bdk	109	8	were	be	VBD
cord-346842-ip4i3bdk	109	9	for	for	IN
cord-346842-ip4i3bdk	109	10	vaccine	vaccine	NN
cord-346842-ip4i3bdk	109	11	development	development	NN
cord-346842-ip4i3bdk	109	12	and	and	CC
cord-346842-ip4i3bdk	109	13	13	13	CD
cord-346842-ip4i3bdk	109	14	(	(	-LRB-
cord-346842-ip4i3bdk	109	15	87	87	CD
cord-346842-ip4i3bdk	109	16	%	%	NN
cord-346842-ip4i3bdk	109	17	)	)	-RRB-
cord-346842-ip4i3bdk	109	18	were	be	VBD
cord-346842-ip4i3bdk	109	19	for	for	IN
cord-346842-ip4i3bdk	109	20	treatment	treatment	NN
cord-346842-ip4i3bdk	109	21	development	development	NN
cord-346842-ip4i3bdk	109	22	.	.	.
cord-346842-ip4i3bdk	110	1	A	a	DT
cord-346842-ip4i3bdk	110	2	total	total	JJ
cord-346842-ip4i3bdk	110	3	10	10	CD
cord-346842-ip4i3bdk	111	1	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	111	2	studies	study	NNS
cord-346842-ip4i3bdk	111	3	(	(	-LRB-
cord-346842-ip4i3bdk	111	4	66	66	CD
cord-346842-ip4i3bdk	111	5	%	%	NN
cord-346842-ip4i3bdk	111	6	)	)	-RRB-
cord-346842-ip4i3bdk	111	7	were	be	VBD
cord-346842-ip4i3bdk	111	8	recruiting	recruit	VBG
cord-346842-ip4i3bdk	111	9	patients	patient	NNS
cord-346842-ip4i3bdk	111	10	or	or	CC
cord-346842-ip4i3bdk	111	11	preparing	prepare	VBG
cord-346842-ip4i3bdk	111	12	for	for	IN
cord-346842-ip4i3bdk	111	13	enrollment	enrollment	NN
cord-346842-ip4i3bdk	111	14	.	.	.
cord-346842-ip4i3bdk	112	1	Of	of	IN
cord-346842-ip4i3bdk	112	2	the	the	DT
cord-346842-ip4i3bdk	112	3	15	15	CD
cord-346842-ip4i3bdk	112	4	trials	trial	NNS
cord-346842-ip4i3bdk	112	5	,	,	,
cord-346842-ip4i3bdk	112	6	investigator	investigator	NN
cord-346842-ip4i3bdk	112	7	-	-	HYPH
cord-346842-ip4i3bdk	112	8	initiated	initiate	VBN
cord-346842-ip4i3bdk	112	9	trials	trial	NNS
cord-346842-ip4i3bdk	112	10	and	and	CC
cord-346842-ip4i3bdk	112	11	sponsor	sponsor	NN
cord-346842-ip4i3bdk	112	12	-	-	HYPH
cord-346842-ip4i3bdk	112	13	initiated	initiate	VBN
cord-346842-ip4i3bdk	112	14	trials	trial	NNS
cord-346842-ip4i3bdk	112	15	accounted	account	VBD
cord-346842-ip4i3bdk	112	16	for	for	IN
cord-346842-ip4i3bdk	112	17	almost	almost	RB
cord-346842-ip4i3bdk	112	18	the	the	DT
cord-346842-ip4i3bdk	112	19	same	same	JJ
cord-346842-ip4i3bdk	112	20	percentage	percentage	NN
cord-346842-ip4i3bdk	112	21	,	,	,
cord-346842-ip4i3bdk	112	22	7	7	CD
cord-346842-ip4i3bdk	112	23	trial	trial	NN
cord-346842-ip4i3bdk	112	24	(	(	-LRB-
cord-346842-ip4i3bdk	112	25	47	47	CD
cord-346842-ip4i3bdk	112	26	%	%	NN
cord-346842-ip4i3bdk	112	27	)	)	-RRB-
cord-346842-ip4i3bdk	112	28	and	and	CC
cord-346842-ip4i3bdk	112	29	8	8	CD
cord-346842-ip4i3bdk	112	30	trials	trial	NNS
cord-346842-ip4i3bdk	112	31	(	(	-LRB-
cord-346842-ip4i3bdk	112	32	53	53	CD
cord-346842-ip4i3bdk	112	33	%	%	NN
cord-346842-ip4i3bdk	112	34	)	)	-RRB-
cord-346842-ip4i3bdk	112	35	each	each	DT
cord-346842-ip4i3bdk	112	36	.	.	.
cord-346842-ip4i3bdk	113	1	Among	among	IN
cord-346842-ip4i3bdk	113	2	the	the	DT
cord-346842-ip4i3bdk	113	3	sponsor	sponsor	NN
cord-346842-ip4i3bdk	113	4	-	-	HYPH
cord-346842-ip4i3bdk	113	5	initiated	initiate	VBN
cord-346842-ip4i3bdk	113	6	trials	trial	NNS
cord-346842-ip4i3bdk	113	7	,	,	,
cord-346842-ip4i3bdk	113	8	phase	phase	NN
cord-346842-ip4i3bdk	113	9	2	2	CD
cord-346842-ip4i3bdk	113	10	occupied	occupy	VBD
cord-346842-ip4i3bdk	113	11	highest	high	JJS
cord-346842-ip4i3bdk	113	12	portion	portion	NN
cord-346842-ip4i3bdk	113	13	(	(	-LRB-
cord-346842-ip4i3bdk	113	14	27	27	CD
cord-346842-ip4i3bdk	113	15	%	%	NN
cord-346842-ip4i3bdk	113	16	)	)	-RRB-
cord-346842-ip4i3bdk	114	1	(	(	-LRB-
cord-346842-ip4i3bdk	114	2	Fig	Fig	NNP
cord-346842-ip4i3bdk	114	3	.	.	NNP
cord-346842-ip4i3bdk	114	4	7	7	CD
cord-346842-ip4i3bdk	114	5	)	)	-RRB-
cord-346842-ip4i3bdk	114	6	.	.	.
cord-346842-ip4i3bdk	115	1	Remdesivir	Remdesivir	NNP
cord-346842-ip4i3bdk	115	2	was	be	VBD
cord-346842-ip4i3bdk	115	3	the	the	DT
cord-346842-ip4i3bdk	115	4	most	most	RBS
cord-346842-ip4i3bdk	115	5	commonly	commonly	RB
cord-346842-ip4i3bdk	115	6	used	use	VBN
cord-346842-ip4i3bdk	115	7	investigational	investigational	JJ
cord-346842-ip4i3bdk	115	8	drug	drug	NN
cord-346842-ip4i3bdk	115	9	(	(	-LRB-
cord-346842-ip4i3bdk	115	10	3	3	CD
cord-346842-ip4i3bdk	115	11	trials	trial	NNS
cord-346842-ip4i3bdk	115	12	)	)	-RRB-
cord-346842-ip4i3bdk	115	13	,	,	,
cord-346842-ip4i3bdk	115	14	followed	follow	VBN
cord-346842-ip4i3bdk	115	15	by	by	IN
cord-346842-ip4i3bdk	115	16	hydroxychloroquine	hydroxychloroquine	NNP
cord-346842-ip4i3bdk	115	17	and	and	CC
cord-346842-ip4i3bdk	115	18	nafamostat	nafamostat	NNP
cord-346842-ip4i3bdk	115	19	mesylate	mesylate	NNP
cord-346842-ip4i3bdk	115	20	with	with	IN
cord-346842-ip4i3bdk	115	21	2	2	CD
cord-346842-ip4i3bdk	115	22	trials	trial	NNS
cord-346842-ip4i3bdk	115	23	.	.	.
cord-346842-ip4i3bdk	116	1	Kyungpook	Kyungpook	NNP
cord-346842-ip4i3bdk	116	2	National	National	NNP
cord-346842-ip4i3bdk	116	3	University	University	NNP
cord-346842-ip4i3bdk	116	4	Hospital	Hospital	NNP
cord-346842-ip4i3bdk	116	5	,	,	,
cord-346842-ip4i3bdk	116	6	located	locate	VBN
cord-346842-ip4i3bdk	116	7	in	in	IN
cord-346842-ip4i3bdk	116	8	Daegu	Daegu	NNP
cord-346842-ip4i3bdk	116	9	,	,	,
cord-346842-ip4i3bdk	116	10	and	and	CC
cord-346842-ip4i3bdk	116	11	Seoul	Seoul	NNP
cord-346842-ip4i3bdk	116	12	Medical	Medical	NNP
cord-346842-ip4i3bdk	116	13	Center	Center	NNP
cord-346842-ip4i3bdk	116	14	in	in	IN
cord-346842-ip4i3bdk	116	15	Seoul	Seoul	NNP
cord-346842-ip4i3bdk	116	16	,	,	,
cord-346842-ip4i3bdk	116	17	which	which	WDT
cord-346842-ip4i3bdk	116	18	operated	operate	VBD
cord-346842-ip4i3bdk	116	19	a	a	DT
cord-346842-ip4i3bdk	116	20	professional	professional	JJ
cord-346842-ip4i3bdk	116	21	negative	negative	JJ
cord-346842-ip4i3bdk	116	22	-	-	HYPH
cord-346842-ip4i3bdk	116	23	pressure	pressure	NN
cord-346842-ip4i3bdk	116	24	isolation	isolation	NN
cord-346842-ip4i3bdk	116	25	ward	ward	NNP
cord-346842-ip4i3bdk	116	26	took	take	VBD
cord-346842-ip4i3bdk	116	27	part	part	NN
cord-346842-ip4i3bdk	116	28	in	in	IN
cord-346842-ip4i3bdk	116	29	the	the	DT
cord-346842-ip4i3bdk	116	30	largest	large	JJS
cord-346842-ip4i3bdk	116	31	number	number	NN
cord-346842-ip4i3bdk	116	32	of	of	IN
cord-346842-ip4i3bdk	116	33	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	116	34	clinical	clinical	JJ
cord-346842-ip4i3bdk	116	35	trials	trial	NNS
cord-346842-ip4i3bdk	116	36	in	in	IN
cord-346842-ip4i3bdk	116	37	Korea	Korea	NNP
cord-346842-ip4i3bdk	116	38	,	,	,
cord-346842-ip4i3bdk	116	39	with	with	IN
cord-346842-ip4i3bdk	116	40	4	4	CD
cord-346842-ip4i3bdk	116	41	trials	trial	NNS
cord-346842-ip4i3bdk	116	42	each	each	DT
cord-346842-ip4i3bdk	116	43	.	.	.
cord-346842-ip4i3bdk	117	1	Globally	globally	RB
cord-346842-ip4i3bdk	117	2	,	,	,
cord-346842-ip4i3bdk	117	3	a	a	DT
cord-346842-ip4i3bdk	117	4	total	total	JJ
cord-346842-ip4i3bdk	117	5	963	963	CD
cord-346842-ip4i3bdk	117	6	drug	drug	NN
cord-346842-ip4i3bdk	117	7	or	or	CC
cord-346842-ip4i3bdk	117	8	biological	biological	JJ
cord-346842-ip4i3bdk	117	9	agent	agent	NN
cord-346842-ip4i3bdk	117	10	intervention	intervention	NN
cord-346842-ip4i3bdk	117	11	clinical	clinical	JJ
cord-346842-ip4i3bdk	117	12	trials	trial	NNS
cord-346842-ip4i3bdk	117	13	were	be	VBD
cord-346842-ip4i3bdk	117	14	registered	register	VBN
cord-346842-ip4i3bdk	117	15	for	for	IN
cord-346842-ip4i3bdk	117	16	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	117	17	.	.	.
cord-346842-ip4i3bdk	117	18	9	9	CD
cord-346842-ip4i3bdk	118	1	In	in	IN
cord-346842-ip4i3bdk	118	2	terms	term	NNS
cord-346842-ip4i3bdk	118	3	of	of	IN
cord-346842-ip4i3bdk	118	4	study	study	NN
cord-346842-ip4i3bdk	118	5	status	status	NN
cord-346842-ip4i3bdk	118	6	,	,	,
cord-346842-ip4i3bdk	118	7	almost	almost	RB
cord-346842-ip4i3bdk	118	8	half	half	PDT
cord-346842-ip4i3bdk	118	9	(	(	-LRB-
cord-346842-ip4i3bdk	118	10	49	49	CD
cord-346842-ip4i3bdk	118	11	%	%	NN
cord-346842-ip4i3bdk	118	12	)	)	-RRB-
cord-346842-ip4i3bdk	118	13	were	be	VBD
cord-346842-ip4i3bdk	118	14	recruitment	recruitment	NN
cord-346842-ip4i3bdk	118	15	phase	phase	NN
cord-346842-ip4i3bdk	118	16	.	.	.
cord-346842-ip4i3bdk	119	1	Regarding	regard	VBG
cord-346842-ip4i3bdk	119	2	initiating	initiate	VBG
cord-346842-ip4i3bdk	119	3	parties	party	NNS
cord-346842-ip4i3bdk	119	4	,	,	,
cord-346842-ip4i3bdk	119	5	591	591	CD
cord-346842-ip4i3bdk	119	6	trials	trial	NNS
cord-346842-ip4i3bdk	119	7	(	(	-LRB-
cord-346842-ip4i3bdk	119	8	63	63	CD
cord-346842-ip4i3bdk	119	9	%	%	NN
cord-346842-ip4i3bdk	119	10	)	)	-RRB-
cord-346842-ip4i3bdk	119	11	were	be	VBD
cord-346842-ip4i3bdk	119	12	investigator	investigator	NN
cord-346842-ip4i3bdk	119	13	-	-	HYPH
cord-346842-ip4i3bdk	119	14	initiated	initiate	VBN
cord-346842-ip4i3bdk	119	15	,	,	,
cord-346842-ip4i3bdk	119	16	297	297	CD
cord-346842-ip4i3bdk	119	17	(	(	-LRB-
cord-346842-ip4i3bdk	119	18	31	31	CD
cord-346842-ip4i3bdk	119	19	%	%	NN
cord-346842-ip4i3bdk	119	20	)	)	-RRB-
cord-346842-ip4i3bdk	119	21	were	be	VBD
cord-346842-ip4i3bdk	119	22	sponsor	sponsor	NN
cord-346842-ip4i3bdk	119	23	initiated	initiate	VBN
cord-346842-ip4i3bdk	119	24	and	and	CC
cord-346842-ip4i3bdk	119	25	17	17	CD
cord-346842-ip4i3bdk	119	26	(	(	-LRB-
cord-346842-ip4i3bdk	119	27	2	2	CD
cord-346842-ip4i3bdk	119	28	%	%	NN
cord-346842-ip4i3bdk	119	29	)	)	-RRB-
cord-346842-ip4i3bdk	119	30	were	be	VBD
cord-346842-ip4i3bdk	119	31	sponsored	sponsor	VBN
cord-346842-ip4i3bdk	119	32	by	by	IN
cord-346842-ip4i3bdk	119	33	the	the	DT
cord-346842-ip4i3bdk	119	34	US	US	NNP
cord-346842-ip4i3bdk	119	35	National	National	NNP
cord-346842-ip4i3bdk	119	36	Institutes	Institutes	NNPS
cord-346842-ip4i3bdk	119	37	of	of	IN
cord-346842-ip4i3bdk	119	38	Health	Health	NNP
cord-346842-ip4i3bdk	119	39	or	or	CC
cord-346842-ip4i3bdk	119	40	US	US	NNP
cord-346842-ip4i3bdk	119	41	Federal	Federal	NNP
cord-346842-ip4i3bdk	119	42	Reserve	Reserve	NNP
cord-346842-ip4i3bdk	119	43	,	,	,
cord-346842-ip4i3bdk	119	44	as	as	IN
cord-346842-ip4i3bdk	119	45	of	of	IN
cord-346842-ip4i3bdk	119	46	June	June	NNP
cord-346842-ip4i3bdk	119	47	22	22	CD
cord-346842-ip4i3bdk	119	48	,	,	,
cord-346842-ip4i3bdk	119	49	2020	2020	CD
cord-346842-ip4i3bdk	119	50	.	.	.
cord-346842-ip4i3bdk	120	1	15	15	CD
cord-346842-ip4i3bdk	121	1	The	the	DT
cord-346842-ip4i3bdk	121	2	majority	majority	NN
cord-346842-ip4i3bdk	121	3	of	of	IN
cord-346842-ip4i3bdk	121	4	studies	study	NNS
cord-346842-ip4i3bdk	121	5	were	be	VBD
cord-346842-ip4i3bdk	121	6	phase	phase	NN
cord-346842-ip4i3bdk	121	7	2	2	CD
cord-346842-ip4i3bdk	121	8	trials	trial	NNS
cord-346842-ip4i3bdk	121	9	(	(	-LRB-
cord-346842-ip4i3bdk	121	10	45	45	CD
cord-346842-ip4i3bdk	121	11	%	%	NN
cord-346842-ip4i3bdk	121	12	)	)	-RRB-
cord-346842-ip4i3bdk	121	13	and	and	CC
cord-346842-ip4i3bdk	121	14	treatment	treatment	NN
cord-346842-ip4i3bdk	121	15	development	development	NN
cord-346842-ip4i3bdk	121	16	trials	trial	NNS
cord-346842-ip4i3bdk	121	17	(	(	-LRB-
cord-346842-ip4i3bdk	121	18	96	96	CD
cord-346842-ip4i3bdk	121	19	%	%	NN
cord-346842-ip4i3bdk	121	20	)	)	-RRB-
cord-346842-ip4i3bdk	121	21	(	(	-LRB-
cord-346842-ip4i3bdk	121	22	Fig	Fig	NNP
cord-346842-ip4i3bdk	121	23	.	.	.
cord-346842-ip4i3bdk	121	24	8)	8)	NNP
cord-346842-ip4i3bdk	121	25	.	.	.
cord-346842-ip4i3bdk	122	1	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-346842-ip4i3bdk	122	2	was	be	VBD
cord-346842-ip4i3bdk	122	3	the	the	DT
cord-346842-ip4i3bdk	122	4	most	most	RBS
cord-346842-ip4i3bdk	122	5	commonly	commonly	RB
cord-346842-ip4i3bdk	122	6	used	use	VBN
cord-346842-ip4i3bdk	122	7	investigational	investigational	JJ
cord-346842-ip4i3bdk	122	8	drug	drug	NN
cord-346842-ip4i3bdk	122	9	(	(	-LRB-
cord-346842-ip4i3bdk	122	10	Table	Table	NNP
cord-346842-ip4i3bdk	122	11	1	1	CD
cord-346842-ip4i3bdk	122	12	)	)	-RRB-
cord-346842-ip4i3bdk	122	13	.	.	.
cord-346842-ip4i3bdk	123	1	multiple	multiple	JJ
cord-346842-ip4i3bdk	123	2	sites	site	NNS
cord-346842-ip4i3bdk	123	3	,	,	,
cord-346842-ip4i3bdk	123	4	they	-PRON-	PRP
cord-346842-ip4i3bdk	123	5	recommended	recommend	VBD
cord-346842-ip4i3bdk	123	6	that	that	IN
cord-346842-ip4i3bdk	123	7	a	a	DT
cord-346842-ip4i3bdk	123	8	joint	joint	JJ
cord-346842-ip4i3bdk	123	9	review	review	NN
cord-346842-ip4i3bdk	123	10	committee	committee	NN
cord-346842-ip4i3bdk	123	11	be	be	VB
cord-346842-ip4i3bdk	123	12	established	establish	VBN
cord-346842-ip4i3bdk	123	13	to	to	TO
cord-346842-ip4i3bdk	123	14	review	review	VB
cord-346842-ip4i3bdk	123	15	each	each	DT
cord-346842-ip4i3bdk	123	16	study	study	NN
cord-346842-ip4i3bdk	123	17	protocol	protocol	NN
cord-346842-ip4i3bdk	123	18	and	and	CC
cord-346842-ip4i3bdk	123	19	make	make	VB
cord-346842-ip4i3bdk	123	20	a	a	DT
cord-346842-ip4i3bdk	123	21	joint	joint	JJ
cord-346842-ip4i3bdk	123	22	decision	decision	NN
cord-346842-ip4i3bdk	123	23	.	.	.
cord-346842-ip4i3bdk	124	1	12	12	CD
cord-346842-ip4i3bdk	125	1	To	to	TO
cord-346842-ip4i3bdk	125	2	prevent	prevent	VB
cord-346842-ip4i3bdk	125	3	the	the	DT
cord-346842-ip4i3bdk	125	4	spread	spread	NN
cord-346842-ip4i3bdk	125	5	of	of	IN
cord-346842-ip4i3bdk	125	6	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	125	7	during	during	IN
cord-346842-ip4i3bdk	125	8	review	review	NN
cord-346842-ip4i3bdk	125	9	meetings	meeting	NNS
cord-346842-ip4i3bdk	125	10	,	,	,
cord-346842-ip4i3bdk	125	11	it	-PRON-	PRP
cord-346842-ip4i3bdk	125	12	was	be	VBD
cord-346842-ip4i3bdk	125	13	suggested	suggest	VBN
cord-346842-ip4i3bdk	125	14	that	that	IN
cord-346842-ip4i3bdk	125	15	the	the	DT
cord-346842-ip4i3bdk	125	16	review	review	NN
cord-346842-ip4i3bdk	125	17	process	process	NN
cord-346842-ip4i3bdk	125	18	be	be	VB
cord-346842-ip4i3bdk	125	19	modified	modify	VBN
cord-346842-ip4i3bdk	125	20	by	by	IN
cord-346842-ip4i3bdk	125	21	having	have	VBG
cord-346842-ip4i3bdk	125	22	non	non	JJ
cord-346842-ip4i3bdk	125	23	-	-	JJ
cord-346842-ip4i3bdk	125	24	contact	contact	JJ
cord-346842-ip4i3bdk	125	25	review	review	NN
cord-346842-ip4i3bdk	125	26	meetings	meeting	NNS
cord-346842-ip4i3bdk	125	27	,	,	,
cord-346842-ip4i3bdk	125	28	and	and	CC
cord-346842-ip4i3bdk	125	29	that	that	IN
cord-346842-ip4i3bdk	125	30	this	this	DT
cord-346842-ip4i3bdk	125	31	be	be	VB
cord-346842-ip4i3bdk	125	32	documented	document	VBN
cord-346842-ip4i3bdk	125	33	.	.	.
cord-346842-ip4i3bdk	126	1	12	12	CD
cord-346842-ip4i3bdk	127	1	In	in	IN
cord-346842-ip4i3bdk	127	2	order	order	NN
cord-346842-ip4i3bdk	127	3	to	to	TO
cord-346842-ip4i3bdk	127	4	support	support	VB
cord-346842-ip4i3bdk	127	5	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	127	6	drug	drug	NN
cord-346842-ip4i3bdk	127	7	development	development	NN
cord-346842-ip4i3bdk	127	8	,	,	,
cord-346842-ip4i3bdk	127	9	the	the	DT
cord-346842-ip4i3bdk	127	10	MFDS	MFDS	NNP
cord-346842-ip4i3bdk	127	11	applied	apply	VBD
cord-346842-ip4i3bdk	127	12	for	for	IN
cord-346842-ip4i3bdk	127	13	expedited	expedited	JJ
cord-346842-ip4i3bdk	127	14	review	review	NN
cord-346842-ip4i3bdk	127	15	of	of	IN
cord-346842-ip4i3bdk	127	16	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	127	17	trial	trial	NN
cord-346842-ip4i3bdk	127	18	protocols	protocol	NNS
cord-346842-ip4i3bdk	127	19	.	.	.
cord-346842-ip4i3bdk	128	1	A	a	DT
cord-346842-ip4i3bdk	128	2	trial	trial	NN
cord-346842-ip4i3bdk	128	3	of	of	IN
cord-346842-ip4i3bdk	128	4	remdesivir	remdesivir	NNP
cord-346842-ip4i3bdk	128	5	for	for	IN
cord-346842-ip4i3bdk	128	6	treatment	treatment	NN
cord-346842-ip4i3bdk	128	7	of	of	IN
cord-346842-ip4i3bdk	128	8	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	128	9	,	,	,
cord-346842-ip4i3bdk	128	10	sponsored	sponsor	VBN
cord-346842-ip4i3bdk	128	11	by	by	IN
cord-346842-ip4i3bdk	128	12	Gilead	Gilead	NNP
cord-346842-ip4i3bdk	128	13	Sciences	Sciences	NNPS
cord-346842-ip4i3bdk	128	14	,	,	,
cord-346842-ip4i3bdk	128	15	Inc	Inc	NNP
cord-346842-ip4i3bdk	128	16	was	be	VBD
cord-346842-ip4i3bdk	128	17	submitted	submit	VBN
cord-346842-ip4i3bdk	128	18	to	to	IN
cord-346842-ip4i3bdk	128	19	the	the	DT
cord-346842-ip4i3bdk	128	20	MFDS	MFDS	NNP
cord-346842-ip4i3bdk	128	21	for	for	IN
cord-346842-ip4i3bdk	128	22	RA	RA	NNP
cord-346842-ip4i3bdk	128	23	approval	approval	NN
cord-346842-ip4i3bdk	128	24	on	on	IN
cord-346842-ip4i3bdk	128	25	February	February	NNP
cord-346842-ip4i3bdk	128	26	27	27	CD
cord-346842-ip4i3bdk	128	27	,	,	,
cord-346842-ip4i3bdk	128	28	2020	2020	CD
cord-346842-ip4i3bdk	128	29	and	and	CC
cord-346842-ip4i3bdk	128	30	approved	approve	VBD
cord-346842-ip4i3bdk	128	31	on	on	IN
cord-346842-ip4i3bdk	128	32	March	March	NNP
cord-346842-ip4i3bdk	128	33	2	2	CD
cord-346842-ip4i3bdk	128	34	,	,	,
cord-346842-ip4i3bdk	128	35	2020	2020	CD
cord-346842-ip4i3bdk	128	36	.	.	.
cord-346842-ip4i3bdk	129	1	The	the	DT
cord-346842-ip4i3bdk	129	2	US	US	NNP
cord-346842-ip4i3bdk	129	3	Food	Food	NNP
cord-346842-ip4i3bdk	129	4	and	and	CC
cord-346842-ip4i3bdk	129	5	Drug	Drug	NNP
cord-346842-ip4i3bdk	129	6	Administration	Administration	NNP
cord-346842-ip4i3bdk	129	7	suggested	suggest	VBD
cord-346842-ip4i3bdk	129	8	that	that	IN
cord-346842-ip4i3bdk	129	9	sponsors	sponsor	NNS
cord-346842-ip4i3bdk	129	10	and	and	CC
cord-346842-ip4i3bdk	129	11	clinical	clinical	JJ
cord-346842-ip4i3bdk	129	12	investigators	investigator	NNS
cord-346842-ip4i3bdk	129	13	document	document	VBP
cord-346842-ip4i3bdk	129	14	the	the	DT
cord-346842-ip4i3bdk	129	15	reason	reason	NN
cord-346842-ip4i3bdk	129	16	for	for	IN
cord-346842-ip4i3bdk	129	17	any	any	DT
cord-346842-ip4i3bdk	129	18	contingency	contingency	NN
cord-346842-ip4i3bdk	129	19	measures	measure	NNS
cord-346842-ip4i3bdk	129	20	implemented	implement	VBN
cord-346842-ip4i3bdk	129	21	,	,	,
cord-346842-ip4i3bdk	129	22	how	how	WRB
cord-346842-ip4i3bdk	129	23	restrictions	restriction	NNS
cord-346842-ip4i3bdk	129	24	related	relate	VBN
cord-346842-ip4i3bdk	129	25	to	to	IN
cord-346842-ip4i3bdk	129	26	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	129	27	led	lead	VBN
cord-346842-ip4i3bdk	129	28	to	to	IN
cord-346842-ip4i3bdk	129	29	changes	change	NNS
cord-346842-ip4i3bdk	129	30	in	in	IN
cord-346842-ip4i3bdk	129	31	the	the	DT
cord-346842-ip4i3bdk	129	32	study	study	NN
cord-346842-ip4i3bdk	129	33	conduct	conduct	NN
cord-346842-ip4i3bdk	129	34	,	,	,
cord-346842-ip4i3bdk	129	35	which	which	WDT
cord-346842-ip4i3bdk	129	36	trial	trial	NN
cord-346842-ip4i3bdk	129	37	participants	participant	NNS
cord-346842-ip4i3bdk	129	38	were	be	VBD
cord-346842-ip4i3bdk	129	39	affected	affect	VBN
cord-346842-ip4i3bdk	129	40	and	and	CC
cord-346842-ip4i3bdk	129	41	how	how	WRB
cord-346842-ip4i3bdk	129	42	these	these	DT
cord-346842-ip4i3bdk	129	43	participants	participant	NNS
cord-346842-ip4i3bdk	129	44	were	be	VBD
cord-346842-ip4i3bdk	129	45	affected	affect	VBN
cord-346842-ip4i3bdk	129	46	in	in	IN
cord-346842-ip4i3bdk	129	47	the	the	DT
cord-346842-ip4i3bdk	129	48	Clinical	Clinical	NNP
cord-346842-ip4i3bdk	129	49	Study	Study	NNP
cord-346842-ip4i3bdk	129	50	Report	Report	NNP
cord-346842-ip4i3bdk	129	51	.	.	.
cord-346842-ip4i3bdk	130	1	17	17	CD
cord-346842-ip4i3bdk	131	1	The	the	DT
cord-346842-ip4i3bdk	131	2	European	European	NNP
cord-346842-ip4i3bdk	131	3	Medicine	Medicine	NNP
cord-346842-ip4i3bdk	131	4	Agency	Agency	NNP
cord-346842-ip4i3bdk	131	5	guided	guide	VBN
cord-346842-ip4i3bdk	131	6	for	for	IN
cord-346842-ip4i3bdk	131	7	regularities	regularity	NNS
cord-346842-ip4i3bdk	131	8	to	to	TO
cord-346842-ip4i3bdk	131	9	put	put	VB
cord-346842-ip4i3bdk	131	10	priority	priority	NN
cord-346842-ip4i3bdk	131	11	on	on	IN
cord-346842-ip4i3bdk	131	12	any	any	DT
cord-346842-ip4i3bdk	131	13	clinical	clinical	JJ
cord-346842-ip4i3bdk	131	14	trial	trial	NN
cord-346842-ip4i3bdk	131	15	application	application	NN
cord-346842-ip4i3bdk	131	16	for	for	IN
cord-346842-ip4i3bdk	131	17	the	the	DT
cord-346842-ip4i3bdk	131	18	treatment	treatment	NN
cord-346842-ip4i3bdk	131	19	or	or	CC
cord-346842-ip4i3bdk	131	20	prevention	prevention	NN
cord-346842-ip4i3bdk	131	21	of	of	IN
cord-346842-ip4i3bdk	131	22	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	131	23	infection	infection	NN
cord-346842-ip4i3bdk	131	24	,	,	,
cord-346842-ip4i3bdk	131	25	and	and	CC
cord-346842-ip4i3bdk	131	26	the	the	DT
cord-346842-ip4i3bdk	131	27	approval	approval	NN
cord-346842-ip4i3bdk	131	28	of	of	IN
cord-346842-ip4i3bdk	131	29	applications	application	NNS
cord-346842-ip4i3bdk	131	30	for	for	IN
cord-346842-ip4i3bdk	131	31	substantial	substantial	JJ
cord-346842-ip4i3bdk	131	32	amendments	amendment	NNS
cord-346842-ip4i3bdk	131	33	to	to	IN
cord-346842-ip4i3bdk	131	34	existing	exist	VBG
cord-346842-ip4i3bdk	131	35	clinical	clinical	JJ
cord-346842-ip4i3bdk	131	36	trials	trial	NNS
cord-346842-ip4i3bdk	131	37	if	if	IN
cord-346842-ip4i3bdk	131	38	necessary	necessary	JJ
cord-346842-ip4i3bdk	131	39	as	as	IN
cord-346842-ip4i3bdk	131	40	a	a	DT
cord-346842-ip4i3bdk	131	41	result	result	NN
cord-346842-ip4i3bdk	131	42	of	of	IN
cord-346842-ip4i3bdk	131	43	the	the	DT
cord-346842-ip4i3bdk	131	44	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	131	45	pandemic	pandemic	NN
cord-346842-ip4i3bdk	131	46	.	.	.
cord-346842-ip4i3bdk	132	1	The	the	DT
cord-346842-ip4i3bdk	132	2	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	132	3	pandemic	pandemic	NN
cord-346842-ip4i3bdk	132	4	is	be	VBZ
cord-346842-ip4i3bdk	132	5	having	have	VBG
cord-346842-ip4i3bdk	132	6	a	a	DT
cord-346842-ip4i3bdk	132	7	global	global	JJ
cord-346842-ip4i3bdk	132	8	impact	impact	NN
cord-346842-ip4i3bdk	132	9	.	.	.
cord-346842-ip4i3bdk	133	1	Clinical	clinical	JJ
cord-346842-ip4i3bdk	133	2	trials	trial	NNS
cord-346842-ip4i3bdk	133	3	are	be	VBP
cord-346842-ip4i3bdk	133	4	one	one	CD
cord-346842-ip4i3bdk	133	5	of	of	IN
cord-346842-ip4i3bdk	133	6	the	the	DT
cord-346842-ip4i3bdk	133	7	areas	area	NNS
cord-346842-ip4i3bdk	133	8	that	that	WDT
cord-346842-ip4i3bdk	133	9	have	have	VBP
cord-346842-ip4i3bdk	133	10	been	be	VBN
cord-346842-ip4i3bdk	133	11	affected	affect	VBN
cord-346842-ip4i3bdk	133	12	.	.	.
cord-346842-ip4i3bdk	134	1	Clinical	clinical	JJ
cord-346842-ip4i3bdk	134	2	trials	trial	NNS
cord-346842-ip4i3bdk	134	3	are	be	VBP
cord-346842-ip4i3bdk	134	4	meaningful	meaningful	JJ
cord-346842-ip4i3bdk	134	5	in	in	IN
cord-346842-ip4i3bdk	134	6	that	that	IN
cord-346842-ip4i3bdk	134	7	they	-PRON-	PRP
cord-346842-ip4i3bdk	134	8	provide	provide	VBP
cord-346842-ip4i3bdk	134	9	patients	patient	NNS
cord-346842-ip4i3bdk	134	10	with	with	IN
cord-346842-ip4i3bdk	134	11	novel	novel	JJ
cord-346842-ip4i3bdk	134	12	treatment	treatment	NN
cord-346842-ip4i3bdk	134	13	options	option	NNS
cord-346842-ip4i3bdk	134	14	during	during	IN
cord-346842-ip4i3bdk	134	15	the	the	DT
cord-346842-ip4i3bdk	134	16	process	process	NN
cord-346842-ip4i3bdk	134	17	,	,	,
cord-346842-ip4i3bdk	134	18	and	and	CC
cord-346842-ip4i3bdk	134	19	if	if	IN
cord-346842-ip4i3bdk	134	20	they	-PRON-	PRP
cord-346842-ip4i3bdk	134	21	lead	lead	VBP
cord-346842-ip4i3bdk	134	22	to	to	IN
cord-346842-ip4i3bdk	134	23	marketing	marketing	NN
cord-346842-ip4i3bdk	134	24	of	of	IN
cord-346842-ip4i3bdk	134	25	new	new	JJ
cord-346842-ip4i3bdk	134	26	treatments	treatment	NNS
cord-346842-ip4i3bdk	134	27	,	,	,
cord-346842-ip4i3bdk	134	28	they	-PRON-	PRP
cord-346842-ip4i3bdk	134	29	may	may	MD
cord-346842-ip4i3bdk	134	30	be	be	VB
cord-346842-ip4i3bdk	134	31	of	of	IN
cord-346842-ip4i3bdk	134	32	benefit	benefit	NN
cord-346842-ip4i3bdk	134	33	to	to	IN
cord-346842-ip4i3bdk	134	34	many	many	JJ
cord-346842-ip4i3bdk	134	35	future	future	JJ
cord-346842-ip4i3bdk	134	36	patients	patient	NNS
cord-346842-ip4i3bdk	134	37	.	.	.
cord-346842-ip4i3bdk	135	1	Moreover	moreover	RB
cord-346842-ip4i3bdk	135	2	,	,	,
cord-346842-ip4i3bdk	135	3	considering	consider	VBG
cord-346842-ip4i3bdk	135	4	that	that	IN
cord-346842-ip4i3bdk	135	5	clinical	clinical	JJ
cord-346842-ip4i3bdk	135	6	trials	trial	NNS
cord-346842-ip4i3bdk	135	7	are	be	VBP
cord-346842-ip4i3bdk	135	8	required	require	VBN
cord-346842-ip4i3bdk	135	9	for	for	IN
cord-346842-ip4i3bdk	135	10	developing	develop	VBG
cord-346842-ip4i3bdk	135	11	COVID-19	covid-19	CD
cord-346842-ip4i3bdk	135	12	treatments	treatment	NNS
cord-346842-ip4i3bdk	135	13	,	,	,
cord-346842-ip4i3bdk	135	14	conditions	condition	NNS
cord-346842-ip4i3bdk	135	15	should	should	MD
cord-346842-ip4i3bdk	135	16	be	be	VB
cord-346842-ip4i3bdk	135	17	established	establish	VBN
cord-346842-ip4i3bdk	135	18	in	in	IN
cord-346842-ip4i3bdk	135	19	which	which	WDT
cord-346842-ip4i3bdk	135	20	necessary	necessary	JJ
cord-346842-ip4i3bdk	135	21	clinical	clinical	JJ
cord-346842-ip4i3bdk	135	22	trials	trial	NNS
cord-346842-ip4i3bdk	135	23	can	can	MD
cord-346842-ip4i3bdk	135	24	be	be	VB
cord-346842-ip4i3bdk	135	25	carried	carry	VBN
cord-346842-ip4i3bdk	135	26	out	out	RP
cord-346842-ip4i3bdk	135	27	smoothly	smoothly	RB
cord-346842-ip4i3bdk	135	28	even	even	RB
cord-346842-ip4i3bdk	135	29	during	during	IN
cord-346842-ip4i3bdk	135	30	the	the	DT
cord-346842-ip4i3bdk	135	31	pandemic	pandemic	NN
cord-346842-ip4i3bdk	135	32	,	,	,
cord-346842-ip4i3bdk	135	33	while	while	IN
cord-346842-ip4i3bdk	135	34	protecting	protect	VBG
cord-346842-ip4i3bdk	135	35	all	all	DT
cord-346842-ip4i3bdk	135	36	trial	trial	NN
cord-346842-ip4i3bdk	135	37	participants	participant	NNS
cord-346842-ip4i3bdk	135	38	'	'	POS
cord-346842-ip4i3bdk	135	39	safety	safety	NN
cord-346842-ip4i3bdk	135	40	.	.	.
cord-346842-ip4i3bdk	136	1	In	in	IN
cord-346842-ip4i3bdk	136	2	Korea	Korea	NNP
cord-346842-ip4i3bdk	136	3	,	,	,
cord-346842-ip4i3bdk	136	4	all	all	DT
cord-346842-ip4i3bdk	136	5	parties	party	NNS
cord-346842-ip4i3bdk	136	6	involved	involve	VBN
cord-346842-ip4i3bdk	136	7	in	in	IN
cord-346842-ip4i3bdk	136	8	the	the	DT
cord-346842-ip4i3bdk	136	9	conduct	conduct	NN
cord-346842-ip4i3bdk	136	10	of	of	IN
cord-346842-ip4i3bdk	136	11	trials	trial	NNS
cord-346842-ip4i3bdk	136	12	have	have	VBP
cord-346842-ip4i3bdk	136	13	been	be	VBN
cord-346842-ip4i3bdk	136	14	affected	affect	VBN
cord-346842-ip4i3bdk	136	15	by	by	IN
cord-346842-ip4i3bdk	136	16	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	136	17	pandemic	pandemic	NN
cord-346842-ip4i3bdk	136	18	.	.	.
cord-346842-ip4i3bdk	137	1	Various	various	JJ
cord-346842-ip4i3bdk	137	2	guidelines	guideline	NNS
cord-346842-ip4i3bdk	137	3	for	for	IN
cord-346842-ip4i3bdk	137	4	conducting	conduct	VBG
cord-346842-ip4i3bdk	137	5	trials	trial	NNS
cord-346842-ip4i3bdk	137	6	during	during	IN
cord-346842-ip4i3bdk	137	7	the	the	DT
cord-346842-ip4i3bdk	137	8	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	137	9	pandemic	pandemic	NN
cord-346842-ip4i3bdk	137	10	have	have	VBP
cord-346842-ip4i3bdk	137	11	been	be	VBN
cord-346842-ip4i3bdk	137	12	released	release	VBN
cord-346842-ip4i3bdk	137	13	both	both	CC
cord-346842-ip4i3bdk	137	14	locally	locally	RB
cord-346842-ip4i3bdk	137	15	and	and	CC
cord-346842-ip4i3bdk	137	16	globally	globally	RB
cord-346842-ip4i3bdk	137	17	for	for	IN
cord-346842-ip4i3bdk	137	18	supporting	support	VBG
cord-346842-ip4i3bdk	137	19	the	the	DT
cord-346842-ip4i3bdk	137	20	operation	operation	NN
cord-346842-ip4i3bdk	137	21	of	of	IN
cord-346842-ip4i3bdk	137	22	trials	trial	NNS
cord-346842-ip4i3bdk	137	23	.	.	.
cord-346842-ip4i3bdk	138	1	Guidelines	guideline	NNS
cord-346842-ip4i3bdk	138	2	developed	develop	VBN
cord-346842-ip4i3bdk	138	3	by	by	IN
cord-346842-ip4i3bdk	138	4	foreign	foreign	JJ
cord-346842-ip4i3bdk	138	5	countries	country	NNS
cord-346842-ip4i3bdk	138	6	should	should	MD
cord-346842-ip4i3bdk	138	7	be	be	VB
cord-346842-ip4i3bdk	138	8	considered	consider	VBN
cord-346842-ip4i3bdk	138	9	and	and	CC
cord-346842-ip4i3bdk	138	10	adopted	adopt	VBN
cord-346842-ip4i3bdk	138	11	in	in	IN
cord-346842-ip4i3bdk	138	12	accordance	accordance	NN
cord-346842-ip4i3bdk	138	13	with	with	IN
cord-346842-ip4i3bdk	138	14	the	the	DT
cord-346842-ip4i3bdk	138	15	situation	situation	NN
cord-346842-ip4i3bdk	138	16	in	in	IN
cord-346842-ip4i3bdk	138	17	Korea	Korea	NNP
cord-346842-ip4i3bdk	138	18	if	if	IN
cord-346842-ip4i3bdk	138	19	they	-PRON-	PRP
cord-346842-ip4i3bdk	138	20	are	be	VBP
cord-346842-ip4i3bdk	138	21	judged	judge	VBN
cord-346842-ip4i3bdk	138	22	to	to	TO
cord-346842-ip4i3bdk	138	23	be	be	VB
cord-346842-ip4i3bdk	138	24	appropriate	appropriate	JJ
cord-346842-ip4i3bdk	138	25	.	.	.
cord-346842-ip4i3bdk	139	1	Twelve	twelve	CD
cord-346842-ip4i3bdk	139	2	percent	percent	NN
cord-346842-ip4i3bdk	139	3	CPMs	cpm	NNS
cord-346842-ip4i3bdk	139	4	responded	respond	VBD
cord-346842-ip4i3bdk	139	5	that	that	IN
cord-346842-ip4i3bdk	139	6	subject	subject	JJ
cord-346842-ip4i3bdk	139	7	study	study	NN
cord-346842-ip4i3bdk	139	8	visits	visit	NNS
cord-346842-ip4i3bdk	139	9	were	be	VBD
cord-346842-ip4i3bdk	139	10	not	not	RB
cord-346842-ip4i3bdk	139	11	performed	perform	VBN
cord-346842-ip4i3bdk	139	12	as	as	IN
cord-346842-ip4i3bdk	139	13	planned	plan	VBN
cord-346842-ip4i3bdk	139	14	according	accord	VBG
cord-346842-ip4i3bdk	139	15	to	to	IN
cord-346842-ip4i3bdk	139	16	the	the	DT
cord-346842-ip4i3bdk	139	17	protocol	protocol	NN
cord-346842-ip4i3bdk	139	18	.	.	.
cord-346842-ip4i3bdk	140	1	Although	although	IN
cord-346842-ip4i3bdk	140	2	the	the	DT
cord-346842-ip4i3bdk	140	3	proportion	proportion	NN
cord-346842-ip4i3bdk	140	4	of	of	IN
cord-346842-ip4i3bdk	140	5	trials	trial	NNS
cord-346842-ip4i3bdk	140	6	not	not	RB
cord-346842-ip4i3bdk	140	7	affected	affect	VBN
cord-346842-ip4i3bdk	140	8	(	(	-LRB-
cord-346842-ip4i3bdk	140	9	55	55	CD
cord-346842-ip4i3bdk	140	10	%	%	NN
cord-346842-ip4i3bdk	140	11	)	)	-RRB-
cord-346842-ip4i3bdk	140	12	was	be	VBD
cord-346842-ip4i3bdk	140	13	higher	high	JJR
cord-346842-ip4i3bdk	140	14	,	,	,
cord-346842-ip4i3bdk	140	15	given	give	VBN
cord-346842-ip4i3bdk	140	16	that	that	IN
cord-346842-ip4i3bdk	140	17	the	the	DT
cord-346842-ip4i3bdk	140	18	provision	provision	NN
cord-346842-ip4i3bdk	140	19	of	of	IN
cord-346842-ip4i3bdk	140	20	treatment	treatment	NN
cord-346842-ip4i3bdk	140	21	is	be	VBZ
cord-346842-ip4i3bdk	140	22	contingent	contingent	JJ
cord-346842-ip4i3bdk	140	23	on	on	IN
cord-346842-ip4i3bdk	140	24	assuring	assure	VBG
cord-346842-ip4i3bdk	140	25	the	the	DT
cord-346842-ip4i3bdk	140	26	safety	safety	NN
cord-346842-ip4i3bdk	140	27	of	of	IN
cord-346842-ip4i3bdk	140	28	subject	subject	NN
cord-346842-ip4i3bdk	140	29	,	,	,
cord-346842-ip4i3bdk	140	30	12	12	CD
cord-346842-ip4i3bdk	140	31	%	%	NN
cord-346842-ip4i3bdk	140	32	is	be	VBZ
cord-346842-ip4i3bdk	140	33	a	a	DT
cord-346842-ip4i3bdk	140	34	sizeable	sizeable	JJ
cord-346842-ip4i3bdk	140	35	proportion	proportion	NN
cord-346842-ip4i3bdk	140	36	that	that	WDT
cord-346842-ip4i3bdk	140	37	can	can	MD
cord-346842-ip4i3bdk	140	38	not	not	RB
cord-346842-ip4i3bdk	140	39	be	be	VB
cord-346842-ip4i3bdk	140	40	overlooked	overlook	VBN
cord-346842-ip4i3bdk	140	41	.	.	.
cord-346842-ip4i3bdk	141	1	If	if	IN
cord-346842-ip4i3bdk	141	2	the	the	DT
cord-346842-ip4i3bdk	141	3	treatment	treatment	NN
cord-346842-ip4i3bdk	141	4	that	that	WDT
cord-346842-ip4i3bdk	141	5	subjects	subject	NNS
cord-346842-ip4i3bdk	141	6	receive	receive	VBP
cord-346842-ip4i3bdk	141	7	through	through	IN
cord-346842-ip4i3bdk	141	8	clinical	clinical	JJ
cord-346842-ip4i3bdk	141	9	trial	trial	NN
cord-346842-ip4i3bdk	141	10	participation	participation	NN
cord-346842-ip4i3bdk	141	11	can	can	MD
cord-346842-ip4i3bdk	141	12	not	not	RB
cord-346842-ip4i3bdk	141	13	be	be	VB
cord-346842-ip4i3bdk	141	14	replaced	replace	VBN
cord-346842-ip4i3bdk	141	15	by	by	IN
cord-346842-ip4i3bdk	141	16	the	the	DT
cord-346842-ip4i3bdk	141	17	standard	standard	NN
cord-346842-ip4i3bdk	141	18	of	of	IN
cord-346842-ip4i3bdk	141	19	care	care	NN
cord-346842-ip4i3bdk	141	20	,	,	,
cord-346842-ip4i3bdk	141	21	action	action	NN
cord-346842-ip4i3bdk	141	22	should	should	MD
cord-346842-ip4i3bdk	141	23	be	be	VB
cord-346842-ip4i3bdk	141	24	taken	take	VBN
cord-346842-ip4i3bdk	141	25	to	to	TO
cord-346842-ip4i3bdk	141	26	maintain	maintain	VB
cord-346842-ip4i3bdk	141	27	the	the	DT
cord-346842-ip4i3bdk	141	28	treatment	treatment	NN
cord-346842-ip4i3bdk	141	29	while	while	IN
cord-346842-ip4i3bdk	141	30	complying	comply	VBG
cord-346842-ip4i3bdk	141	31	with	with	IN
cord-346842-ip4i3bdk	141	32	the	the	DT
cord-346842-ip4i3bdk	141	33	KCDC	KCDC	NNP
cord-346842-ip4i3bdk	141	34	guideline	guideline	NN
cord-346842-ip4i3bdk	141	35	.	.	.
cord-346842-ip4i3bdk	142	1	Under	under	IN
cord-346842-ip4i3bdk	142	2	the	the	DT
cord-346842-ip4i3bdk	142	3	current	current	JJ
cord-346842-ip4i3bdk	142	4	Article	article	NN
cord-346842-ip4i3bdk	142	5	50	50	CD
cord-346842-ip4i3bdk	142	6	(	(	-LRB-
cord-346842-ip4i3bdk	142	7	1	1	CD
cord-346842-ip4i3bdk	142	8	)	)	-RRB-
cord-346842-ip4i3bdk	142	9	of	of	IN
cord-346842-ip4i3bdk	142	10	the	the	DT
cord-346842-ip4i3bdk	142	11	Pharmaceutical	Pharmaceutical	NNP
cord-346842-ip4i3bdk	142	12	Affairs	Affairs	NNPS
cord-346842-ip4i3bdk	142	13	Act	Act	NNP
cord-346842-ip4i3bdk	142	14	,	,	,
cord-346842-ip4i3bdk	142	15	the	the	DT
cord-346842-ip4i3bdk	142	16	sale	sale	NN
cord-346842-ip4i3bdk	142	17	of	of	IN
cord-346842-ip4i3bdk	142	18	medicines	medicine	NNS
cord-346842-ip4i3bdk	142	19	outside	outside	IN
cord-346842-ip4i3bdk	142	20	pharmacies	pharmacy	NNS
cord-346842-ip4i3bdk	142	21	is	be	VBZ
cord-346842-ip4i3bdk	142	22	prohibited	prohibit	VBN
cord-346842-ip4i3bdk	142	23	in	in	IN
cord-346842-ip4i3bdk	142	24	Korea	Korea	NNP
cord-346842-ip4i3bdk	142	25	,	,	,
cord-346842-ip4i3bdk	142	26	which	which	WDT
cord-346842-ip4i3bdk	142	27	makes	make	VBZ
cord-346842-ip4i3bdk	142	28	it	-PRON-	PRP
cord-346842-ip4i3bdk	142	29	impossible	impossible	JJ
cord-346842-ip4i3bdk	142	30	to	to	TO
cord-346842-ip4i3bdk	142	31	deliver	deliver	VB
cord-346842-ip4i3bdk	142	32	medicines	medicine	NNS
cord-346842-ip4i3bdk	142	33	by	by	IN
cord-346842-ip4i3bdk	142	34	courier	courier	NN
cord-346842-ip4i3bdk	142	35	.	.	.
cord-346842-ip4i3bdk	143	1	19	19	CD
cord-346842-ip4i3bdk	144	1	However	however	RB
cord-346842-ip4i3bdk	144	2	,	,	,
cord-346842-ip4i3bdk	144	3	MFDS	MFDS	NNP
cord-346842-ip4i3bdk	144	4	released	release	VBD
cord-346842-ip4i3bdk	144	5	a	a	DT
cord-346842-ip4i3bdk	144	6	guideline	guideline	NN
cord-346842-ip4i3bdk	144	7	that	that	WDT
cord-346842-ip4i3bdk	144	8	allows	allow	VBZ
cord-346842-ip4i3bdk	144	9	investigational	investigational	JJ
cord-346842-ip4i3bdk	144	10	products	product	NNS
cord-346842-ip4i3bdk	144	11	to	to	TO
cord-346842-ip4i3bdk	144	12	be	be	VB
cord-346842-ip4i3bdk	144	13	delivered	deliver	VBN
cord-346842-ip4i3bdk	144	14	to	to	IN
cord-346842-ip4i3bdk	144	15	subjects	subject	NNS
cord-346842-ip4i3bdk	144	16	directly	directly	RB
cord-346842-ip4i3bdk	144	17	on	on	IN
cord-346842-ip4i3bdk	144	18	a	a	DT
cord-346842-ip4i3bdk	144	19	temporary	temporary	JJ
cord-346842-ip4i3bdk	144	20	basis	basis	NN
cord-346842-ip4i3bdk	144	21	,	,	,
cord-346842-ip4i3bdk	144	22	to	to	TO
cord-346842-ip4i3bdk	144	23	enable	enable	VB
cord-346842-ip4i3bdk	144	24	them	-PRON-	PRP
cord-346842-ip4i3bdk	144	25	to	to	TO
cord-346842-ip4i3bdk	144	26	receive	receive	VB
cord-346842-ip4i3bdk	144	27	the	the	DT
cord-346842-ip4i3bdk	144	28	products	product	NNS
cord-346842-ip4i3bdk	144	29	while	while	IN
cord-346842-ip4i3bdk	144	30	reducing	reduce	VBG
cord-346842-ip4i3bdk	144	31	the	the	DT
cord-346842-ip4i3bdk	144	32	risk	risk	NN
cord-346842-ip4i3bdk	144	33	of	of	IN
cord-346842-ip4i3bdk	144	34	SARS	SARS	NNP
cord-346842-ip4i3bdk	144	35	-	-	HYPH
cord-346842-ip4i3bdk	144	36	CoV-2	CoV-2	NNP
cord-346842-ip4i3bdk	144	37	infection	infection	NN
cord-346842-ip4i3bdk	144	38	that	that	IN
cord-346842-ip4i3bdk	144	39	they	-PRON-	PRP
cord-346842-ip4i3bdk	144	40	could	could	MD
cord-346842-ip4i3bdk	144	41	face	face	VB
cord-346842-ip4i3bdk	144	42	on	on	IN
cord-346842-ip4i3bdk	144	43	their	-PRON-	PRP$
cord-346842-ip4i3bdk	144	44	way	way	NN
cord-346842-ip4i3bdk	144	45	to	to	IN
cord-346842-ip4i3bdk	144	46	hospital	hospital	NN
cord-346842-ip4i3bdk	144	47	.	.	.
cord-346842-ip4i3bdk	145	1	12	12	CD
cord-346842-ip4i3bdk	146	1	The	the	DT
cord-346842-ip4i3bdk	146	2	guideline	guideline	NN
cord-346842-ip4i3bdk	146	3	stipulates	stipulate	VBZ
cord-346842-ip4i3bdk	146	4	that	that	IN
cord-346842-ip4i3bdk	146	5	the	the	DT
cord-346842-ip4i3bdk	146	6	products	product	NNS
cord-346842-ip4i3bdk	146	7	be	be	VB
cord-346842-ip4i3bdk	146	8	stored	store	VBN
cord-346842-ip4i3bdk	146	9	according	accord	VBG
cord-346842-ip4i3bdk	146	10	to	to	IN
cord-346842-ip4i3bdk	146	11	protocol	protocol	NN
cord-346842-ip4i3bdk	146	12	requirements	requirement	NNS
cord-346842-ip4i3bdk	146	13	during	during	IN
cord-346842-ip4i3bdk	146	14	the	the	DT
cord-346842-ip4i3bdk	146	15	delivery	delivery	NN
cord-346842-ip4i3bdk	146	16	process	process	NN
cord-346842-ip4i3bdk	146	17	by	by	IN
cord-346842-ip4i3bdk	146	18	a	a	DT
cord-346842-ip4i3bdk	146	19	certified	certify	VBN
cord-346842-ip4i3bdk	146	20	carrier	carrier	NN
cord-346842-ip4i3bdk	146	21	.	.	.
cord-346842-ip4i3bdk	147	1	12	12	CD
cord-346842-ip4i3bdk	148	1	The	the	DT
cord-346842-ip4i3bdk	148	2	US	US	NNP
cord-346842-ip4i3bdk	148	3	FDA	FDA	NNP
cord-346842-ip4i3bdk	148	4	guidance	guidance	NN
cord-346842-ip4i3bdk	148	5	advises	advise	VBZ
cord-346842-ip4i3bdk	148	6	investigators	investigator	NNS
cord-346842-ip4i3bdk	148	7	to	to	TO
cord-346842-ip4i3bdk	148	8	confirm	confirm	VB
cord-346842-ip4i3bdk	148	9	that	that	IN
cord-346842-ip4i3bdk	148	10	subjects	subject	NNS
cord-346842-ip4i3bdk	148	11	voluntarily	voluntarily	RB
cord-346842-ip4i3bdk	148	12	consent	consent	VBP
cord-346842-ip4i3bdk	148	13	to	to	TO
cord-346842-ip4i3bdk	148	14	receive	receive	VB
cord-346842-ip4i3bdk	148	15	investigational	investigational	JJ
cord-346842-ip4i3bdk	148	16	products	product	NNS
cord-346842-ip4i3bdk	148	17	via	via	IN
cord-346842-ip4i3bdk	148	18	courier	courier	NN
cord-346842-ip4i3bdk	148	19	.	.	.
cord-346842-ip4i3bdk	149	1	The	the	DT
cord-346842-ip4i3bdk	149	2	Italy	Italy	NNP
cord-346842-ip4i3bdk	149	3	RA	RA	NNP
cord-346842-ip4i3bdk	149	4	,	,	,
cord-346842-ip4i3bdk	149	5	decrees	decree	NNS
cord-346842-ip4i3bdk	149	6	of	of	IN
cord-346842-ip4i3bdk	149	7	the	the	DT
cord-346842-ip4i3bdk	149	8	Italian	italian	JJ
cord-346842-ip4i3bdk	149	9	President	President	NNP
cord-346842-ip4i3bdk	149	10	of	of	IN
cord-346842-ip4i3bdk	149	11	the	the	DT
cord-346842-ip4i3bdk	149	12	Council	Council	NNP
cord-346842-ip4i3bdk	149	13	of	of	IN
cord-346842-ip4i3bdk	149	14	Ministers	Ministers	NNPS
cord-346842-ip4i3bdk	149	15	allow	allow	VBP
cord-346842-ip4i3bdk	149	16	healthcare	healthcare	NN
cord-346842-ip4i3bdk	149	17	providers	provider	NNS
cord-346842-ip4i3bdk	149	18	to	to	TO
cord-346842-ip4i3bdk	149	19	provide	provide	VB
cord-346842-ip4i3bdk	149	20	an	an	DT
cord-346842-ip4i3bdk	149	21	increased	increase	VBN
cord-346842-ip4i3bdk	149	22	amount	amount	NN
cord-346842-ip4i3bdk	149	23	of	of	IN
cord-346842-ip4i3bdk	149	24	investigational	investigational	JJ
cord-346842-ip4i3bdk	149	25	product	product	NN
cord-346842-ip4i3bdk	149	26	,	,	,
cord-346842-ip4i3bdk	149	27	to	to	TO
cord-346842-ip4i3bdk	149	28	cover	cover	VB
cord-346842-ip4i3bdk	149	29	an	an	DT
cord-346842-ip4i3bdk	149	30	extended	extended	JJ
cord-346842-ip4i3bdk	149	31	period	period	NN
cord-346842-ip4i3bdk	149	32	of	of	IN
cord-346842-ip4i3bdk	149	33	treatment	treatment	NN
cord-346842-ip4i3bdk	149	34	if	if	IN
cord-346842-ip4i3bdk	149	35	it	-PRON-	PRP
cord-346842-ip4i3bdk	149	36	is	be	VBZ
cord-346842-ip4i3bdk	149	37	beneficial	beneficial	JJ
cord-346842-ip4i3bdk	149	38	and	and	CC
cord-346842-ip4i3bdk	149	39	safe	safe	JJ
cord-346842-ip4i3bdk	149	40	for	for	IN
cord-346842-ip4i3bdk	149	41	the	the	DT
cord-346842-ip4i3bdk	149	42	subjects	subject	NNS
cord-346842-ip4i3bdk	149	43	.	.	.
cord-346842-ip4i3bdk	150	1	For	for	IN
cord-346842-ip4i3bdk	150	2	the	the	DT
cord-346842-ip4i3bdk	150	3	products	product	NNS
cord-346842-ip4i3bdk	150	4	that	that	WDT
cord-346842-ip4i3bdk	150	5	are	be	VBP
cord-346842-ip4i3bdk	150	6	administered	administer	VBN
cord-346842-ip4i3bdk	150	7	in	in	IN
cord-346842-ip4i3bdk	150	8	a	a	DT
cord-346842-ip4i3bdk	150	9	health	health	NN
cord-346842-ip4i3bdk	150	10	care	care	NN
cord-346842-ip4i3bdk	150	11	setting	setting	NN
cord-346842-ip4i3bdk	150	12	,	,	,
cord-346842-ip4i3bdk	150	13	the	the	DT
cord-346842-ip4i3bdk	150	14	US	US	NNP
cord-346842-ip4i3bdk	150	15	FDA	FDA	NNP
cord-346842-ip4i3bdk	150	16	permits	permit	NNS
cord-346842-ip4i3bdk	150	17	utilize	utilize	VBP
cord-346842-ip4i3bdk	150	18	home	home	NN
cord-346842-ip4i3bdk	150	19	nursing	nursing	NN
cord-346842-ip4i3bdk	150	20	services	service	NNS
cord-346842-ip4i3bdk	150	21	or	or	CC
cord-346842-ip4i3bdk	150	22	healthcare	healthcare	NN
cord-346842-ip4i3bdk	150	23	professionals	professional	NNS
cord-346842-ip4i3bdk	150	24	to	to	TO
cord-346842-ip4i3bdk	150	25	serve	serve	VB
cord-346842-ip4i3bdk	150	26	as	as	IN
cord-346842-ip4i3bdk	150	27	alternative	alternative	JJ
cord-346842-ip4i3bdk	150	28	sites	site	NNS
cord-346842-ip4i3bdk	150	29	,	,	,
cord-346842-ip4i3bdk	150	30	in	in	IN
cord-346842-ip4i3bdk	150	31	order	order	NN
cord-346842-ip4i3bdk	150	32	to	to	TO
cord-346842-ip4i3bdk	150	33	keep	keep	VB
cord-346842-ip4i3bdk	150	34	access	access	NN
cord-346842-ip4i3bdk	150	35	to	to	IN
cord-346842-ip4i3bdk	150	36	medical	medical	JJ
cord-346842-ip4i3bdk	150	37	products	product	NNS
cord-346842-ip4i3bdk	150	38	from	from	IN
cord-346842-ip4i3bdk	150	39	being	be	VBG
cord-346842-ip4i3bdk	150	40	cut	cut	VBN
cord-346842-ip4i3bdk	150	41	off	off	RP
cord-346842-ip4i3bdk	150	42	even	even	RB
cord-346842-ip4i3bdk	150	43	if	if	IN
cord-346842-ip4i3bdk	150	44	the	the	DT
cord-346842-ip4i3bdk	150	45	products	product	NNS
cord-346842-ip4i3bdk	150	46	needs	need	VBZ
cord-346842-ip4i3bdk	150	47	to	to	TO
cord-346842-ip4i3bdk	150	48	be	be	VB
cord-346842-ip4i3bdk	150	49	administered	administer	VBN
cord-346842-ip4i3bdk	150	50	by	by	IN
cord-346842-ip4i3bdk	150	51	professionals	professional	NNS
cord-346842-ip4i3bdk	150	52	with	with	IN
cord-346842-ip4i3bdk	150	53	specialized	specialized	JJ
cord-346842-ip4i3bdk	150	54	skills	skill	NNS
cord-346842-ip4i3bdk	150	55	.	.	.
cord-346842-ip4i3bdk	151	1	17	17	CD
cord-346842-ip4i3bdk	152	1	The	the	DT
cord-346842-ip4i3bdk	152	2	guidance	guidance	NN
cord-346842-ip4i3bdk	152	3	of	of	IN
cord-346842-ip4i3bdk	152	4	the	the	DT
cord-346842-ip4i3bdk	152	5	European	European	NNP
cord-346842-ip4i3bdk	152	6	Medicines	Medicines	NNPS
cord-346842-ip4i3bdk	152	7	Agency	Agency	NNP
cord-346842-ip4i3bdk	152	8	(	(	-LRB-
cord-346842-ip4i3bdk	152	9	EMA	EMA	NNP
cord-346842-ip4i3bdk	152	10	)	)	-RRB-
cord-346842-ip4i3bdk	152	11	states	state	VBZ
cord-346842-ip4i3bdk	152	12	that	that	IN
cord-346842-ip4i3bdk	152	13	it	-PRON-	PRP
cord-346842-ip4i3bdk	152	14	is	be	VBZ
cord-346842-ip4i3bdk	152	15	acceptable	acceptable	JJ
cord-346842-ip4i3bdk	152	16	for	for	IN
cord-346842-ip4i3bdk	152	17	laboratory	laboratory	NN
cord-346842-ip4i3bdk	152	18	,	,	,
cord-346842-ip4i3bdk	152	19	imaging	imaging	NN
cord-346842-ip4i3bdk	152	20	or	or	CC
cord-346842-ip4i3bdk	152	21	other	other	JJ
cord-346842-ip4i3bdk	152	22	diagnostic	diagnostic	JJ
cord-346842-ip4i3bdk	152	23	tests	test	NNS
cord-346842-ip4i3bdk	152	24	to	to	TO
cord-346842-ip4i3bdk	152	25	be	be	VB
cord-346842-ip4i3bdk	152	26	conducted	conduct	VBN
cord-346842-ip4i3bdk	152	27	at	at	IN
cord-346842-ip4i3bdk	152	28	a	a	DT
cord-346842-ip4i3bdk	152	29	local	local	JJ
cord-346842-ip4i3bdk	152	30	laboratory	laboratory	NN
cord-346842-ip4i3bdk	152	31	or	or	CC
cord-346842-ip4i3bdk	152	32	relevant	relevant	JJ
cord-346842-ip4i3bdk	152	33	clinical	clinical	JJ
cord-346842-ip4i3bdk	152	34	facility	facility	NN
cord-346842-ip4i3bdk	152	35	certified	certify	VBN
cord-346842-ip4i3bdk	152	36	to	to	TO
cord-346842-ip4i3bdk	152	37	perform	perform	VB
cord-346842-ip4i3bdk	152	38	such	such	JJ
cord-346842-ip4i3bdk	152	39	tests	test	NNS
cord-346842-ip4i3bdk	152	40	routinely	routinely	RB
cord-346842-ip4i3bdk	152	41	.	.	.
cord-346842-ip4i3bdk	153	1	18	18	CD
cord-346842-ip4i3bdk	154	1	For	for	IN
cord-346842-ip4i3bdk	154	2	the	the	DT
cord-346842-ip4i3bdk	154	3	introduction	introduction	NN
cord-346842-ip4i3bdk	154	4	of	of	IN
cord-346842-ip4i3bdk	154	5	these	these	DT
cord-346842-ip4i3bdk	154	6	foreign	foreign	JJ
cord-346842-ip4i3bdk	154	7	guidelines	guideline	NNS
cord-346842-ip4i3bdk	154	8	in	in	IN
cord-346842-ip4i3bdk	154	9	Korea	Korea	NNP
cord-346842-ip4i3bdk	154	10	,	,	,
cord-346842-ip4i3bdk	154	11	policies	policy	NNS
cord-346842-ip4i3bdk	154	12	on	on	IN
cord-346842-ip4i3bdk	154	13	the	the	DT
cord-346842-ip4i3bdk	154	14	supply	supply	NN
cord-346842-ip4i3bdk	154	15	and	and	CC
cord-346842-ip4i3bdk	154	16	demand	demand	NN
cord-346842-ip4i3bdk	154	17	of	of	IN
cord-346842-ip4i3bdk	154	18	necessary	necessary	JJ
cord-346842-ip4i3bdk	154	19	personnel	personnel	NNS
cord-346842-ip4i3bdk	154	20	or	or	CC
cord-346842-ip4i3bdk	154	21	the	the	DT
cord-346842-ip4i3bdk	154	22	designation	designation	NN
cord-346842-ip4i3bdk	154	23	criteria	criterion	NNS
cord-346842-ip4i3bdk	154	24	of	of	IN
cord-346842-ip4i3bdk	154	25	alternative	alternative	JJ
cord-346842-ip4i3bdk	154	26	institutions	institution	NNS
cord-346842-ip4i3bdk	154	27	must	must	MD
cord-346842-ip4i3bdk	154	28	first	first	RB
cord-346842-ip4i3bdk	154	29	be	be	VB
cord-346842-ip4i3bdk	154	30	in	in	IN
cord-346842-ip4i3bdk	154	31	place	place	NN
cord-346842-ip4i3bdk	154	32	.	.	.
cord-346842-ip4i3bdk	155	1	Comparing	compare	VBG
cord-346842-ip4i3bdk	155	2	monitoring	monitor	VBG
cord-346842-ip4i3bdk	155	3	room	room	NN
cord-346842-ip4i3bdk	155	4	availability	availability	NN
cord-346842-ip4i3bdk	155	5	for	for	IN
cord-346842-ip4i3bdk	155	6	source	source	NN
cord-346842-ip4i3bdk	155	7	data	datum	NNS
cord-346842-ip4i3bdk	155	8	verification	verification	NN
cord-346842-ip4i3bdk	155	9	in	in	IN
cord-346842-ip4i3bdk	155	10	February	February	NNP
cord-346842-ip4i3bdk	155	11	and	and	CC
cord-346842-ip4i3bdk	155	12	April	April	NNP
cord-346842-ip4i3bdk	155	13	2020	2020	CD
cord-346842-ip4i3bdk	155	14	,	,	,
cord-346842-ip4i3bdk	155	15	it	-PRON-	PRP
cord-346842-ip4i3bdk	155	16	is	be	VBZ
cord-346842-ip4i3bdk	155	17	evident	evident	JJ
cord-346842-ip4i3bdk	155	18	that	that	IN
cord-346842-ip4i3bdk	155	19	it	-PRON-	PRP
cord-346842-ip4i3bdk	155	20	is	be	VBZ
cord-346842-ip4i3bdk	155	21	affected	affect	VBN
cord-346842-ip4i3bdk	155	22	by	by	IN
cord-346842-ip4i3bdk	155	23	the	the	DT
cord-346842-ip4i3bdk	155	24	number	number	NN
cord-346842-ip4i3bdk	155	25	of	of	IN
cord-346842-ip4i3bdk	155	26	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	155	27	confirmed	confirm	VBN
cord-346842-ip4i3bdk	155	28	cases	case	NNS
cord-346842-ip4i3bdk	155	29	per	per	IN
cord-346842-ip4i3bdk	155	30	day	day	NN
cord-346842-ip4i3bdk	155	31	.	.	.
cord-346842-ip4i3bdk	156	1	Given	give	VBN
cord-346842-ip4i3bdk	156	2	the	the	DT
cord-346842-ip4i3bdk	156	3	possibility	possibility	NN
cord-346842-ip4i3bdk	156	4	of	of	IN
cord-346842-ip4i3bdk	156	5	worsening	worsen	VBG
cord-346842-ip4i3bdk	156	6	of	of	IN
cord-346842-ip4i3bdk	156	7	the	the	DT
cord-346842-ip4i3bdk	156	8	pandemic	pandemic	NN
cord-346842-ip4i3bdk	156	9	situation	situation	NN
cord-346842-ip4i3bdk	156	10	,	,	,
cord-346842-ip4i3bdk	156	11	monitoring	monitor	VBG
cord-346842-ip4i3bdk	156	12	rooms	room	NNS
cord-346842-ip4i3bdk	156	13	may	may	MD
cord-346842-ip4i3bdk	156	14	be	be	VB
cord-346842-ip4i3bdk	156	15	forced	force	VBN
cord-346842-ip4i3bdk	156	16	to	to	TO
cord-346842-ip4i3bdk	156	17	close	close	VB
cord-346842-ip4i3bdk	156	18	again	again	RB
cord-346842-ip4i3bdk	156	19	and	and	CC
cord-346842-ip4i3bdk	156	20	considering	consider	VBG
cord-346842-ip4i3bdk	156	21	the	the	DT
cord-346842-ip4i3bdk	156	22	limited	limited	JJ
cord-346842-ip4i3bdk	156	23	seats	seat	NNS
cord-346842-ip4i3bdk	156	24	available	available	JJ
cord-346842-ip4i3bdk	156	25	and	and	CC
cord-346842-ip4i3bdk	156	26	the	the	DT
cord-346842-ip4i3bdk	156	27	high	high	JJ
cord-346842-ip4i3bdk	156	28	demand	demand	NN
cord-346842-ip4i3bdk	156	29	on	on	IN
cord-346842-ip4i3bdk	156	30	monitor	monitor	NN
cord-346842-ip4i3bdk	156	31	to	to	TO
cord-346842-ip4i3bdk	156	32	verify	verify	VB
cord-346842-ip4i3bdk	156	33	cumulative	cumulative	JJ
cord-346842-ip4i3bdk	156	34	clinical	clinical	JJ
cord-346842-ip4i3bdk	156	35	trial	trial	NN
cord-346842-ip4i3bdk	156	36	data	datum	NNS
cord-346842-ip4i3bdk	156	37	,	,	,
cord-346842-ip4i3bdk	156	38	measures	measure	NNS
cord-346842-ip4i3bdk	156	39	should	should	MD
cord-346842-ip4i3bdk	156	40	be	be	VB
cord-346842-ip4i3bdk	156	41	introduced	introduce	VBN
cord-346842-ip4i3bdk	156	42	to	to	TO
cord-346842-ip4i3bdk	156	43	verify	verify	VB
cord-346842-ip4i3bdk	156	44	clinical	clinical	JJ
cord-346842-ip4i3bdk	156	45	data	datum	NNS
cord-346842-ip4i3bdk	156	46	efficiently	efficiently	RB
cord-346842-ip4i3bdk	156	47	with	with	IN
cord-346842-ip4i3bdk	156	48	fewer	few	JJR
cord-346842-ip4i3bdk	156	49	site	site	NN
cord-346842-ip4i3bdk	156	50	visits	visit	NNS
cord-346842-ip4i3bdk	156	51	or	or	CC
cord-346842-ip4i3bdk	156	52	the	the	DT
cord-346842-ip4i3bdk	156	53	methods	method	NNS
cord-346842-ip4i3bdk	156	54	of	of	IN
cord-346842-ip4i3bdk	156	55	obtaining	obtain	VBG
cord-346842-ip4i3bdk	156	56	clinical	clinical	JJ
cord-346842-ip4i3bdk	156	57	data	datum	NNS
cord-346842-ip4i3bdk	156	58	that	that	WDT
cord-346842-ip4i3bdk	156	59	require	require	VBP
cord-346842-ip4i3bdk	156	60	less	less	JJR
cord-346842-ip4i3bdk	156	61	verification	verification	NN
cord-346842-ip4i3bdk	156	62	should	should	MD
cord-346842-ip4i3bdk	156	63	be	be	VB
cord-346842-ip4i3bdk	156	64	considered	consider	VBN
cord-346842-ip4i3bdk	156	65	.	.	.
cord-346842-ip4i3bdk	157	1	Risk	risk	NN
cord-346842-ip4i3bdk	157	2	-	-	HYPH
cord-346842-ip4i3bdk	157	3	based	base	VBN
cord-346842-ip4i3bdk	157	4	monitoring	monitoring	NN
cord-346842-ip4i3bdk	157	5	can	can	MD
cord-346842-ip4i3bdk	157	6	be	be	VB
cord-346842-ip4i3bdk	157	7	recommended	recommend	VBN
cord-346842-ip4i3bdk	157	8	.	.	.
cord-346842-ip4i3bdk	158	1	It	-PRON-	PRP
cord-346842-ip4i3bdk	158	2	enables	enable	VBZ
cord-346842-ip4i3bdk	158	3	earlier	early	JJR
cord-346842-ip4i3bdk	158	4	detection	detection	NN
cord-346842-ip4i3bdk	158	5	of	of	IN
cord-346842-ip4i3bdk	158	6	issues	issue	NNS
cord-346842-ip4i3bdk	158	7	through	through	IN
cord-346842-ip4i3bdk	158	8	focused	focus	VBN
cord-346842-ip4i3bdk	158	9	centralized	centralized	JJ
cord-346842-ip4i3bdk	158	10	and	and	CC
cord-346842-ip4i3bdk	158	11	remote	remote	JJ
cord-346842-ip4i3bdk	158	12	monitoring	monitoring	NN
cord-346842-ip4i3bdk	158	13	activities	activity	NNS
cord-346842-ip4i3bdk	158	14	,	,	,
cord-346842-ip4i3bdk	158	15	and	and	CC
cord-346842-ip4i3bdk	158	16	targeted	target	VBN
cord-346842-ip4i3bdk	158	17	on	on	IN
cord-346842-ip4i3bdk	158	18	-	-	HYPH
cord-346842-ip4i3bdk	158	19	site	site	NN
cord-346842-ip4i3bdk	158	20	visit	visit	NN
cord-346842-ip4i3bdk	158	21	only	only	RB
cord-346842-ip4i3bdk	158	22	for	for	IN
cord-346842-ip4i3bdk	158	23	key	key	JJ
cord-346842-ip4i3bdk	158	24	risk	risk	NN
cord-346842-ip4i3bdk	158	25	indicators	indicator	NNS
cord-346842-ip4i3bdk	158	26	.	.	.
cord-346842-ip4i3bdk	159	1	This	this	DT
cord-346842-ip4i3bdk	159	2	can	can	MD
cord-346842-ip4i3bdk	159	3	reduce	reduce	VB
cord-346842-ip4i3bdk	159	4	the	the	DT
cord-346842-ip4i3bdk	159	5	total	total	JJ
cord-346842-ip4i3bdk	159	6	number	number	NN
cord-346842-ip4i3bdk	159	7	of	of	IN
cord-346842-ip4i3bdk	159	8	on	on	IN
cord-346842-ip4i3bdk	159	9	-	-	HYPH
cord-346842-ip4i3bdk	159	10	site	site	NN
cord-346842-ip4i3bdk	159	11	monitoring	monitoring	NN
cord-346842-ip4i3bdk	159	12	visits	visit	NNS
cord-346842-ip4i3bdk	159	13	required	require	VBN
cord-346842-ip4i3bdk	159	14	.	.	.
cord-346842-ip4i3bdk	160	1	Association	Association	NNP
cord-346842-ip4i3bdk	160	2	of	of	IN
cord-346842-ip4i3bdk	160	3	clinical	clinical	JJ
cord-346842-ip4i3bdk	160	4	research	research	NN
cord-346842-ip4i3bdk	160	5	organizations	organization	NNS
cord-346842-ip4i3bdk	160	6	has	have	VBZ
cord-346842-ip4i3bdk	160	7	suggested	suggest	VBN
cord-346842-ip4i3bdk	160	8	that	that	IN
cord-346842-ip4i3bdk	160	9	even	even	RB
cord-346842-ip4i3bdk	160	10	after	after	IN
cord-346842-ip4i3bdk	160	11	routine	routine	JJ
cord-346842-ip4i3bdk	160	12	monitoring	monitoring	NN
cord-346842-ip4i3bdk	160	13	is	be	VBZ
cord-346842-ip4i3bdk	160	14	resumed	resume	VBN
cord-346842-ip4i3bdk	160	15	,	,	,
cord-346842-ip4i3bdk	160	16	it	-PRON-	PRP
cord-346842-ip4i3bdk	160	17	is	be	VBZ
cord-346842-ip4i3bdk	160	18	not	not	RB
cord-346842-ip4i3bdk	160	19	necessary	necessary	JJ
cord-346842-ip4i3bdk	160	20	to	to	TO
cord-346842-ip4i3bdk	160	21	perform	perform	VB
cord-346842-ip4i3bdk	160	22	100	100	CD
cord-346842-ip4i3bdk	160	23	%	%	NN
cord-346842-ip4i3bdk	160	24	source	source	NN
cord-346842-ip4i3bdk	160	25	data	data	NN
cord-346842-ip4i3bdk	160	26	verification	verification	NN
cord-346842-ip4i3bdk	160	27	if	if	IN
cord-346842-ip4i3bdk	160	28	remote	remote	JJ
cord-346842-ip4i3bdk	160	29	monitoring	monitoring	NN
cord-346842-ip4i3bdk	160	30	was	be	VBD
cord-346842-ip4i3bdk	160	31	closely	closely	RB
cord-346842-ip4i3bdk	160	32	performed	perform	VBN
cord-346842-ip4i3bdk	160	33	during	during	IN
cord-346842-ip4i3bdk	160	34	the	the	DT
cord-346842-ip4i3bdk	160	35	closure	closure	NN
cord-346842-ip4i3bdk	160	36	of	of	IN
cord-346842-ip4i3bdk	160	37	monitoring	monitor	VBG
cord-346842-ip4i3bdk	160	38	room	room	NN
cord-346842-ip4i3bdk	160	39	.	.	.
cord-346842-ip4i3bdk	161	1	20	20	CD
cord-346842-ip4i3bdk	161	2	Regulations	regulation	NNS
cord-346842-ip4i3bdk	161	3	in	in	IN
cord-346842-ip4i3bdk	161	4	Italy	Italy	NNP
cord-346842-ip4i3bdk	161	5	have	have	VBP
cord-346842-ip4i3bdk	161	6	allowed	allow	VBN
cord-346842-ip4i3bdk	161	7	remote	remote	JJ
cord-346842-ip4i3bdk	161	8	source	source	NN
cord-346842-ip4i3bdk	161	9	data	datum	NNS
cord-346842-ip4i3bdk	161	10	verification	verification	NN
cord-346842-ip4i3bdk	161	11	exceptionally	exceptionally	RB
cord-346842-ip4i3bdk	161	12	,	,	,
cord-346842-ip4i3bdk	161	13	limited	limit	VBN
cord-346842-ip4i3bdk	161	14	to	to	IN
cord-346842-ip4i3bdk	161	15	COVID-19	covid-19	VB
cord-346842-ip4i3bdk	161	16	pandemic	pandemic	NN
cord-346842-ip4i3bdk	161	17	once	once	IN
cord-346842-ip4i3bdk	161	18	these	these	DT
cord-346842-ip4i3bdk	161	19	methods	method	NNS
cord-346842-ip4i3bdk	161	20	are	be	VBP
cord-346842-ip4i3bdk	161	21	described	describe	VBN
cord-346842-ip4i3bdk	161	22	in	in	IN
cord-346842-ip4i3bdk	161	23	a	a	DT
cord-346842-ip4i3bdk	161	24	specific	specific	JJ
cord-346842-ip4i3bdk	161	25	guideline	guideline	NN
cord-346842-ip4i3bdk	161	26	by	by	IN
cord-346842-ip4i3bdk	161	27	the	the	DT
cord-346842-ip4i3bdk	161	28	sponsor	sponsor	NN
cord-346842-ip4i3bdk	161	29	and	and	CC
cord-346842-ip4i3bdk	161	30	clinical	clinical	JJ
cord-346842-ip4i3bdk	161	31	research	research	NN
cord-346842-ip4i3bdk	161	32	organization	organization	NN
cord-346842-ip4i3bdk	161	33	and	and	CC
cord-346842-ip4i3bdk	161	34	approved	approve	VBN
cord-346842-ip4i3bdk	161	35	by	by	IN
cord-346842-ip4i3bdk	161	36	the	the	DT
cord-346842-ip4i3bdk	161	37	Personal	Personal	NNP
cord-346842-ip4i3bdk	161	38	Data	Data	NNP
cord-346842-ip4i3bdk	161	39	Protection	Protection	NNP
cord-346842-ip4i3bdk	161	40	Officer	Officer	NNP
cord-346842-ip4i3bdk	161	41	of	of	IN
cord-346842-ip4i3bdk	161	42	the	the	DT
cord-346842-ip4i3bdk	161	43	trial	trial	NN
cord-346842-ip4i3bdk	161	44	site	site	NN
cord-346842-ip4i3bdk	161	45	.	.	.
cord-346842-ip4i3bdk	162	1	21	21	CD
cord-346842-ip4i3bdk	163	1	Once	once	IN
cord-346842-ip4i3bdk	163	2	the	the	DT
cord-346842-ip4i3bdk	163	3	research	research	NN
cord-346842-ip4i3bdk	163	4	is	be	VBZ
cord-346842-ip4i3bdk	163	5	equipped	equip	VBN
cord-346842-ip4i3bdk	163	6	with	with	IN
cord-346842-ip4i3bdk	163	7	a	a	DT
cord-346842-ip4i3bdk	163	8	mechanism	mechanism	NN
cord-346842-ip4i3bdk	163	9	for	for	IN
cord-346842-ip4i3bdk	163	10	collecting	collect	VBG
cord-346842-ip4i3bdk	163	11	data	datum	NNS
cord-346842-ip4i3bdk	163	12	remotely	remotely	RB
cord-346842-ip4i3bdk	163	13	and	and	CC
cord-346842-ip4i3bdk	163	14	directly	directly	RB
cord-346842-ip4i3bdk	163	15	from	from	IN
cord-346842-ip4i3bdk	163	16	the	the	DT
cord-346842-ip4i3bdk	163	17	patient	patient	NN
cord-346842-ip4i3bdk	163	18	or	or	CC
cord-346842-ip4i3bdk	163	19	vendor	vendor	NN
cord-346842-ip4i3bdk	163	20	,	,	,
cord-346842-ip4i3bdk	163	21	by	by	IN
cord-346842-ip4i3bdk	163	22	using	use	VBG
cord-346842-ip4i3bdk	163	23	methods	method	NNS
cord-346842-ip4i3bdk	163	24	such	such	JJ
cord-346842-ip4i3bdk	163	25	as	as	IN
cord-346842-ip4i3bdk	163	26	electronic	electronic	JJ
cord-346842-ip4i3bdk	163	27	questionnaires	questionnaire	NNS
cord-346842-ip4i3bdk	163	28	,	,	,
cord-346842-ip4i3bdk	163	29	centralized	centralized	JJ
cord-346842-ip4i3bdk	163	30	laboratories	laboratory	NNS
cord-346842-ip4i3bdk	163	31	or	or	CC
cord-346842-ip4i3bdk	163	32	electronic	electronic	JJ
cord-346842-ip4i3bdk	163	33	image	image	NN
cord-346842-ip4i3bdk	163	34	data	datum	NNS
cord-346842-ip4i3bdk	163	35	,	,	,
cord-346842-ip4i3bdk	163	36	remote	remote	JJ
cord-346842-ip4i3bdk	163	37	verification	verification	NN
cord-346842-ip4i3bdk	163	38	can	can	MD
cord-346842-ip4i3bdk	163	39	supplement	supplement	VB
cord-346842-ip4i3bdk	163	40	on	on	IN
cord-346842-ip4i3bdk	163	41	-	-	HYPH
cord-346842-ip4i3bdk	163	42	site	site	NN
cord-346842-ip4i3bdk	163	43	monitoring	monitoring	NN
cord-346842-ip4i3bdk	163	44	.	.	.
cord-346842-ip4i3bdk	164	1	The	the	DT
cord-346842-ip4i3bdk	164	2	increasing	increase	VBG
cord-346842-ip4i3bdk	164	3	number	number	NN
cord-346842-ip4i3bdk	164	4	of	of	IN
cord-346842-ip4i3bdk	164	5	investigator	investigator	NN
cord-346842-ip4i3bdk	164	6	-	-	HYPH
cord-346842-ip4i3bdk	164	7	initiated	initiate	VBN
cord-346842-ip4i3bdk	164	8	trials	trial	NNS
cord-346842-ip4i3bdk	164	9	and	and	CC
cord-346842-ip4i3bdk	164	10	trials	trial	NNS
cord-346842-ip4i3bdk	164	11	conducted	conduct	VBN
cord-346842-ip4i3bdk	164	12	under	under	IN
cord-346842-ip4i3bdk	164	13	the	the	DT
cord-346842-ip4i3bdk	164	14	auspices	auspex	NNS
cord-346842-ip4i3bdk	164	15	of	of	IN
cord-346842-ip4i3bdk	164	16	US	US	NNP
cord-346842-ip4i3bdk	164	17	Federal	Federal	NNP
cord-346842-ip4i3bdk	164	18	Reserve	Reserve	NNP
cord-346842-ip4i3bdk	164	19	and	and	CC
cord-346842-ip4i3bdk	164	20	the	the	DT
cord-346842-ip4i3bdk	164	21	US	US	NNP
cord-346842-ip4i3bdk	164	22	National	National	NNP
cord-346842-ip4i3bdk	164	23	Institutes	Institutes	NNPS
cord-346842-ip4i3bdk	164	24	of	of	IN
cord-346842-ip4i3bdk	164	25	Health	Health	NNP
cord-346842-ip4i3bdk	164	26	indicates	indicate	VBZ
cord-346842-ip4i3bdk	164	27	that	that	IN
cord-346842-ip4i3bdk	164	28	all	all	DT
cord-346842-ip4i3bdk	164	29	parties	party	NNS
cord-346842-ip4i3bdk	164	30	are	be	VBP
cord-346842-ip4i3bdk	164	31	making	make	VBG
cord-346842-ip4i3bdk	164	32	concerted	concerted	JJ
cord-346842-ip4i3bdk	164	33	efforts	effort	NNS
cord-346842-ip4i3bdk	164	34	to	to	TO
cord-346842-ip4i3bdk	164	35	develop	develop	VB
cord-346842-ip4i3bdk	164	36	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	164	37	treatments	treatment	NNS
cord-346842-ip4i3bdk	164	38	and	and	CC
cord-346842-ip4i3bdk	164	39	vaccines	vaccine	NNS
cord-346842-ip4i3bdk	164	40	.	.	.
cord-346842-ip4i3bdk	165	1	9	9	CD
cord-346842-ip4i3bdk	166	1	Considering	consider	VBG
cord-346842-ip4i3bdk	166	2	that	that	IN
cord-346842-ip4i3bdk	166	3	the	the	DT
cord-346842-ip4i3bdk	166	4	number	number	NN
cord-346842-ip4i3bdk	166	5	of	of	IN
cord-346842-ip4i3bdk	166	6	clinical	clinical	JJ
cord-346842-ip4i3bdk	166	7	trials	trial	NNS
cord-346842-ip4i3bdk	166	8	of	of	IN
cord-346842-ip4i3bdk	166	9	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	166	10	related	related	JJ
cord-346842-ip4i3bdk	166	11	products	product	NNS
cord-346842-ip4i3bdk	166	12	is	be	VBZ
cord-346842-ip4i3bdk	166	13	rapidly	rapidly	RB
cord-346842-ip4i3bdk	166	14	increasing	increase	VBG
cord-346842-ip4i3bdk	166	15	and	and	CC
cord-346842-ip4i3bdk	166	16	that	that	IN
cord-346842-ip4i3bdk	166	17	most	most	JJS
cord-346842-ip4i3bdk	166	18	patients	patient	NNS
cord-346842-ip4i3bdk	166	19	are	be	VBP
cord-346842-ip4i3bdk	166	20	being	be	VBG
cord-346842-ip4i3bdk	166	21	recruited	recruit	VBN
cord-346842-ip4i3bdk	166	22	,	,	,
cord-346842-ip4i3bdk	166	23	measures	measure	NNS
cord-346842-ip4i3bdk	166	24	are	be	VBP
cord-346842-ip4i3bdk	166	25	needed	need	VBN
cord-346842-ip4i3bdk	166	26	to	to	TO
cord-346842-ip4i3bdk	166	27	ensure	ensure	VB
cord-346842-ip4i3bdk	166	28	an	an	DT
cord-346842-ip4i3bdk	166	29	ongoing	ongoing	JJ
cord-346842-ip4i3bdk	166	30	supply	supply	NN
cord-346842-ip4i3bdk	166	31	of	of	IN
cord-346842-ip4i3bdk	166	32	clinical	clinical	JJ
cord-346842-ip4i3bdk	166	33	trial	trial	NN
cord-346842-ip4i3bdk	166	34	drugs	drug	NNS
cord-346842-ip4i3bdk	166	35	.	.	.
cord-346842-ip4i3bdk	167	1	It	-PRON-	PRP
cord-346842-ip4i3bdk	167	2	is	be	VBZ
cord-346842-ip4i3bdk	167	3	necessary	necessary	JJ
cord-346842-ip4i3bdk	167	4	to	to	TO
cord-346842-ip4i3bdk	167	5	diversify	diversify	VB
cord-346842-ip4i3bdk	167	6	supply	supply	NN
cord-346842-ip4i3bdk	167	7	and	and	CC
cord-346842-ip4i3bdk	167	8	demand	demand	NN
cord-346842-ip4i3bdk	167	9	channels	channel	NNS
cord-346842-ip4i3bdk	167	10	for	for	IN
cord-346842-ip4i3bdk	167	11	raw	raw	JJ
cord-346842-ip4i3bdk	167	12	materials	material	NNS
cord-346842-ip4i3bdk	167	13	and	and	CC
cord-346842-ip4i3bdk	167	14	to	to	TO
cord-346842-ip4i3bdk	167	15	establish	establish	VB
cord-346842-ip4i3bdk	167	16	regular	regular	JJ
cord-346842-ip4i3bdk	167	17	import	import	NN
cord-346842-ip4i3bdk	167	18	and	and	CC
cord-346842-ip4i3bdk	167	19	export	export	NN
cord-346842-ip4i3bdk	167	20	channels	channel	NNS
cord-346842-ip4i3bdk	167	21	between	between	IN
cord-346842-ip4i3bdk	167	22	countries	country	NNS
cord-346842-ip4i3bdk	167	23	.	.	.
cord-346842-ip4i3bdk	168	1	Given	give	VBN
cord-346842-ip4i3bdk	168	2	that	that	IN
cord-346842-ip4i3bdk	168	3	the	the	DT
cord-346842-ip4i3bdk	168	4	studies	study	NNS
cord-346842-ip4i3bdk	168	5	target	target	VBP
cord-346842-ip4i3bdk	168	6	patients	patient	NNS
cord-346842-ip4i3bdk	168	7	with	with	IN
cord-346842-ip4i3bdk	168	8	SARS	SARS	NNP
cord-346842-ip4i3bdk	168	9	-	-	HYPH
cord-346842-ip4i3bdk	168	10	CoV-2	CoV-2	NNP
cord-346842-ip4i3bdk	168	11	infection	infection	NN
cord-346842-ip4i3bdk	168	12	,	,	,
cord-346842-ip4i3bdk	168	13	relevant	relevant	JJ
cord-346842-ip4i3bdk	168	14	regulations	regulation	NNS
cord-346842-ip4i3bdk	168	15	should	should	MD
cord-346842-ip4i3bdk	168	16	be	be	VB
cord-346842-ip4i3bdk	168	17	implemented	implement	VBN
cord-346842-ip4i3bdk	168	18	and	and	CC
cord-346842-ip4i3bdk	168	19	facilities	facility	NNS
cord-346842-ip4i3bdk	168	20	should	should	MD
cord-346842-ip4i3bdk	168	21	be	be	VB
cord-346842-ip4i3bdk	168	22	supported	support	VBN
cord-346842-ip4i3bdk	168	23	to	to	TO
cord-346842-ip4i3bdk	168	24	use	use	VB
cord-346842-ip4i3bdk	168	25	non	non	JJ
cord-346842-ip4i3bdk	168	26	-	-	JJ
cord-346842-ip4i3bdk	168	27	contact	contact	JJ
cord-346842-ip4i3bdk	168	28	methods	method	NNS
cord-346842-ip4i3bdk	168	29	in	in	IN
cord-346842-ip4i3bdk	168	30	order	order	NN
cord-346842-ip4i3bdk	168	31	to	to	TO
cord-346842-ip4i3bdk	168	32	protect	protect	VB
cord-346842-ip4i3bdk	168	33	investigators	investigator	NNS
cord-346842-ip4i3bdk	168	34	and	and	CC
cord-346842-ip4i3bdk	168	35	trial	trial	NN
cord-346842-ip4i3bdk	168	36	staff	staff	NN
cord-346842-ip4i3bdk	168	37	.	.	.
cord-346842-ip4i3bdk	169	1	As	as	IN
cord-346842-ip4i3bdk	169	2	one	one	CD
cord-346842-ip4i3bdk	169	3	of	of	IN
cord-346842-ip4i3bdk	169	4	non	non	JJ
cord-346842-ip4i3bdk	169	5	-	-	JJ
cord-346842-ip4i3bdk	169	6	contact	contact	JJ
cord-346842-ip4i3bdk	169	7	approaches	approach	NNS
cord-346842-ip4i3bdk	169	8	,	,	,
cord-346842-ip4i3bdk	169	9	telephone	telephone	NN
cord-346842-ip4i3bdk	169	10	consent	consent	NN
cord-346842-ip4i3bdk	169	11	process	process	NN
cord-346842-ip4i3bdk	169	12	is	be	VBZ
cord-346842-ip4i3bdk	169	13	allowed	allow	VBN
cord-346842-ip4i3bdk	169	14	for	for	IN
cord-346842-ip4i3bdk	169	15	patients	patient	NNS
cord-346842-ip4i3bdk	169	16	during	during	IN
cord-346842-ip4i3bdk	169	17	isolation	isolation	NN
cord-346842-ip4i3bdk	169	18	.	.	.
cord-346842-ip4i3bdk	170	1	12	12	CD
cord-346842-ip4i3bdk	170	2	Guidance	guidance	NN
cord-346842-ip4i3bdk	170	3	on	on	IN
cord-346842-ip4i3bdk	170	4	the	the	DT
cord-346842-ip4i3bdk	170	5	management	management	NN
cord-346842-ip4i3bdk	170	6	of	of	IN
cord-346842-ip4i3bdk	170	7	clinical	clinical	JJ
cord-346842-ip4i3bdk	170	8	trials	trial	NNS
cord-346842-ip4i3bdk	170	9	during	during	IN
cord-346842-ip4i3bdk	170	10	the	the	DT
cord-346842-ip4i3bdk	170	11	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	170	12	pandemic	pandemic	NN
cord-346842-ip4i3bdk	170	13	by	by	IN
cord-346842-ip4i3bdk	170	14	EMA	EMA	NNP
cord-346842-ip4i3bdk	170	15	advises	advise	VBZ
cord-346842-ip4i3bdk	170	16	the	the	DT
cord-346842-ip4i3bdk	170	17	presence	presence	NN
cord-346842-ip4i3bdk	170	18	of	of	IN
cord-346842-ip4i3bdk	170	19	an	an	DT
cord-346842-ip4i3bdk	170	20	impartial	impartial	JJ
cord-346842-ip4i3bdk	170	21	witness	witness	NN
cord-346842-ip4i3bdk	170	22	,	,	,
cord-346842-ip4i3bdk	170	23	if	if	IN
cord-346842-ip4i3bdk	170	24	written	write	VBN
cord-346842-ip4i3bdk	170	25	consent	consent	NN
cord-346842-ip4i3bdk	170	26	by	by	IN
cord-346842-ip4i3bdk	170	27	the	the	DT
cord-346842-ip4i3bdk	170	28	trial	trial	NN
cord-346842-ip4i3bdk	170	29	participant	participant	NN
cord-346842-ip4i3bdk	170	30	is	be	VBZ
cord-346842-ip4i3bdk	170	31	not	not	RB
cord-346842-ip4i3bdk	170	32	possible	possible	JJ
cord-346842-ip4i3bdk	170	33	.	.	.
cord-346842-ip4i3bdk	171	1	18	18	CD
cord-346842-ip4i3bdk	172	1	To	to	TO
cord-346842-ip4i3bdk	172	2	enable	enable	VB
cord-346842-ip4i3bdk	172	3	trial	trial	NN
cord-346842-ip4i3bdk	172	4	facilities	facility	NNS
cord-346842-ip4i3bdk	172	5	to	to	TO
cord-346842-ip4i3bdk	172	6	maintain	maintain	VB
cord-346842-ip4i3bdk	172	7	the	the	DT
cord-346842-ip4i3bdk	172	8	non	non	JJ
cord-346842-ip4i3bdk	172	9	-	-	JJ
cord-346842-ip4i3bdk	172	10	contact	contact	NN
cord-346842-ip4i3bdk	172	11	between	between	IN
cord-346842-ip4i3bdk	172	12	investigators	investigator	NNS
cord-346842-ip4i3bdk	172	13	and	and	CC
cord-346842-ip4i3bdk	172	14	trial	trial	NN
cord-346842-ip4i3bdk	172	15	subjects	subject	NNS
cord-346842-ip4i3bdk	172	16	,	,	,
cord-346842-ip4i3bdk	172	17	they	-PRON-	PRP
cord-346842-ip4i3bdk	172	18	should	should	MD
cord-346842-ip4i3bdk	172	19	be	be	VB
cord-346842-ip4i3bdk	172	20	well	well	RB
cord-346842-ip4i3bdk	172	21	equipped	equipped	JJ
cord-346842-ip4i3bdk	172	22	for	for	IN
cord-346842-ip4i3bdk	172	23	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	172	24	trials	trial	NNS
cord-346842-ip4i3bdk	172	25	with	with	IN
cord-346842-ip4i3bdk	172	26	capabilities	capability	NNS
cord-346842-ip4i3bdk	172	27	such	such	JJ
cord-346842-ip4i3bdk	172	28	as	as	IN
cord-346842-ip4i3bdk	172	29	electronic	electronic	JJ
cord-346842-ip4i3bdk	172	30	informed	informed	JJ
cord-346842-ip4i3bdk	172	31	consent	consent	NN
cord-346842-ip4i3bdk	172	32	or	or	CC
cord-346842-ip4i3bdk	172	33	device	device	NN
cord-346842-ip4i3bdk	172	34	to	to	TO
cord-346842-ip4i3bdk	172	35	electronically	electronically	RB
cord-346842-ip4i3bdk	172	36	scan	scan	VB
cord-346842-ip4i3bdk	172	37	and	and	CC
cord-346842-ip4i3bdk	172	38	save	save	VB
cord-346842-ip4i3bdk	172	39	the	the	DT
cord-346842-ip4i3bdk	172	40	signed	sign	VBN
cord-346842-ip4i3bdk	172	41	informed	informed	JJ
cord-346842-ip4i3bdk	172	42	consent	consent	NN
cord-346842-ip4i3bdk	172	43	without	without	IN
cord-346842-ip4i3bdk	172	44	bringing	bring	VBG
cord-346842-ip4i3bdk	172	45	the	the	DT
cord-346842-ip4i3bdk	172	46	form	form	NN
cord-346842-ip4i3bdk	172	47	out	out	IN
cord-346842-ip4i3bdk	172	48	of	of	IN
cord-346842-ip4i3bdk	172	49	the	the	DT
cord-346842-ip4i3bdk	172	50	subjects	subject	NNS
cord-346842-ip4i3bdk	172	51	'	'	POS
cord-346842-ip4i3bdk	172	52	ward	ward	NN
cord-346842-ip4i3bdk	172	53	.	.	.
cord-346842-ip4i3bdk	173	1	This	this	DT
cord-346842-ip4i3bdk	173	2	study	study	NN
cord-346842-ip4i3bdk	173	3	has	have	VBZ
cord-346842-ip4i3bdk	173	4	some	some	DT
cord-346842-ip4i3bdk	173	5	limitations	limitation	NNS
cord-346842-ip4i3bdk	173	6	.	.	.
cord-346842-ip4i3bdk	174	1	Although	although	IN
cord-346842-ip4i3bdk	174	2	a	a	DT
cord-346842-ip4i3bdk	174	3	single	single	JJ
cord-346842-ip4i3bdk	174	4	indicator	indicator	NN
cord-346842-ip4i3bdk	174	5	was	be	VBD
cord-346842-ip4i3bdk	174	6	used	use	VBN
cord-346842-ip4i3bdk	174	7	to	to	TO
cord-346842-ip4i3bdk	174	8	identify	identify	VB
cord-346842-ip4i3bdk	174	9	the	the	DT
cord-346842-ip4i3bdk	174	10	impact	impact	NN
cord-346842-ip4i3bdk	174	11	of	of	IN
cord-346842-ip4i3bdk	174	12	the	the	DT
cord-346842-ip4i3bdk	174	13	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	174	14	pandemic	pandemic	NN
cord-346842-ip4i3bdk	174	15	on	on	IN
cord-346842-ip4i3bdk	174	16	each	each	DT
cord-346842-ip4i3bdk	174	17	party	party	NN
cord-346842-ip4i3bdk	174	18	,	,	,
cord-346842-ip4i3bdk	174	19	the	the	DT
cord-346842-ip4i3bdk	174	20	effects	effect	NNS
cord-346842-ip4i3bdk	174	21	of	of	IN
cord-346842-ip4i3bdk	174	22	more	more	RBR
cord-346842-ip4i3bdk	174	23	diverse	diverse	JJ
cord-346842-ip4i3bdk	174	24	areas	area	NNS
cord-346842-ip4i3bdk	174	25	needs	need	VBZ
cord-346842-ip4i3bdk	174	26	to	to	TO
cord-346842-ip4i3bdk	174	27	be	be	VB
cord-346842-ip4i3bdk	174	28	assessed	assess	VBN
cord-346842-ip4i3bdk	174	29	using	use	VBG
cord-346842-ip4i3bdk	174	30	a	a	DT
cord-346842-ip4i3bdk	174	31	greater	great	JJR
cord-346842-ip4i3bdk	174	32	diversity	diversity	NN
cord-346842-ip4i3bdk	174	33	of	of	IN
cord-346842-ip4i3bdk	174	34	indicators	indicator	NNS
cord-346842-ip4i3bdk	174	35	.	.	.
cord-346842-ip4i3bdk	175	1	The	the	DT
cord-346842-ip4i3bdk	175	2	analysis	analysis	NN
cord-346842-ip4i3bdk	175	3	of	of	IN
cord-346842-ip4i3bdk	175	4	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	175	5	related	related	JJ
cord-346842-ip4i3bdk	175	6	trials	trial	NNS
cord-346842-ip4i3bdk	175	7	was	be	VBD
cord-346842-ip4i3bdk	175	8	based	base	VBN
cord-346842-ip4i3bdk	175	9	on	on	IN
cord-346842-ip4i3bdk	175	10	a	a	DT
cord-346842-ip4i3bdk	175	11	search	search	NN
cord-346842-ip4i3bdk	175	12	of	of	IN
cord-346842-ip4i3bdk	175	13	ClinicalTrials.gov	ClinicalTrials.gov	NNP
cord-346842-ip4i3bdk	175	14	,	,	,
cord-346842-ip4i3bdk	175	15	so	so	CC
cord-346842-ip4i3bdk	175	16	the	the	DT
cord-346842-ip4i3bdk	175	17	trials	trial	NNS
cord-346842-ip4i3bdk	175	18	not	not	RB
cord-346842-ip4i3bdk	175	19	registered	register	VBN
cord-346842-ip4i3bdk	175	20	in	in	IN
cord-346842-ip4i3bdk	175	21	this	this	DT
cord-346842-ip4i3bdk	175	22	database	database	NN
cord-346842-ip4i3bdk	175	23	were	be	VBD
cord-346842-ip4i3bdk	175	24	not	not	RB
cord-346842-ip4i3bdk	175	25	included	include	VBN
cord-346842-ip4i3bdk	175	26	in	in	IN
cord-346842-ip4i3bdk	175	27	the	the	DT
cord-346842-ip4i3bdk	175	28	analysis	analysis	NN
cord-346842-ip4i3bdk	175	29	.	.	.
cord-346842-ip4i3bdk	176	1	We	-PRON-	PRP
cord-346842-ip4i3bdk	176	2	only	only	RB
cord-346842-ip4i3bdk	176	3	consider	consider	VBP
cord-346842-ip4i3bdk	176	4	the	the	DT
cord-346842-ip4i3bdk	176	5	guidance	guidance	NN
cord-346842-ip4i3bdk	176	6	from	from	IN
cord-346842-ip4i3bdk	176	7	RAs	ra	NNS
cord-346842-ip4i3bdk	176	8	in	in	IN
cord-346842-ip4i3bdk	176	9	the	the	DT
cord-346842-ip4i3bdk	176	10	US	US	NNP
cord-346842-ip4i3bdk	176	11	,	,	,
cord-346842-ip4i3bdk	176	12	Korea	Korea	NNP
cord-346842-ip4i3bdk	176	13	,	,	,
cord-346842-ip4i3bdk	176	14	European	European	NNP
cord-346842-ip4i3bdk	176	15	Union	Union	NNP
cord-346842-ip4i3bdk	176	16	and	and	CC
cord-346842-ip4i3bdk	176	17	the	the	DT
cord-346842-ip4i3bdk	176	18	United	United	NNP
cord-346842-ip4i3bdk	176	19	Kingdom	Kingdom	NNP
cord-346842-ip4i3bdk	176	20	,	,	,
cord-346842-ip4i3bdk	176	21	so	so	RB
cord-346842-ip4i3bdk	176	22	referring	refer	VBG
cord-346842-ip4i3bdk	176	23	to	to	IN
cord-346842-ip4i3bdk	176	24	the	the	DT
cord-346842-ip4i3bdk	176	25	guidance	guidance	NN
cord-346842-ip4i3bdk	176	26	of	of	IN
cord-346842-ip4i3bdk	176	27	other	other	JJ
cord-346842-ip4i3bdk	176	28	RA	RA	NNP
cord-346842-ip4i3bdk	176	29	could	could	MD
cord-346842-ip4i3bdk	176	30	help	help	VB
cord-346842-ip4i3bdk	176	31	to	to	TO
cord-346842-ip4i3bdk	176	32	suggest	suggest	VB
cord-346842-ip4i3bdk	176	33	more	more	JJR
cord-346842-ip4i3bdk	176	34	various	various	JJ
cord-346842-ip4i3bdk	176	35	measures	measure	NNS
cord-346842-ip4i3bdk	176	36	.	.	.
cord-346842-ip4i3bdk	177	1	All	all	DT
cord-346842-ip4i3bdk	177	2	RA	RA	NNP
cord-346842-ip4i3bdk	177	3	guidelines	guideline	NNS
cord-346842-ip4i3bdk	177	4	put	put	VBP
cord-346842-ip4i3bdk	177	5	patient	patient	JJ
cord-346842-ip4i3bdk	177	6	safety	safety	NN
cord-346842-ip4i3bdk	177	7	first	first	RB
cord-346842-ip4i3bdk	177	8	,	,	,
cord-346842-ip4i3bdk	177	9	and	and	CC
cord-346842-ip4i3bdk	177	10	MFDS	MFDS	NNP
cord-346842-ip4i3bdk	177	11	is	be	VBZ
cord-346842-ip4i3bdk	177	12	making	make	VBG
cord-346842-ip4i3bdk	177	13	continuous	continuous	JJ
cord-346842-ip4i3bdk	177	14	efforts	effort	NNS
cord-346842-ip4i3bdk	177	15	to	to	TO
cord-346842-ip4i3bdk	177	16	conduct	conduct	VB
cord-346842-ip4i3bdk	177	17	clinical	clinical	JJ
cord-346842-ip4i3bdk	177	18	trials	trial	NNS
cord-346842-ip4i3bdk	177	19	that	that	WDT
cord-346842-ip4i3bdk	177	20	are	be	VBP
cord-346842-ip4i3bdk	177	21	beneficial	beneficial	JJ
cord-346842-ip4i3bdk	177	22	to	to	IN
cord-346842-ip4i3bdk	177	23	participants	participant	NNS
cord-346842-ip4i3bdk	177	24	.	.	.
cord-346842-ip4i3bdk	178	1	Health	health	NN
cord-346842-ip4i3bdk	178	2	authorities	authority	NNS
cord-346842-ip4i3bdk	178	3	and	and	CC
cord-346842-ip4i3bdk	178	4	policymaker	policymaker	NN
cord-346842-ip4i3bdk	178	5	should	should	MD
cord-346842-ip4i3bdk	178	6	refer	refer	VB
cord-346842-ip4i3bdk	178	7	to	to	IN
cord-346842-ip4i3bdk	178	8	various	various	JJ
cord-346842-ip4i3bdk	178	9	guidelines	guideline	NNS
cord-346842-ip4i3bdk	178	10	and	and	CC
cord-346842-ip4i3bdk	178	11	consider	consider	VB
cord-346842-ip4i3bdk	178	12	alternative	alternative	JJ
cord-346842-ip4i3bdk	178	13	measures	measure	NNS
cord-346842-ip4i3bdk	178	14	to	to	TO
cord-346842-ip4i3bdk	178	15	conduct	conduct	VB
cord-346842-ip4i3bdk	178	16	trials	trial	NNS
cord-346842-ip4i3bdk	178	17	during	during	IN
cord-346842-ip4i3bdk	178	18	this	this	DT
cord-346842-ip4i3bdk	178	19	pandemic	pandemic	NN
cord-346842-ip4i3bdk	178	20	situation	situation	NN
cord-346842-ip4i3bdk	178	21	,	,	,
cord-346842-ip4i3bdk	178	22	taking	take	VBG
cord-346842-ip4i3bdk	178	23	the	the	DT
cord-346842-ip4i3bdk	178	24	scope	scope	NN
cord-346842-ip4i3bdk	178	25	of	of	IN
cord-346842-ip4i3bdk	178	26	the	the	DT
cord-346842-ip4i3bdk	178	27	application	application	NN
cord-346842-ip4i3bdk	178	28	into	into	IN
cord-346842-ip4i3bdk	178	29	consideration	consideration	NN
cord-346842-ip4i3bdk	178	30	while	while	IN
cord-346842-ip4i3bdk	178	31	prioritizing	prioritize	VBG
cord-346842-ip4i3bdk	178	32	subject	subject	JJ
cord-346842-ip4i3bdk	178	33	safety	safety	NN
cord-346842-ip4i3bdk	178	34	,	,	,
cord-346842-ip4i3bdk	178	35	so	so	IN
cord-346842-ip4i3bdk	178	36	that	that	IN
cord-346842-ip4i3bdk	178	37	the	the	DT
cord-346842-ip4i3bdk	178	38	most	most	RBS
cord-346842-ip4i3bdk	178	39	appropriate	appropriate	JJ
cord-346842-ip4i3bdk	178	40	method	method	NN
cord-346842-ip4i3bdk	178	41	can	can	MD
cord-346842-ip4i3bdk	178	42	be	be	VB
cord-346842-ip4i3bdk	178	43	implemented	implement	VBN
cord-346842-ip4i3bdk	178	44	and	and	CC
cord-346842-ip4i3bdk	178	45	adopted	adopt	VBN
cord-346842-ip4i3bdk	178	46	in	in	IN
cord-346842-ip4i3bdk	178	47	Korea	Korea	NNP
cord-346842-ip4i3bdk	178	48	,	,	,
cord-346842-ip4i3bdk	178	49	in	in	IN
cord-346842-ip4i3bdk	178	50	a	a	DT
cord-346842-ip4i3bdk	178	51	timely	timely	JJ
cord-346842-ip4i3bdk	178	52	manner	manner	NN
cord-346842-ip4i3bdk	178	53	.	.	.
cord-346842-ip4i3bdk	179	1	At	at	IN
cord-346842-ip4i3bdk	179	2	this	this	DT
cord-346842-ip4i3bdk	179	3	time	time	NN
cord-346842-ip4i3bdk	179	4	,	,	,
cord-346842-ip4i3bdk	179	5	the	the	DT
cord-346842-ip4i3bdk	179	6	impact	impact	NN
cord-346842-ip4i3bdk	179	7	of	of	IN
cord-346842-ip4i3bdk	179	8	the	the	DT
cord-346842-ip4i3bdk	179	9	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	179	10	pandemic	pandemic	NN
cord-346842-ip4i3bdk	179	11	on	on	IN
cord-346842-ip4i3bdk	179	12	clinical	clinical	JJ
cord-346842-ip4i3bdk	179	13	trials	trial	NNS
cord-346842-ip4i3bdk	179	14	in	in	IN
cord-346842-ip4i3bdk	179	15	Korea	Korea	NNP
cord-346842-ip4i3bdk	179	16	has	have	VBZ
cord-346842-ip4i3bdk	179	17	not	not	RB
cord-346842-ip4i3bdk	179	18	been	be	VBN
cord-346842-ip4i3bdk	179	19	as	as	RB
cord-346842-ip4i3bdk	179	20	marked	mark	VBN
cord-346842-ip4i3bdk	179	21	as	as	IN
cord-346842-ip4i3bdk	179	22	in	in	IN
cord-346842-ip4i3bdk	179	23	some	some	DT
cord-346842-ip4i3bdk	179	24	other	other	JJ
cord-346842-ip4i3bdk	179	25	countries	country	NNS
cord-346842-ip4i3bdk	179	26	.	.	.
cord-346842-ip4i3bdk	180	1	However	however	RB
cord-346842-ip4i3bdk	180	2	,	,	,
cord-346842-ip4i3bdk	180	3	restrictions	restriction	NNS
cord-346842-ip4i3bdk	180	4	on	on	IN
cord-346842-ip4i3bdk	180	5	subject	subject	JJ
cord-346842-ip4i3bdk	180	6	study	study	NN
cord-346842-ip4i3bdk	180	7	visits	visit	NNS
cord-346842-ip4i3bdk	180	8	to	to	IN
cord-346842-ip4i3bdk	180	9	hospital	hospital	NN
cord-346842-ip4i3bdk	180	10	can	can	MD
cord-346842-ip4i3bdk	180	11	directly	directly	RB
cord-346842-ip4i3bdk	180	12	impact	impact	VB
cord-346842-ip4i3bdk	180	13	on	on	IN
cord-346842-ip4i3bdk	180	14	subject	subject	JJ
cord-346842-ip4i3bdk	180	15	safety	safety	NN
cord-346842-ip4i3bdk	180	16	and	and	CC
cord-346842-ip4i3bdk	180	17	monitor	monitor	NN
cord-346842-ip4i3bdk	180	18	's	's	POS
cord-346842-ip4i3bdk	180	19	restricted	restricted	JJ
cord-346842-ip4i3bdk	180	20	access	access	NN
cord-346842-ip4i3bdk	180	21	to	to	IN
cord-346842-ip4i3bdk	180	22	site	site	NN
cord-346842-ip4i3bdk	180	23	caused	cause	VBD
cord-346842-ip4i3bdk	180	24	a	a	DT
cord-346842-ip4i3bdk	180	25	delayed	delay	VBN
cord-346842-ip4i3bdk	180	26	safety	safety	NN
cord-346842-ip4i3bdk	180	27	review	review	NN
cord-346842-ip4i3bdk	180	28	for	for	IN
cord-346842-ip4i3bdk	180	29	subjects	subject	NNS
cord-346842-ip4i3bdk	180	30	.	.	.
cord-346842-ip4i3bdk	181	1	Therefore	therefore	RB
cord-346842-ip4i3bdk	181	2	all	all	PDT
cord-346842-ip4i3bdk	181	3	the	the	DT
cord-346842-ip4i3bdk	181	4	lessons	lesson	NNS
cord-346842-ip4i3bdk	181	5	learned	learn	VBN
cord-346842-ip4i3bdk	181	6	and	and	CC
cord-346842-ip4i3bdk	181	7	policies	policy	NNS
cord-346842-ip4i3bdk	181	8	implemented	implement	VBD
cord-346842-ip4i3bdk	181	9	internally	internally	RB
cord-346842-ip4i3bdk	181	10	and	and	CC
cord-346842-ip4i3bdk	181	11	externally	externally	RB
cord-346842-ip4i3bdk	181	12	should	should	MD
cord-346842-ip4i3bdk	181	13	be	be	VB
cord-346842-ip4i3bdk	181	14	evaluated	evaluate	VBN
cord-346842-ip4i3bdk	181	15	,	,	,
cord-346842-ip4i3bdk	181	16	in	in	IN
cord-346842-ip4i3bdk	181	17	order	order	NN
cord-346842-ip4i3bdk	181	18	to	to	TO
cord-346842-ip4i3bdk	181	19	be	be	VB
cord-346842-ip4i3bdk	181	20	prepared	prepare	VBN
cord-346842-ip4i3bdk	181	21	for	for	IN
cord-346842-ip4i3bdk	181	22	persistence	persistence	NN
cord-346842-ip4i3bdk	181	23	of	of	IN
cord-346842-ip4i3bdk	181	24	the	the	DT
cord-346842-ip4i3bdk	181	25	COVID-19	covid-19	JJ
cord-346842-ip4i3bdk	181	26	pandemic	pandemic	NN
cord-346842-ip4i3bdk	181	27	or	or	CC
cord-346842-ip4i3bdk	181	28	future	future	JJ
cord-346842-ip4i3bdk	181	29	pandemics	pandemic	NNS
cord-346842-ip4i3bdk	181	30	.	.	.
cord-346842-ip4i3bdk	182	1	Development	development	NN
cord-346842-ip4i3bdk	182	2	of	of	IN
cord-346842-ip4i3bdk	182	3	the	the	DT
cord-346842-ip4i3bdk	182	4	required	require	VBN
cord-346842-ip4i3bdk	182	5	regulations	regulation	NNS
cord-346842-ip4i3bdk	182	6	,	,	,
cord-346842-ip4i3bdk	182	7	strategies	strategy	NNS
cord-346842-ip4i3bdk	182	8	,	,	,
cord-346842-ip4i3bdk	182	9	facilities	facility	NNS
cord-346842-ip4i3bdk	182	10	,	,	,
cord-346842-ip4i3bdk	182	11	and	and	CC
cord-346842-ip4i3bdk	182	12	platform	platform	NN
cord-346842-ip4i3bdk	182	13	could	could	MD
cord-346842-ip4i3bdk	182	14	help	help	VB
cord-346842-ip4i3bdk	182	15	Korea	Korea	NNP
cord-346842-ip4i3bdk	182	16	not	not	RB
cord-346842-ip4i3bdk	182	17	only	only	RB
cord-346842-ip4i3bdk	182	18	adapt	adapt	VB
cord-346842-ip4i3bdk	182	19	to	to	IN
cord-346842-ip4i3bdk	182	20	the	the	DT
cord-346842-ip4i3bdk	182	21	rapidly	rapidly	RB
cord-346842-ip4i3bdk	182	22	changed	change	VBN
cord-346842-ip4i3bdk	182	23	environments	environment	NNS
cord-346842-ip4i3bdk	182	24	and	and	CC
cord-346842-ip4i3bdk	182	25	protection	protection	NN
cord-346842-ip4i3bdk	182	26	of	of	IN
cord-346842-ip4i3bdk	182	27	trial	trial	NN
cord-346842-ip4i3bdk	182	28	participants	participant	NNS
cord-346842-ip4i3bdk	182	29	,	,	,
cord-346842-ip4i3bdk	182	30	but	but	CC
cord-346842-ip4i3bdk	182	31	also	also	RB
cord-346842-ip4i3bdk	182	32	emerge	emerge	VBP
cord-346842-ip4i3bdk	182	33	as	as	IN
cord-346842-ip4i3bdk	182	34	a	a	DT
cord-346842-ip4i3bdk	182	35	contributing	contribute	VBG
cord-346842-ip4i3bdk	182	36	country	country	NN
cord-346842-ip4i3bdk	182	37	in	in	IN
cord-346842-ip4i3bdk	182	38	the	the	DT
cord-346842-ip4i3bdk	182	39	field	field	NN
cord-346842-ip4i3bdk	182	40	of	of	IN
cord-346842-ip4i3bdk	182	41	trials	trial	NNS
cord-346842-ip4i3bdk	182	42	.	.	.
cord-346842-ip4i3bdk	183	1	In	in	IN
cord-346842-ip4i3bdk	183	2	order	order	NN
cord-346842-ip4i3bdk	183	3	to	to	TO
cord-346842-ip4i3bdk	183	4	increase	increase	VB
cord-346842-ip4i3bdk	183	5	in	in	IN
cord-346842-ip4i3bdk	183	6	the	the	DT
cord-346842-ip4i3bdk	183	7	number	number	NN
cord-346842-ip4i3bdk	183	8	of	of	IN
cord-346842-ip4i3bdk	183	9	clinical	clinical	JJ
cord-346842-ip4i3bdk	183	10	trials	trial	NNS
cord-346842-ip4i3bdk	183	11	for	for	IN
cord-346842-ip4i3bdk	183	12	treatment	treatment	NN
cord-346842-ip4i3bdk	183	13	of	of	IN
cord-346842-ip4i3bdk	183	14	serious	serious	JJ
cord-346842-ip4i3bdk	183	15	diseases	disease	NNS
cord-346842-ip4i3bdk	183	16	,	,	,
cord-346842-ip4i3bdk	183	17	consideration	consideration	NN
cord-346842-ip4i3bdk	183	18	should	should	MD
cord-346842-ip4i3bdk	183	19	be	be	VB
cord-346842-ip4i3bdk	183	20	given	give	VBN
cord-346842-ip4i3bdk	183	21	to	to	IN
cord-346842-ip4i3bdk	183	22	developing	develop	VBG
cord-346842-ip4i3bdk	183	23	regulations	regulation	NNS
cord-346842-ip4i3bdk	183	24	that	that	WDT
cord-346842-ip4i3bdk	183	25	will	will	MD
cord-346842-ip4i3bdk	183	26	enable	enable	VB
cord-346842-ip4i3bdk	183	27	patients	patient	NNS
cord-346842-ip4i3bdk	183	28	who	who	WP
cord-346842-ip4i3bdk	183	29	have	have	VBP
cord-346842-ip4i3bdk	183	30	difficulty	difficulty	NN
cord-346842-ip4i3bdk	183	31	with	with	IN
cord-346842-ip4i3bdk	183	32	visiting	visit	VBG
cord-346842-ip4i3bdk	183	33	hospital	hospital	NN
cord-346842-ip4i3bdk	183	34	physically	physically	RB
cord-346842-ip4i3bdk	183	35	even	even	RB
cord-346842-ip4i3bdk	183	36	after	after	IN
cord-346842-ip4i3bdk	183	37	pandemic	pandemic	NN
cord-346842-ip4i3bdk	183	38	is	be	VBZ
cord-346842-ip4i3bdk	183	39	controlled	control	VBN
cord-346842-ip4i3bdk	183	40	,	,	,
cord-346842-ip4i3bdk	183	41	so	so	IN
cord-346842-ip4i3bdk	183	42	that	that	IN
cord-346842-ip4i3bdk	183	43	varying	vary	VBG
cord-346842-ip4i3bdk	183	44	methods	method	NNS
cord-346842-ip4i3bdk	183	45	can	can	MD
cord-346842-ip4i3bdk	183	46	be	be	VB
cord-346842-ip4i3bdk	183	47	applied	apply	VBN
cord-346842-ip4i3bdk	183	48	to	to	IN
cord-346842-ip4i3bdk	183	49	patients	patient	NNS
cord-346842-ip4i3bdk	183	50	with	with	IN
cord-346842-ip4i3bdk	183	51	different	different	JJ
cord-346842-ip4i3bdk	183	52	clinical	clinical	JJ
cord-346842-ip4i3bdk	183	53	conditions	condition	NNS
cord-346842-ip4i3bdk	183	54	.	.	.
cord-346842-ip4i3bdk	184	1	Presentation	presentation	NN
cord-346842-ip4i3bdk	184	2	of	of	IN
cord-346842-ip4i3bdk	184	3	the	the	DT
cord-346842-ip4i3bdk	184	4	results	result	NNS
cord-346842-ip4i3bdk	184	5	of	of	IN
cord-346842-ip4i3bdk	184	6	approval	approval	NN
cord-346842-ip4i3bdk	184	7	of	of	IN
cord-346842-ip4i3bdk	184	8	clinical	clinical	JJ
cord-346842-ip4i3bdk	184	9	trials	trial	NNS
cord-346842-ip4i3bdk	184	10	for	for	IN
cord-346842-ip4i3bdk	184	11	medicines	medicine	NNS
cord-346842-ip4i3bdk	184	12	in	in	IN
cord-346842-ip4i3bdk	184	13	Korea	Korea	NNP
cord-346842-ip4i3bdk	184	14	ICH	ICH	NNP
cord-346842-ip4i3bdk	184	15	harmonized	harmonize	VBD
cord-346842-ip4i3bdk	184	16	guideline	guideline	NN
cord-346842-ip4i3bdk	184	17	integrated	integrate	VBN
cord-346842-ip4i3bdk	184	18	addendum	addendum	NN
cord-346842-ip4i3bdk	184	19	to	to	IN
cord-346842-ip4i3bdk	184	20	ICH	ICH	NNP
cord-346842-ip4i3bdk	184	21	E6(R1	e6(r1	NN
cord-346842-ip4i3bdk	184	22	)	)	-RRB-
cord-346842-ip4i3bdk	185	1	:	:	:
cord-346842-ip4i3bdk	185	2	Guideline	guideline	NN
cord-346842-ip4i3bdk	185	3	for	for	IN
cord-346842-ip4i3bdk	185	4	Good	Good	NNP
cord-346842-ip4i3bdk	185	5	Clinical	Clinical	NNP
cord-346842-ip4i3bdk	185	6	Practice	Practice	NNP
cord-346842-ip4i3bdk	185	7	ICH	ICH	NNP
cord-346842-ip4i3bdk	186	1	E6(R2	e6(r2	LS
cord-346842-ip4i3bdk	186	2	)	)	-RRB-
cord-346842-ip4i3bdk	186	3	ICH	ICH	NNP
cord-346842-ip4i3bdk	186	4	Consensus	Consensus	NNP
cord-346842-ip4i3bdk	186	5	Guideline	Guideline	NNP
cord-346842-ip4i3bdk	186	6	Report	Report	NNP
cord-346842-ip4i3bdk	186	7	on	on	IN
cord-346842-ip4i3bdk	186	8	the	the	DT
cord-346842-ip4i3bdk	186	9	epidemiological	epidemiological	JJ
cord-346842-ip4i3bdk	186	10	features	feature	NNS
cord-346842-ip4i3bdk	186	11	of	of	IN
cord-346842-ip4i3bdk	186	12	coronavirus	coronavirus	NN
cord-346842-ip4i3bdk	186	13	disease	disease	NN
cord-346842-ip4i3bdk	186	14	2019	2019	CD
cord-346842-ip4i3bdk	186	15	(	(	-LRB-
cord-346842-ip4i3bdk	186	16	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	186	17	)	)	-RRB-
cord-346842-ip4i3bdk	186	18	outbreak	outbreak	NN
cord-346842-ip4i3bdk	186	19	in	in	IN
cord-346842-ip4i3bdk	186	20	the	the	DT
cord-346842-ip4i3bdk	186	21	Republic	Republic	NNP
cord-346842-ip4i3bdk	186	22	of	of	IN
cord-346842-ip4i3bdk	186	23	Korea	Korea	NNP
cord-346842-ip4i3bdk	186	24	from	from	IN
cord-346842-ip4i3bdk	186	25	Daily	Daily	NNP
cord-346842-ip4i3bdk	186	26	status	status	NN
cord-346842-ip4i3bdk	186	27	of	of	IN
cord-346842-ip4i3bdk	186	28	Middle	Middle	NNP
cord-346842-ip4i3bdk	186	29	East	East	NNP
cord-346842-ip4i3bdk	186	30	Respiratory	Respiratory	NNP
cord-346842-ip4i3bdk	186	31	Syndrome	Syndrome	NNP
cord-346842-ip4i3bdk	187	1	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	187	2	response	response	NN
cord-346842-ip4i3bdk	187	3	guideline	guideline	NN
cord-346842-ip4i3bdk	187	4	9th	9th	JJ
cord-346842-ip4i3bdk	187	5	edition	edition	NN
cord-346842-ip4i3bdk	187	6	by	by	IN
cord-346842-ip4i3bdk	187	7	Central	Central	NNP
cord-346842-ip4i3bdk	187	8	Disaster	Disaster	NNP
cord-346842-ip4i3bdk	187	9	Management	Management	NNP
cord-346842-ip4i3bdk	187	10	Headquarters	Headquarters	NNPS
cord-346842-ip4i3bdk	187	11	·	·	NFP
cord-346842-ip4i3bdk	187	12	Central	Central	NNP
cord-346842-ip4i3bdk	187	13	Disease	Disease	NNP
cord-346842-ip4i3bdk	187	14	Control	Control	NNP
cord-346842-ip4i3bdk	187	15	Headquarters	Headquarters	NNPS
cord-346842-ip4i3bdk	187	16	Korea	Korea	NNP
cord-346842-ip4i3bdk	187	17	Pharmaceutical	Pharmaceutical	NNP
cord-346842-ip4i3bdk	187	18	and	and	CC
cord-346842-ip4i3bdk	187	19	Bio	Bio	NNP
cord-346842-ip4i3bdk	187	20	-	-	HYPH
cord-346842-ip4i3bdk	187	21	Pharma	Pharma	NNP
cord-346842-ip4i3bdk	187	22	Manufacturers	Manufacturers	NNPS
cord-346842-ip4i3bdk	187	23	'	'	POS
cord-346842-ip4i3bdk	187	24	Association	Association	NNP
cord-346842-ip4i3bdk	187	25	Integrated	Integrated	NNP
cord-346842-ip4i3bdk	187	26	drug	drug	NN
cord-346842-ip4i3bdk	187	27	information	information	NN
cord-346842-ip4i3bdk	187	28	system	system	NN
cord-346842-ip4i3bdk	187	29	Ministry	Ministry	NNP
cord-346842-ip4i3bdk	187	30	Health	Health	NNP
cord-346842-ip4i3bdk	187	31	and	and	CC
cord-346842-ip4i3bdk	187	32	Welfare	Welfare	NNP
cord-346842-ip4i3bdk	187	33	.	.	.
cord-346842-ip4i3bdk	188	1	Daily	daily	JJ
cord-346842-ip4i3bdk	188	2	status	status	NN
cord-346842-ip4i3bdk	188	3	of	of	IN
cord-346842-ip4i3bdk	188	4	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	188	5	Considerations	Considerations	NNPS
cord-346842-ip4i3bdk	188	6	for	for	IN
cord-346842-ip4i3bdk	188	7	clinical	clinical	JJ
cord-346842-ip4i3bdk	188	8	trials	trial	NNS
cord-346842-ip4i3bdk	188	9	in	in	IN
cord-346842-ip4i3bdk	188	10	a	a	DT
cord-346842-ip4i3bdk	188	11	situation	situation	NN
cord-346842-ip4i3bdk	188	12	of	of	IN
cord-346842-ip4i3bdk	188	13	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	188	14	Notice	notice	NN
cord-346842-ip4i3bdk	188	15	of	of	IN
cord-346842-ip4i3bdk	188	16	training	training	NN
cord-346842-ip4i3bdk	188	17	considerations	consideration	NNS
cord-346842-ip4i3bdk	188	18	for	for	IN
cord-346842-ip4i3bdk	188	19	clinical	clinical	JJ
cord-346842-ip4i3bdk	188	20	trial	trial	NN
cord-346842-ip4i3bdk	188	21	workers	worker	NNS
cord-346842-ip4i3bdk	188	22	according	accord	VBG
cord-346842-ip4i3bdk	188	23	to	to	IN
cord-346842-ip4i3bdk	188	24	corona	corona	NN
cord-346842-ip4i3bdk	188	25	19	19	CD
cord-346842-ip4i3bdk	188	26	situation	situation	NN
cord-346842-ip4i3bdk	188	27	United	United	NNP
cord-346842-ip4i3bdk	188	28	Kingdom	Kingdom	NNP
cord-346842-ip4i3bdk	188	29	Medicines	Medicines	NNPS
cord-346842-ip4i3bdk	188	30	and	and	CC
cord-346842-ip4i3bdk	188	31	Healthcare	Healthcare	NNP
cord-346842-ip4i3bdk	188	32	Products	Products	NNPS
cord-346842-ip4i3bdk	188	33	Regulatory	Regulatory	NNP
cord-346842-ip4i3bdk	188	34	Agency	Agency	NNP
cord-346842-ip4i3bdk	188	35	.	.	.
cord-346842-ip4i3bdk	189	1	Synopsis	Synopsis	NNP
cord-346842-ip4i3bdk	189	2	of	of	IN
cord-346842-ip4i3bdk	189	3	MHRA	MHRA	NNP
cord-346842-ip4i3bdk	189	4	advice	advice	NN
cord-346842-ip4i3bdk	189	5	on	on	IN
cord-346842-ip4i3bdk	189	6	management	management	NN
cord-346842-ip4i3bdk	189	7	of	of	IN
cord-346842-ip4i3bdk	189	8	clinical	clinical	JJ
cord-346842-ip4i3bdk	189	9	trials	trial	NNS
cord-346842-ip4i3bdk	189	10	in	in	IN
cord-346842-ip4i3bdk	189	11	relation	relation	NN
cord-346842-ip4i3bdk	189	12	to	to	IN
cord-346842-ip4i3bdk	189	13	coronavirus	coronavirus	NN
cord-346842-ip4i3bdk	189	14	Analysis	analysis	NN
cord-346842-ip4i3bdk	189	15	of	of	IN
cord-346842-ip4i3bdk	189	16	domestic	domestic	JJ
cord-346842-ip4i3bdk	189	17	and	and	CC
cord-346842-ip4i3bdk	189	18	international	international	JJ
cord-346842-ip4i3bdk	189	19	clinical	clinical	JJ
cord-346842-ip4i3bdk	189	20	trials	trial	NNS
cord-346842-ip4i3bdk	189	21	Guidance	Guidance	NNP
cord-346842-ip4i3bdk	189	22	on	on	IN
cord-346842-ip4i3bdk	189	23	Conduct	conduct	NN
cord-346842-ip4i3bdk	189	24	of	of	IN
cord-346842-ip4i3bdk	189	25	Clinical	Clinical	NNP
cord-346842-ip4i3bdk	189	26	Trials	Trials	NNPS
cord-346842-ip4i3bdk	189	27	of	of	IN
cord-346842-ip4i3bdk	189	28	Medical	Medical	NNP
cord-346842-ip4i3bdk	189	29	Products	Products	NNPS
cord-346842-ip4i3bdk	189	30	during	during	IN
cord-346842-ip4i3bdk	189	31	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	189	32	Public	Public	NNP
cord-346842-ip4i3bdk	189	33	Health	Health	NNP
cord-346842-ip4i3bdk	189	34	Emergency	Emergency	NNP
cord-346842-ip4i3bdk	189	35	Guidance	Guidance	NNP
cord-346842-ip4i3bdk	189	36	on	on	IN
cord-346842-ip4i3bdk	189	37	the	the	DT
cord-346842-ip4i3bdk	189	38	management	management	NN
cord-346842-ip4i3bdk	189	39	of	of	IN
cord-346842-ip4i3bdk	189	40	clinical	clinical	JJ
cord-346842-ip4i3bdk	189	41	trials	trial	NNS
cord-346842-ip4i3bdk	189	42	during	during	IN
cord-346842-ip4i3bdk	189	43	the	the	DT
cord-346842-ip4i3bdk	189	44	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	189	45	Pandemic	Pandemic	NNP
cord-346842-ip4i3bdk	189	46	ACRO	ACRO	NNP
cord-346842-ip4i3bdk	189	47	's	's	POS
cord-346842-ip4i3bdk	189	48	considerations	consideration	NNS
cord-346842-ip4i3bdk	189	49	on	on	IN
cord-346842-ip4i3bdk	189	50	monitoring	monitoring	NN
cord-346842-ip4i3bdk	189	51	during	during	IN
cord-346842-ip4i3bdk	189	52	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	189	53	Clinical	clinical	JJ
cord-346842-ip4i3bdk	189	54	trials	trial	NNS
cord-346842-ip4i3bdk	189	55	'	'	POS
cord-346842-ip4i3bdk	189	56	management	management	NN
cord-346842-ip4i3bdk	189	57	in	in	IN
cord-346842-ip4i3bdk	189	58	Italy	Italy	NNP
cord-346842-ip4i3bdk	189	59	during	during	IN
cord-346842-ip4i3bdk	189	60	the	the	DT
cord-346842-ip4i3bdk	189	61	COVID-19	COVID-19	NNP
cord-346842-ip4i3bdk	189	62	(	(	-LRB-
cord-346842-ip4i3bdk	189	63	coronavirus	coronavirus	NN
cord-346842-ip4i3bdk	189	64	disease	disease	NN
cord-346842-ip4i3bdk	189	65	19	19	CD
cord-346842-ip4i3bdk	190	1	We	-PRON-	PRP
cord-346842-ip4i3bdk	190	2	express	express	VBP
cord-346842-ip4i3bdk	190	3	our	-PRON-	PRP$
cord-346842-ip4i3bdk	190	4	sincere	sincere	JJ
cord-346842-ip4i3bdk	190	5	appreciation	appreciation	NN
cord-346842-ip4i3bdk	190	6	for	for	IN
cord-346842-ip4i3bdk	190	7	all	all	DT
cord-346842-ip4i3bdk	190	8	clinical	clinical	JJ
cord-346842-ip4i3bdk	190	9	project	project	NN
cord-346842-ip4i3bdk	190	10	managers	manager	NNS
cord-346842-ip4i3bdk	190	11	who	who	WP
cord-346842-ip4i3bdk	190	12	conducted	conduct	VBD
cord-346842-ip4i3bdk	190	13	the	the	DT
cord-346842-ip4i3bdk	190	14	survey	survey	NN
cord-346842-ip4i3bdk	190	15	and	and	CC
cord-346842-ip4i3bdk	190	16	all	all	DT
cord-346842-ip4i3bdk	190	17	clinical	clinical	JJ
cord-346842-ip4i3bdk	190	18	trial	trial	NN
cord-346842-ip4i3bdk	190	19	participants	participant	NNS
cord-346842-ip4i3bdk	190	20	who	who	WP
cord-346842-ip4i3bdk	190	21	contributed	contribute	VBD
cord-346842-ip4i3bdk	190	22	new	new	JJ
cord-346842-ip4i3bdk	190	23	drug	drug	NN
cord-346842-ip4i3bdk	190	24	developments	development	NNS
cord-346842-ip4i3bdk	190	25	.	.	.